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Myocardial blood flow (MBF) is regulated by the coronary resistive vessels which continuously adapt the coronary blood flow
he myocardial metabolic requirements, modulated by neural and humoral mechanisms, and this adaptation can compensate for
increased resistance of an epicardial stenosis to a considerable extent. In patients with coronary artery disease, we postulate
t dysfunction of the coronary resistive vessels may cause or contribute to myocardial ischaemia. Thus, impaired myocardial
fusion maybe due to the abnormal behaviour of collateral and resistive vessels rather than to epicardial disease alone. We
ipose that this alteration in resistive vessel function occurs, not only in regions subtended by epicardial disease, but is present in
rote myocardium and may be altered by coronary intervention such as coronary angioplasty (PTCA) and after myocardial
irction (MI). To investigate coronary resistive vessel function, positron emission tomography (PET) may be used to evaluate
ional MBF using the flow tracer lsO-labelled water. Using vasodilator (or vasoconstrictor) stimuli, the coronary vasodilator
ponse (CVR=maximal/basal coronary [myocardial] blood flow), an index of coronary resistive vessel function, may be measured
1 compared in regions of interest and in remote myocardium.
Recovery of Resistive Vessel Dysfunction After Successful PTCA. To investigate the frequency and the time course of abnormal
onary resistive vessel function after successful PTCA, patients with single vessel coronary disease and normal left ventricular
ction underwent intracoronary (IC) Doppler measurement of coronary flow velocity, before and after successful PTCA, at basal
I after intravenous (IV) dipyridamole. PET was performed on 3 occasions after PTCA. There was no change in CVR at Doppler
;r PTCA. In patients without restenosis, the CVR was reduced in the PTCA region for >7 days, but returned to normal at 3
nths, due to increased basal MBF for >7 days in the PTCA region, with a reduction in the dipyridamole-induced maximal MBF
> 24 hours.
Altered Nitric Oxide Synthesis/Release and Resistive Vessel Dysfunction After PTCA. Impaired production or release of nitric
de (NO) in the from resistive vessel endothelium may cause this alteration in the CVR after PTCA. As the CVR to exogenous
■ates is enhanced by the endothelial dysfunction, large doses of IC sodium nitroprusside, an NO donor, were infused at the peak
?ct of IV dipyridamole to test this hypothesis using Doppler catheterisation in patients with single vessel disease,
roprusside in doses sufficient to cause ultimately a fall in blood pressure did not augment the dipyridamole-induced increase in
onary blood flow velocity.
Altered Flow and Metabolism in Regions Subtended by Angiographically Normal Arteries in Coronary Artery Disease. The
ional CVR was measured using PET in patients with stable single vessel disease. In a second group of patients and controls,
[ultaneous arterial and great cardiac vein catheterisation was done at rest and during atrial pacing to measure myocardial
tabolism in regions subtended by a diseased artery or by an angiographically normal artery with epicardial disease elsewhere.
; CVR was reduced in remote regions compared to controls. In the second group, at maximal pacing, there was net lactate
duction in the diseased region compared to net extraction in both the remote and control regions. However, glucose and alanine
raction were increased in both diseased region and remote regions compared to control.
Resistive Vessel Dysfunction in Infarcted and Remote Myocardium After MI. To investigate acute resistive vessel dysfunction,
ients were studied after thrombolysis for MI. Regional MBF and the CVR in infarct and remote regions was assessed, after a
an of 8 days and 6 months after MI by PET. At early scanning^ the CVR was markedly reduced in the infarct region, and was
tted to the amount of residual viable tissue. There was no correlation between the CVR and residual stenosis area. The remote
R was less than that in remote regions, subtended by a normal artery, in controls with stable single vessel disease without MI.
late scanning, the CVR improved in the infarct region, but the CVR in the remote region still remained lower than in controls.
Impaired Flow Response to Cold Pressor in Collateral-Dependent Myocardium. To investigate the response of collateral-
pendent myocardium to reflex sympathetic stimulation (cold pressor stress), patients with stable angina and normal left
itricular function were studied, in whom one coronary artery was occluded (without previous MI), and the other arteries were
;iographically normal supplying collaterals. Regional MBF and glucose uptake (using 18F-deoxyglucose) was measured using
r at basal and at cold pressor. With cold pressor, no patients developed ECG changes. The cold pressor response (cold
ssor/basal MBF) was low in the collateralised region, compared to remote regions, due to vasoconstriction in the majority, but in
absence of demonstrable ischaemia.
In summary, there is coronary resistive vessel dysfunction after PTCA which recovers over 3 months due to acute impairment of
response to dipyridamole and a longer increase in basal flow, possibly due to the previous stenosis. This impairment is not due
iltered production or release of NO in the microcirculation. In stable disease, there is both an impaired CVR and altered
tabolism during pacing in regions subtended by a normal artery. This remote alteration is impaired acutely by myocardial
irction elsewhere, with only incomplete recovery over at least 6 months. In addition to reduced vasodilator function, resistive
sels in patients with atherosclerosis, have an increased tendency to vasoconstrict to a sympathetic stimulus. Thus, the
erosclerotic process and the sympathetic nervous system may both play a role in determining the degree of resistive vessel
function, which may cause or contribute to myocardial ischaemia in patients with coronary artery disease.
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CHAPTER 1. CORONARY RESISTIVE VESSEL
FUNCTION AND THE CONTROL OF THE
CORONARY CIRCULATION
1.1 Introduction
In the normal heart, myocardial blood flow is regulated by the coronary resistive
vessels which continuously adapt the coronary blood flow to the myocardial metabolic
requirements. This local metabolic autoregulatory control is also modulated by neural
and by humoral mechanisms. In the presence of an epicardial coronary artery
stenosis, this mechanism can compensate for the resistance created by the stenosis to a
considerable extent, as animal studies show that myocardial blood flow can still
increase 3-4 times above resting levels even distal to a 70% diameter stenosis (Gould
et al, 1975).
In patients with coronary artery disease, recent observations suggest that the
behaviour of the resistive vessels is abnormal and may contribute to the development
ofmyocardial ischaemia. However, in the presence of a coronary artery stenosis, it is
impossible to separate modulation of coronary blood flow at the level of the stenosis
(Epstein & Talbot, 1981), from that occurring in the resistive vessels. Therefore, in
order to obviate the difficulty in establishing whether or not the modulation of
coronary blood flow is caused by changes in the calibre of the coronary stenosis
(Wilson et al, 1987), we propose to assess the modulation of coronary blood flow in
models of disease which would allow us to exclude this possibility. Furthermore, it is
possible that resistive vessel dysfunction may occur as part of the generalised process
of atherosclerosis or through local changes in autoregulation or autonomic modulation,
and may occur in coronary vascular beds subtended by angiographically normal
epicardial arteries. Thus, it is important when observing resistive vessel function that
1
simultaneous assessment is made in such regions when comparing with regions
subtended by epicardial arteries with obvious disease.
The function of the human coronary resistive vessels in vivo can only be assessed
by measurement of myocardial blood flow. Whether or not resistive vessel
dysfunction leads to recurrent myocardial ischaemia is more difficult to ascertain. In
the presence of abnormal resistive vessel function, ischaemia must be assessed directly
because, as in syndrome X which may be characterised by dysfunction of the
coronary resistive vessels (Cannon et al, 1992), ischaemic electrocardiographic (ECG)
changes may not be associated with direct evidence of myocardial ischaemia (Crake et
al, 1988).
1.2 Coronary Blood Flow
Myocardial performance is determined by coronary blood flow which is
dependent on the coronary perfusion pressure and the coronary vascular resistance.
Unlike other vascular beds, the resistance of the coronary circulation is influenced by
the phasic systolic compression of the coronary vessels within the myocardium. The
effective coronary perfusion pressure is the pressure gradient between the large
coronary arteries and the right atrium or left ventricle in end-diastole, which change
with the cardiac cycle. Coronary vascular resistance is influenced both by extrinsic
factors such as myocardial compression and by intrinsic factors such as tissue
metabolism, and neural and humoral influences. Although coronary flow occurs in
both systole and diastole, this is mainly true only of the right coronary artery, as flow
is predominately diastolic in the left coronary circulation. The calculation of coronary
vascular resistance is complicated by the fact that coronary blood flow ceases when the
coronary perfusion pressure falls to approximately 40 mmHg (pressure at zero flow),
still substantially above coronary venous pressure (Klocke et al, 1985). Although the
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exact mechanism for this is unclear, intra-myocardial pressure accounts for most of
this pressure.
With the penetration of the myocardium from the epicardial surface, smaller
coronary arteries are exposed to progressively greater systolic pressures, with greatest
extravascular resistance to flow in the subendocardial myocardial layers. Because of
its increased dependence on diastolic perfusion and the greater degree of systolic
shortening (and thus of energy expenditure), the subendocardium has an increased
susceptibility to the development of myocardial ischaemia (Bell & Fox, 1974). Under
normal circumstances, secondary to this increased wall stress and thus increased
myocardial oxygen consumption, but lower perfusion pressure, in the
subendocardium, there is preferential subendocardial vasodilatation with flow 25%
greater than in the subepicardium (Klocke, 1976). This means that the coronary
vasodilator reserve (Chapter 2, Section 2.3) is lower in the subendocardium and that it
is more susceptible to myocardial ischaemia when there is an increase in myocardial
oxygen demand or a decrease in myocardial oxygen supply such as seen with a
vasodilator stimulus in the presence of an epicardial stenosis. This is because resistive
vessel dilatation leads to a reduction in perfusion pressure as the stenosis prevents an
increase in flow in response (Bache & Schwartz, 1982). A reduced intravascular
distending pressure and increased extravascular compression redistribute flow away
from the subendocardium, leading to ischaemia.
1.3 The Coronary Resistive Vessels
The coronary circulation has been traditionally divided into two arterial
compartments; the large epicardial conduit vessels and the small resistance (resistive)
vessels, and one venous compartment, which regulate the How of blood. It was
previously believed that the control of coronary resistance resided entirely in this
3
homogeneous compartment of resistive vessels throughout the myocardium, modified
in normal subjects by the coronary perfusion pressure, myocardial oxygen demand,
ventricular wall tension and the metabolic state of the coronary vascular bed. In recent
times, it has become apparent that there is substantial heterogeneity of function in each
of the vascular compartments, but particularly with respect to the regulation of
coronary flow by the resistive vessels.
Resistive vessels have two major functions; i) to match myocardial blood flow to
oxygen consumption when myocardial demand varies, and ii) to match myocardial
blood flow to myocardial demand when aortic pressure (coronary perfusion pressure)
varies. Resistive vessels function to continually match blood supply to metabolic
requirements such that myocardial oxygen extraction is virtually constant over a wide
range of cardiac work and coronary perfusion pressure.
Several techniques have been developed over the years to study the coronary
microcirculation with direct visualisation. These methods have employed an animal
model using regional immobilisation and microscopic examination (Tillmanns et al,
1981). With the development of a stroboscopic method (Nellis et al, 1981) has come
additional refinements requiring limited restriction of cardiac movement, although
confined to study of only the microvessels closest to the surface of the heart (Marcus
et al, 1990). Techniques have also been developed to study vessels in vitro and it is
now possible to visualize vessels as small as 15 Jim in the beating heart (Kuo et al,
1988). From these studies, much of what is known about resistive vessel function
has been discovered, although it is important to add the caveat that these studies have
been done in an artificial environment free from the physiological constraints of
normal cardiac metabolism and varying myocardial oxygen consumption.
1.3.1. Distribution of the Coronary Resistance/
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1.3.1. Distribution of the Coronary Resistance
Conventional teaching believed that most of the resistance to coronary flow
resided in arterioles smaller than 100 prrt (Zweifach et al, 1984). However, it has
become apparent that a significant proportion of resistance is present in larger
arterioles. In the cat, 50% of coronary resistance is in vessels >100 (im (Chilian et al,
1986a), and 25% of coronary resistance is in vessels >170 (im under basal conditions
(Chilian et al, 1989a). As 10% of resistance is in the venous compartment, this leaves
about 40% of resistance in the pre-capillary resistive vessels <100 gm.
Pharmacological vasodilatation can shift the distribution of resistance from one
compartment to another; dipyridamole (and adenosine) reduces resistance in resistive
vessels <150-170 pm (Chilian et al, 1989a; Kanatsuka et al, 1989a). This causes an
increased proportion of total resistance to move to the venous compartment and larger
arteries (Chilian et al, 1989a) (Figure 1.1), implying that flow-mediated vasodilatation
in the larger resistive vessels was less than required to fully compensate for the
increase in flow. By contrast, papaverine preferentially vasodilates larger coronary
arterioles and small coronary arteries (>200 pm) (Chilian et al, 1986a). The concept
that coronary resistance coexists in different arteriolar compartments and that the
relationship may change depending on the perfusion pressure and local metabolic
environment is of importance in understanding the control of coronary flow (Section
1.4.1.4). That this relationship may be disturbed in patients with coronary artery
disease is central to the working hypothesis of this thesis.
1.4 The Control of Myocardial Perfusion
Myocardial perfusion is controlled by the modulation of coronary flow to
perfusion pressure - autoregulation - and by tissue metabolism. Coronary









Figure 1.1. Distribution of microvascular pressure measured using the servonull
technique in relation to aortic pressure in different sized coronary arterioles and
venules in the normal left ventricle in pentobarbitol anaesthetized cats during control
conditions (thin line) and intravenous dipyridamole at 0.4 mg-kg^-min"1 (thick line).
During infusion of dipyridamole, there is a redistribution of microvascular resistance
such that larger arteries and veins account for a greater portion of resistance. The
dashed line identifies 100 |im diameter arterioles (Modified from Chilian et al, 1989a).
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relatively constant following changes in perfusion pressure when myocardial oxygen
demands are constant (Dole, 1987). This a local autonomous form of control which
may be influenced by extrinsic factors such as autonomic nervous system activity and
circulating hormones. To study autoregulation, it is important to separate the effects
of aortic pressure from coronary perfusion pressure since changes in the former, a
determinant ofmyocardial oxygen demand, may lead to changes in myocardial tissue
metabolism (the other major determinant of myocardial perfusion). Autoregulation can
be said to occur where the relative change in flow is proportionally less than a change
in perfusion pressure, such that vascular resistance changes in the same direction as
pressure, whether acutely or as a chronic adaptation, to return flow to or close to basal
steady state values (Mosher et al, 1964). In the coronary circulation, this generally
occurs between perfusion pressures of 60 and 140 mmHg (Klocke, 1987) (Figure
1.2).
Autoregulation is an important homeostatic mechanism for maintaining nutritive
flow in the face of a reduction in perfusion pressure whether caused by systemic
hypotension or a proximal flow obstruction. Conventionally, it may be demonstrated
by measuring coronary flow over a range of coronary perfusion pressures. At a
perfusion pressure of 60 mmHg coronary flow is maintained because of vasodilatation
of the resistive vessels <100 |im diameter and the magnitude of vasodilatation is
inversely proportional to the vessel diameter. At a perfusion pressure of 40 mmHg
which is below the autoregulatory range, although these vessels <100 |im diameter
dilate towards their physiological maximum, vessels >100 (im decrease in diameter
(Kanatsuka et al, 1989b). This reduction in diameter is passive to an extent as these
vessels are still amenable to vasodilatation with nitroglycerin and adenosine. This may
be evidence for an abnormality in these resistive vessels >100 (im (the so-called pre-
arteriolar vessels) occurring in the equivalent, albeit more chronic, setting of a
proximal flow obstruction. These myogenic responses (Section 1.4.1.2) are less
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apparent in subendocardial vessels: perhaps another reason for the reduced efficacy of
autoregulation in the subendocardium (Section 1.2). An increase in myocardial
oxygen demand with pacing leading to an increase in tissue metabolism leads to a
generalised vasodilatation in all resistive vessels, although again related inversely to
initial diameter (Kanatsuka et al, 1989a). This may be because the arterioles (<100
(im) are subject to a lower transmural pressure (Nellis et al, 1981; Tillmanns et al,
1981), but also, these arterioles are only resistive vessels influenced by the tissue
metabolic state (Section 1.4.1.4). Thus, the response of the resistive vessels to
different physiological stimuli is heterogeneous.
It is likely that several different mechanisms may account for the heterogeneity of
the vasodilator response of the resistive vessels. Comparing large and small
arterioles, there may be differential receptor populations with different receptor
subtypes for vasoactive substances released in the coronary microcirculation such as
5-HTi and 5-HT2 receptors for serotonin (Lamping et al, 1989). It is also possible
that endothelium-derived relaxing factor (EDRF; nitric oxide) is released to a varying
degree in differently sized vessels (Kurz et al, 1989) or that differently sized vessels
respond according to the immediate coronary flow at the origin of that vascular bed,
dependent on the vasodilated/vasoconstricted state of the upstream resistive vessels.
To some extent, this may also account for the differential roles these vessels have in
the autoregulation of blood flow (Section 1.4.1.4).
The reasons for the apparent submaximal dilatation of the resistive vessels when
perfusion pressure is reduced below autoregulatory range (Canty et al, 1985),
manifest by residual dilatation to adenosine for example (Grattan et al, 1986; Chilian &
Layne, 1990), are not known. There would seem to be a difference between the
ability to vasodilate endogenously and to vasodilate to a pharmacological stimulus.
This may be due to a reduction in the production of vasodilator metabolites through
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Figure 1.2. Autoregulation of coronary blood flow in the beating dog heart. The
point where the curves cross represents control steady-state pressure and flow. A
sudden sustained change in perfusion pressure leads to an abrupt change in flow
represented by the closed symbols and the thick line (transient flow). The open
symbols and thin line represent steady-state flows obtained at each perfusion pressure.
(Modified from Rubio & Berne, 1975).
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irreversible ischaemic dysfunction, the experimental equivalent of myocardial
stunning. Alternatively, it is possible that pharmacological vasodilatation overcomes a
strong endogenous vasoconstrictor component due to metabolites such as
prostaglandins or leucotrienes (Aversano & Becker, 1985) or through post-junctional
(X2-adrenergic mediated vasoconstriction (Heusch & Deussen, 1983) (Section
1.4.2.1).
1.4.1. Mechanisms of Coronary Autoregulation
1.4.1.1. The Tissue Pressure Theory
This hypothesis postulates that autoregulation occurs through passive changes in
extravascular compression of compliant vessels due to increased or decreased capillary
filtration in response to changes in perfusion pressure. However, it is unlikely that
such a mechanism could account for rapid dynamic changes in perfusion pressure
(Driscol et al, 1963). Furthermore, using a micropipette system to measure
intramyocardial pressure in the beating dog heart, it has been shown that changes in
aortic pressure, and thus perfusion pressure, did not affect diastolic tissue pressure
(Heineman & Grayson, 1985).
1.4.1.2. The Myogenic Theory
This hypothesis proposes that vascular resistance is proportional to transmural
pressure in the microcirculation, through the effect of pressure on vascular smooth
muscle (Folkow, 1964). This mechanism does contribute to autoregulation in
vascular beds of other organs, and although the evidence from the coronary vascular
bed is less firm, adaptive vasomotor changes do occur through alterations in myogenic
tone in concert with intravascular distending pressure and tissue metabolism (McHale
et al, 1987). The argument that myogenic regulation might occur was based on the
assumption that brief periods of occlusion were insufficient to alter tissue metabolism.
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However, it has been shown by 3 ^-magnetic resonance spectroscopy that the
metabolic response of the heart to changes in flow is very rapid (Fossel et al, 1980).
In addition, by reducing myocardial oxygen demand through lowering heart rate, it is
possible to attenuate autoregulation, again against a myogenic mechanism (Dole &
Nuno, 1986).
1.4.1.3. The Metabolic Theory
This hypothesis proposes that tissue metabolism feeds back through the
production of vasoactive metabolites to control coronary vascular resistance. A major
problem in distinguishing metabolic and myogenic mechanisms of autoregulation has
been because changes in coronary perfusion pressure (the myogenic stimulus) result
directly in similar changes in blood flow (the metabolic stimulus). Indeed, when
myocardial oxygen consumption is constant, coronary flow autoregulation may still
occur. Much research into the metabolic control of autoregulation has been to observe
flow during interventions which alter the myocardial oxygen demand. Reducing
demand may attenuate autoregulation completely or may simply move the pressure-
flow relationship down parallel to basal conditions. This variability could be due to
the effects of any given intervention on myocardial oxygen tension, as it has been
demonstrated that the degree of autoregulation may depend largely on the balance
between myocardial oxygen supply and demand rather than on the absolute level of
myocardial oxygen consumption (Dole & Nuno, 1986).
Coronary autoregulation appears to be closely related to myocardial oxidative
metabolism. It is likely that no one substrate, such as adenosine, or metabolite
accounts for this and that autoregulation results from the concerted interaction of
several different mediators, such that one may compensate for another should it be
reduced or blocked by pharmacological means ormyocardial ischaemia.
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1 A. 1.4. The Pre-arteriolar/Arteriolar Theory
All the above theories on autoregulation ofmyocardial blood flow rely on an over-
simplistic and unitary understanding of the coronary resistive vessels, despite much
recent evidence for distinct functional heterogeneity of these vessels (Marcus et al,
1990). It is likely that there is both a myogenic and a metabolic component to the
control of regional transmural coronary microvascular flow and that under normal
conditions, these mechanisms act to complement each other.
There is existing evidence to show that myocardial ischaemia may be caused by
inappropriate vasoconstriction of resistive vessels (Wilson et al, 1988; Pupita et al,
1990; Marcus et al, 1990) and the vessels involved in such vasoconstriction may not
necessarily the same as those involved in metabolically-mediated vasoconstriction. As
described above, reduction of the coronary perfusion pressure below the
autoregulatory range dilates vessels <100 p.m diameter but ultimately leads to
constriction of the larger resistive vessels with an increasingly severe stenosis
(Kanatsuka et al, 1989b). This constriction could occur passively and reflect the
reduced distending pressure and myogenic tone, but also account for their residual
response to pharmacological vasodilatation (Berne & Rubio, 1979). An alternative
explanation is the presence of a-adrenergic vasoconstriction which occurs with the
reduction of perfusion pressure (Feigl et al, 1987) (Section 1.4.2.1). Sympathetic
nerve stimulation or noradrenaline infusion (Chilian et al, 1989b) and serotonin
infusion (Lamping et al, 1989) constrict vessels >90-100 fim, dilating smaller vessels.
This may be evidence for the compensatory response of metabolic vasodilatation to
counter pre-arteriolar constriction to allow maintenance of perfusion pressure.
On theoretical grounds, one can separate these resistive vessels into two groups
on the basis of function and diameter (Epstein & Cannon, 1986). These are the distal
"arteriolar" vessels (<100 (im) - predominately responsive to local tissue metabolism
and which directly match supply to demand (Kanatsuka et al, 1989a). This occurs to
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maintain the intracellular environment with optimal biochemical limits for myocardial
contractile function and is modulated primarily by tissue oxygen and carbon dioxide
tension (Hoffman & Spaan, 1990). The flow in the arterioles is dependent on their
inherent tone and the perfusion pressure at origin. This is determined by the second
group - the proximal "pre-arteriolar" vessels (100-350 |im) - influenced only by
coronary perfusion pressure, and thus coronary flow and distending pressure, and by
myogenic tone (Maseri et al, 1991). Although there is no obvious histological
demarcation between these two groups, it is likely that the pre-arteriolar vessels have a
supply of autonomic afferent nerves which may serve to modulate inherent myogenic
tone. When there is an increase in myocardial oxygen demand with arteriolar
vasodilatation, a pressure drop would potentially occur across the pre-arteriolar
vessels with increasing flow. Flow-mediated vasodilatation at this level allows
maintenance of increased flow sufficient to meet tissue needs. With an increase in
aortic pressure, arteriolar pressure may be maintained by pre-arteriolar constriction
through an increase in myogenic tone. A marked decrease in aortic pressure leads to
dilatation of all resistive vessels (Kanatsuka et al, 1989a). In pathological conditions,
a failure of pre-arteriolar vessels to dilate or to constrict inappropriately would lead to a
reduction in flow in the arteriolar bed despite maximal dilatation in response to tissue
metabolism (Figure 1.3).
This hypothesis of the regulation of myocardial perfusion at a microvascular level
may be viewed to encompass both the metabolic theory and myogenic theory
described above.
i) Regulation ofmyocardial blood flow when aortic pressure changes
As described above, the process of autoregulation allows very little change in
myocardial blood flow over a wide range of perfusion pressures. The regulatory















Figure 1.3. Schematic representation of a conduit (conductive) artery and pre-arteriolar
and arteriolar vessels with patchily distributed pre-arteriolar constriction in control
conditions (A, upper panel) and during arteriolar vasodilatation (B, upper panel). In
this functional classification, conduit coronary arteries do not have appreciable flow
resistance, arteriolar vessels are responsible for the metabolic autoregulation of coronary
blood flow and pre-arteriolar vessels are those segments interposed between conductive
and arteriolar vessels, with appreciable coronary flow resistance that are responsible for
maintaining perfusion pressure at the origin of arterioles within optimal levels. The
vasodilator reserve of arterioles distal to constricted pre-arteriolar vessels is reduced
because they are already dilated to preserve flow.
In conduit coronary arteries, the pressure remains similar to aortic pressure, but
decreases progressively across pre-arteriolar vessels in proportion to their degree of
constriction (A, lower panel). During metabolic or pharmacological arteriolar
vasodilatation, the pressure drop increases only slightly distal to some pre-arteriolar
vessels (ai, a2, b2) because vasodilatation related to flow-mediated release of
endothelium-derived relaxing factor compensates nearly completely for the increased
flow. The pressure drop increases markedly across more constricted pre-arteriolar
vessels (bi, ci, c2) (B, lower panel). Steal can develop when an increase in flow through
c2 causes a pressure decrease at the branching point distal to the constricted segment c,
so that the driving pressure becomes insufficient to perfuse adequately the most
constricted branch cj and blood flow (as indicated by arrows) can become lower than
during rest conditions. The possibility of flow steal is greatly enhanced if branch c2
perfuses subepicardial layers of the ventricular wall with a greater flow reserve and if
branch Cj perfuses perfuses the subendocardial layers with a smaller flow reserve. At the
end of the pre-arteriolar vessels with the most marked increase in tone (bi), intravascular
pressure may become insufficient to maintain lumen patency, resulting in vessel collapse
(From Maseri et al, 1991).
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autoregulatory range. With such a change, the myogenic response in the pre-
arteriolar vessels may be reset as they are more sensitive to intravascular distending
pressure because of their larger size (Chilian et al, 1986a). This resetting would allow
arteriolar pressure to remain within its usual optimal range for matching supply to
demand. This mechanism may be insufficient to maintain flow at low perfusion
pressures, such as in the presence of a severe epicardial stenosis, where distending
pressure and myogenic tone are markedly reduced. This situation leads to a resetting
of the composition of the interstitial fluid such that the arterioles move into a
permanent state of "vasodilatation", exhausting the coronary vasodilator reserve
(Chapter 2, Section 2.3)
ii) Regulation of myocardial blood flow when myocardial oxygen consumption
changes
Vasodilatory metabolites such as ADP, adenosine, H+ and lactate vary in
concentration in the intracellular and hence extravascular compartments in relation to
myocardial metabolic activity (Berne & Rubio, 1979). Increased production of these
metabolites occurs with increased myocardial oxygen consumption, and thereby
arteriolar vasodilatation is produced and an increase in coronary blood flow occurs
with maintained perfusion pressure. Pre-arteriolar vessels vasodilate in response to
increased flow velocity in order to maintain optimal pressure across the arteriolar bed.
The mechanisms whereby these vessels dilate is uncertain although flow-mediated
release of EDRF has been postulated. An inability to vasodilate in response to flow
would diminish this metabolically-mediated vasodilatation, particularly in the
subendocardium which is more susceptible to a reduction in coronary flow. Thus, the
ability of the arteriolar vessels to match flow through resetting of the extravascular
fluid composition requires a relatively constant flow at origin.
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From this theoretical perspective, it is apparent that alterations in the autonomic
modulation of coronary flow and in endothelial function occurring as part of the
atherosclerotic process may lead to abnormalities in pre-arteriolar vasodilator
responsiveness, and thus, resistive vessel dysfunction. With pre-arteriolar
constriction or an inability to vasodilate adequately, and thus compensatory arteriolar
vasodilatation, there is a reduction in the coronary flow reserve. In addition, there is
also a reduction of pressure at the origin of the arteriolar vessels to maintain flow and a
sustained increase in interstitial adenosine concentration.
1.4.2. Autonomic Modulation of Coronary Blood Flow
The autonomic nervous system acts to modulate coronary blood flow through a
direct effect on coronary arteries which have a neural supply and through humoral
means by the release of adrenaline and noradrenaline. Epicardial coronary arteries
account for less than 5% of total coronary resistance under normal conditions (Forman
& Kirk, 1980). In the presence of coronary artery disease, the effect of the
sympathetic nervous system on epicardial vessels may assume a greater importance
because of coronary artery spasm and dynamic coronary artery stenoses (Maseri et al,
1987), and the wide acceptance of the importance of coronary vasomotion in the
genesis of stable angina (Deanfield et al, 1983), unstable angina (Vetrovec et al, 1982)
and myocardial infarction (Hackett et al, 1987). There are sympathetic neural efferents
to coronary vessels as small as 100 pim (Chilian et al, 1989b), which account for at
least 50% of coronary resistance. It remains entirely likely that alterations in
autonomic nervous system activity at the level of the coronary resistive vessels could
account for altered coronary blood flow in pathological disease states.
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1.4.2.1. g-Adrenergic Modulation of the Coronary Circulation
1. Resistive Vessels
Experimentally, it has remained difficult to demonstrate isolated a-adrenergic
vasoconstriction in the coronary resistive vessels because of the effect of sympathetic
nervous stimulation/noradrenaline infusion on heart rate and contractility, which lead
to an increase in myocardial oxygen demand and metabolic vasodilatation (Section
1.4.1.3). P-blockade as pre-treatment may diminish these cardiac effects but does not
remove the effect of the metabolic state on coronary autoregulation. Selective ai-
adrenergic agonists such as phenylephrine and methoxamine may induce
vasoconstriction in the coronary circulation (Williams & Most, 1980) and it is
generally accepted that stimulation of coronary a-adrenergic receptors causes
vasoconstriction, and may limit metabolic vasodilatation by 30% (Mohrman & Feigl,
1978). This is not necessarily a detrimental effect as a-adrenergic vasoconstriction
may lessen transmural steal during coronary hypoperfusion distal to a significant
epicardial stenosis. When flow becomes pressure-dependent (below the
autoregulatory range), a-adrenergic vasoconstriction in the subepicardium lessens
steal from the subendocardium presumably by competing more effectively with
metabolic vasodilatation in the subepicardium where ischaemia is less severe (Feigl et
al, 1987).
Coronary vasoconstriction occurs through stimulation of both post-synaptic ai-
and a2-adrenergic receptors (Woodman & Vatner, 1987). ai-adrenergic
vasoconstriction occurs throughout the coronary microcirculation but predominately in
the small arteries up to 250|im in diameter ("pre-arterioles"), whereas a2-adrenergic
vasoconstriction predominates in arterioles <100|im (in the absence of autoregulatory
escape) (Chilian et al, 1989b). However, in the presence of intact autoregulatory
mechanisms, dilatation occurs in the small arterioles (Chilian, 1991). The magnitude
of arteriolar a2-adrenergic vasoconstriction is three-fold that of ai-adrenergic
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vasoconstriction. This indicates a preferential number of 0C2-adrenergic receptors on
small downstream coronary arterioles, although the exact density and function of both
receptor subtypes on the endothelium and vascular smooth muscle remains uncertain
(Chilian, 1991). Thus, in summary, there is a heterogeneous response to a-
adrenergic activation in the coronary microcirculation.
Alpha-adrenergic constriction has been implicated in the causation of myocardial
ischaemia distal to a severe epicardial stenosis which may be due to ai- (Jones et al,
1986) or 0C2-mediated vasoconstriction (Heusch & Deussen, 1983). Reflex activation
of the sympathetic nervous system eg. following carotid sinus hypotension, elicits
peripheral vasoconstriction, increases cardiac contractility and heart rate but with
predominant coronary vasodilatation through increased cardiac metabolism with a
component of (relative) oc-adrenergic constriction (Feigl, 1967). With the converse,
a-adrenergic constriction is withdrawn, again with coronary vasodilatation. The
central modulation of this reflex arc is not well understood.
The role of reflex a-adrenergic vasoconstriction in the human coronary vascular
bed is of importance in elucidating the mechanism of enhanced vasoconstriction which
occurs in resistive vessels (Mudge et al, 1976) and in epicardial vessels (Raizner et al,
1980) in patients with coronary artery disease. Studies of animals undergoing
exercise have confirmed that a-adrenergically mediated vasoconstriction which
attenuates exercise-induced metabolic vasodilatation arises predominately from
circulating catecholamines (Chilian et al, 1986b). This vasodilatation is modulated by
ai-adrenergic vasoconstriction and by pre-synaptic a2-adrenergically mediated re¬
uptake of noradrenaline (Hendrickx et al, 1984). Thus, a-adrenergic vasoconstriction
acts as a brake to excessive vasodilatation such that myocardial function may be
limited. The afferent stimulus to this increase in a-adrenergic tone on exercise may
come from arterial baroreceptors, chemoreceptor reflexes and from central
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neurological sites, with an additional reflex arc from skeletal muscle afferents (Aung-
Din et al, 1981).
The role of the sympathetic nervous system in the control of basal coronary blood
flow is less well understood. However, in man, a-adrenergic receptor blockade
causes an increase in basal coronary blood flow perhaps implying tonic sympathetic
control of basal coronary flow (Orlick et al, 1978). In experimental studies however,
it remains controversial whether or not regional myocardial sympathectomy leads to an
increase (Holtz et al, 1977) or to no change in basal flow (Chilian et al, 1981) and its
transmural distribution. In conscious dogs, a-receptor blockade increases coronary
flow by only 30% (Macho et al, 1982), less than seen with other interventions,
suggesting that a-adrenergic sympathetic tone contributes in part to maintenance of
coronary flow at rest.
Recent work has demonstrated an inter-relationship between a-adrenergic
vasoconstriction and endothelial-dependent vasodilatation in the control of the
coronary microcirculation and which strengthens the hypothesis of pre-arteriolar
resistive vessel dysfunction as a mechanism for ischaemia in coronary artery disease.
In this study, Jones et al demonstrated in the beating dog heart model that coronary
microvascular vasoconstriction by both ai- and a2-adrenergic activation was
accentuated by inhibition of nitric oxide synthesis (Jones et al, 1993). This implied
that nitric oxide release modulated resting coronary microvascular tone, opposing the
constrictor action of catecholamines. It has been previously demonstrated that a.2-
adrenergic activation may induce endothelial-dependent vasodilatation in isolated
canine arteries (Cocks & Angus, 1983) and that both control mechanisms may interact
in the systemic circulation (Ohyanagi et al, 1992). In the normal state, the mechanism
whereby the endothelium may modify a-adrenergic vasoconstriction is through nitric
oxide release through the shear stress of increased coronary flow, thus limiting the
reduction in myocardial perfusion induced by this increased sympatho-adrenal drive.
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In pathological states such as hypertension (Panza et al, 1990), hypercholesterolaemia
(Drexler et al, 1991), diabetes (Saenz de Tejada et al, 1989) and ultimately
atherosclerosis (Zeiher et al, 1991), it is possible to see how endothelial dysfunction
may lead to the unopposed action of a-adrenergic vasoconstriction on the coronary
microcirculation and subsequent pre-arteriolar resistive vessel dysfunction (Section
1.4.3).
2. Epicardial Vessels
The significance of a-adrenergic tone in the vasomotor control of large epicardial
vessels is unclear. Even during a-adrenergic activation through stellate ganglion
stimulation and noradrenaline infusion in dogs, constriction of large coronary arteries
is only sufficient to increase their contribution to coronary resistance to 10% (Kelley &
Feigl, 1978). Alpha-adrenergic receptor selectivity is controversial and appears to be
species-specific. In dogs, a i-adrenergic constriction predominates in epicardial
vessels (Heusch et al, 1984), whereas both ai- and a2-adrenergic constriction of
large arteries occurs in calves (Young et al, 1988). Of greater interest, a2-adrenergic
receptors are present on the endothelial cell surface and their stimulation may mediate
the release of endothelium-derived relaxant factor (Cocks & Angus, 1983). In the
normal human coronary circulation, ai-adrenergic stimulation reduces flow (and
epicardial diameter) but a2-adrenergic blockade does not alter flow, implying no basal
a2-adrenergic vasoconstrictor tone (Indolfi et al, 1992). In contrast, in patients with
coronary artery disease, a2-adrenergic blockade with yohimbine reduced coronary
flow, possibly through noradrenaline stimulation of post-synaptic ai-adrenoceptors
(Indolfi et al, 1992).
Elevated sympathetic tone has been implicated in the causation of epicardial
coronary vasospasm (Yasue et al, 1974; Mudge et al 1976; Raizner et al, 1980).
Studies have shown that subcutaneous methacholine or adrenaline may induce
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coronary vasospasm demonstrated by ST segment elevation (Yasue et al, 1974) and at
angiography (Yasue et al, 1976) and may be prevented by phenoxybenzamine in
patients with variant (Prinzmetal) angina. Increased sympathetic activity has also been
implicated in the genesis of coronary spasm in patients with variant angina undergoing
angiography during cold pressor (Raizner et al, 1980), although autonomic stimulation
did not induce angina in patients who did not have variant angina. However, trials
with prazosin (the selective ai-adrenergic antagonist) (Winniford et al, 1983) or
phentolamine (Chierchia et al, 1984) failed to show a reduction in ischaemic episodes
in patients with variant angina. Furthermore, cold pressor, phenylephrine and
noradrenaline were ineffective in eliciting vasospasm despite a positive ergonovine
stress test (Chierchia et al, 1984). It may be that autonomic dysfunction is a highly
localised phenomenon occurring in large vessels perhaps where there is localised
atheromatous plaque with associated endothelial rupture and denudation and standard
methods of detection of ischaemia are insufficient in demonstrating this interaction
between the a-adrenergic component of sympathetic activity and coronary artery
disease.
1.4.2.2. p-Adrenergic Modulation of the Coronary Circulation
1. Resistive Vessels
P-adrenergic receptor stimulation may dilate resistive vessels by two mechanisms:
i) direct stimulation of vascular receptors, and ii) by increasing tissue metabolic
demand. P-adrenergic receptor activation leads to primary resistive vessel dilatation
measured as an increase in coronary sinus oxygen saturation with isoprenaline
(Klocke et al, 1965). With Pi-receptor blockade, although heart rate and contractility
may be reduced, the coronary vasodilator response to isoprenaline remains,
concluding that the major mechanism is through P2-receptor activation, confirmed by
direct P2-receptor stimulation (Vatner et al, 1982). Additional work has suggested that
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direct pi-receptor stimulation may also dilate coronary resistive vessels (Vatner et al,
1984). However, there is little evidence to show that electrical stimulation of
sympathetic nerves leads to P2-mediated vasodilatation (Hamilton & Feigl, 1976).
2. Epicardial Vessels
The functional importance of p-adrenergic receptors in the control of epicardial
coronary vasomotion is unknown. Larger epicardial coronary arteries are less
sensitive to P-adrenergic stimulation: canine coronary arteries less than 500 |im dilate
to adrenaline/noradrenaline whereas vessels greater than 1.5 mm constrict suggesting a
segmental divergence of a- and p-receptors in the coronary vascular bed (Ziiberbuhler
& Bohr, 1965). However, the response to neural activation of p-receptors in vivo is
not known. The predominant subtype in epicardial vessels is the Pi-receptor, with
p2-receptors predominating in the peripheral circulation. As described above, it is
difficult to distinguish between direct p-adrenergic activation/inhibition and the indirect
effects of changes in coronary blood flow and metabolism on the regulation of
epicardial coronary artery diameter (Macho et al, 1981). When coronary flow is held
constant, both Pi- and p2- selective agonists (prenalterol and pirbuterol, respectively)
induce epicardial vasodilatation (Vatner et al, 1986).
The effect of p-blockade on coronary artery diameter and coronary flow is
controversial. It has been reported that non-selective P-blockade with propranolol
worsens variant angina (Yasue et al, 1974), although it is no longer believed that this
is due to unopposed a-adrenergic vasoconstriction (Vatner & Hintze, 1983).
Coronary resistance is increased after propranolol in patients with coronary artery
disease (Kern et al, 1983) which suggests that irrespective of any effect on large
coronary arteries, p-receptors have a role to play in the coronary resistive vessels,
even if to counter the underlying effect of the a-adrenergic system on the coronary
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resistive vessels under normal circumstances and in patients with coronary artery
disease.
1.4.2.3. Cholinergic Modulation of the Coronary Circulation
1. Resistive Vessels
The role of the parasympathetic nervous system in the control of the coronary
circulation remains the least well defined of all the constituent parts of the autonomic
nervous system. As with the (3-adrenergic component of the sympathetic nervous
system, both coronary perfusion pressure and myocardial metabolic demand may be
altered by parasympathetic stimulation. In addition, the neural and humoral
components are different and wide differences exist between species. In anaesthetised
dogs, controlling for heart rate, left ventricular pressure, and arterial pressure,
parasympathetic activation by acetylcholine administration or vagal stimulation leads to
coronary vasodilatation (Feigl, 1969). In contrast, in the calf model, there is initial
vasoconstriction followed by dilatation with acetylcholine (Young et al, 1987).
However, in other species such as primates, acetylcholine causes vasoconstriction
(Sakai, 1981). Much of this difference may be explained by the balance between the
endothelium-dependent vasodilator and the vascular smooth muscle constrictor
components of acetylcholine.
2. Epicardial Vessels
Acetylcholine has a dual action in the coronary circulation. It is an endothelium-
dependent vasodilator at lower molar doses, but at higher doses, its direct smooth
muscle constrictor action becomes more prevalent (Furchgott & Zawadzki, 1980). In
the presence of endothelial dysfunction, the vasoconstrictor action persists. For this
reason, the major interest in clinical studies remains the role of the cholinergic system
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in the vasoconstrictor response of atherosclerotic coronary arteries to acetylcholine
(Ludmeretal, 1986).
There is little evidence that there is significant cholinergic neural activation of the
epicardial vessels, despite a rich parasympathetic innervation of the adventitia of these
arteries. It has been suggested that these nerves may modulate noradrenaline release
from sympathetic nerve endings (Vanhoutte et al, 1981), although there is no evidence
for this in humans (Kalsner, 1985).
1.4.3. Endothelial Modulation of Coronary Blood Flow
Endothelial cells produce and release factors which play a central role in the local
control of the circulation in any vascular bed. Both vasodilator and vasoconstrictor
substances are produced and under normal conditions, vasodilatation predominates
(Figure 1.4). In the presence of atherosclerosis and coronary artery disease, this
balance may be upset such that vasoconstrictive factors dominate and the anti-platelet
and anti-thrombotic properties of normally functioning endothelium are lost.
Since Furchgott and Zawadzki published their initial findings describing
endothelium-dependent vasodilatation to acetylcholine (Furchgott and Zawadzki,
1980), there has been a large body of research published defining the role of the
endothelium and its modulation of vascular smooth muscle tone and the control of
coronary blood flow. The major humoral factor which modulates this vasodilatation is
called endothelium derived relaxing factor (EDRF) and is thought to be nitric oxide
(Palmer et al, 1987), although it has been suggested that in vivo it may be a closely
related molecule such as S-nitrosocysteine, a nitrosothiol (Myers et al, 1990). It is
produced by endothelial cells from L-arginine by the enzyme, nitric oxide synthetase
(Palmer et al, 1988), but has a very short half-life limiting its effect to the immediate
vascular smooth muscle. EDRF may be released in response to a variety of different
stimuli; flow (shear stress), platelet-derived products (ADP, thrombin, serotonin) and
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Figure 1.4. Overall view of endothelium-derived factors and modulation of vascular
smooth muscle contraction. Endothelium-derived relaxing factor (EDRF) increases cyclic
GMP (cGMP) levels through activation of soluble guanylate cyclase. Prostacyclin (PGI2)
is another vasodilator released from the endothelium which stimulates adenylate cyclase,
and increases cyclic AMP (cAMP) levels. EDRF and prostacyclin could act
synergistically to relax vascular smooth muscle and inhibit platelet aggregation.
Endothelial cells also produce a hyperpolarising factor (EDHF) which is probably a
metabolite of arachidonic acid, such as an endoxide or lipoxide, and which is also a
vasodilator. Two endothelium -derived contracting factors exist; the first endothelial-
derived contracting factor (EDCFi) may be endothelin, and EDCF2 may be superoxide
anions. ACh = acetylcholine, 5-HT = 5-hydroxytryptamine (serotonin), ADP =
adenosine diphosphate, AA = arachidonic acid. M = muscarinic receptor, S =
serotonergic receptor, P = purinergic receptor, T = thrombin receptor, V =
vasopressinergic receptor (Modified from Vanhoutte & Shimokawa, 1989).
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hormones/vasoactive products (bradykinin, histamine, noradrenaline, substance P,
vasopressin) all stimulate production and release of EDRF. It acts on vascular smooth
muscle by activating guanylate cyclase to increase intracellular levels of cyclic
guanosine 3',5'-monophosphate (cGMP). This in turn inhibits agonist-induced
activation of the phosphoinositol pathway, which normally increases free calcium in
the cytosol (Vanhoutte & Shimokawa, 1989).
The interaction between endothelium and platelets is complex (Figure 1.4).
Prostacyclin (PGI2) is produced in the main by endothelial cells (Moncada & Vane,
1979) and is a potent inhibitor of platelet aggregation with a direct vasodilator effect on
vascular smooth muscle. Its mechanism of action involves the increased production of
cyclic adenosine 3',5'-monophosphate (cAMP). Low doses of PGI2 and EDRF
enhance the anti-aggregatory and vasodilator action of each other. EDRF is a potent
inhibitor of platelet adhesion and aggregation, and the release of ADP from platelets
induces further EDRF release. Serotonin and thromboxane A2 act directly on vascular
smooth muscle as vasodilators. In the coronary circulation, this interaction with
platelets in the presence of intact or normally functioning endothelium protects against
vasoconstriction, thrombus formation and the likelihood ofmyocardial ischaemia.
Another endothelial vasoactive compound is endothelium-derived hyperpolarising
factor (EDHF) (Vanhoutte & Shimokawa, 1989). This compound is less well defined
than EDRF and its existence is suggested by the demonstration that endothelium-
dependent relaxation to acetylcholine and the effect of acetylcholine on vascular
smooth muscle membrane potential is reduced by ouabain, an inhibitor of the sodium-
potassium ATPase, and independent of an EDRF action. EDHF may contribute to a
more sustained vasodilator action and thus complement the action ofEDRF. In certain
circumstances, the endothelium may release factors which cause vasoconstriction.
Endothelin is a potent vasoconstrictor peptide (Yanagisawa et al, 1988) which may
cause prolonged contraction of vascular smooth muscle (Hirata et al, 1988). Whether
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the endothelium-derived contracting factor described in hypoxic canine arteries is
endothelin is uncertain (Rubanyi & Vanhoutte, 1985). High local concentrations of
angiotensin II may also be produced by the endothelium (Dzau, 1986), which could
contribute to predominant vasoconstriction. Thus, in pathological states these
vasoconstrictor compounds could override the normal vasomotor tone associated with
endothelium-dependent vasodilatation (Liischer, 1989) (Figure 1.5).
1.4.3.1. Endothelium and Coronary Autoregulation
Although EDRF release is a universally demonstrated constituent of all vascular
beds, its activity varies in different vascular beds in terms of basal release, flow-
induced release and release by specific vasoactive compounds. This variability is
compounded by the fact that endothelial-active agents, acetylcholine for example, may
have a vasoconstrictor action on vascular smooth muscle.
Although much research into the physiological properties of EDRF has used
isolated vascular rings (from large vessels) in organ baths, it is the role of EDRF in the
control of the coronary microcirculation and on resistive vessel function that is ofmost
relevance in the study of the coronary microcirculation. By infusing an inhibitor of
nitric oxide production, forearm blood flow may be reduced implying tonic release of
EDRF as a modulator of basal arteriolar tone (Vallance et al, 1989). In the coronary
circulation, infusion of an inhibitor of nitric oxide production caused a small but
significant reduction in coronary blood flow in normal coronary arteries (Lefroy et al,
1993), indicating a basal release of nitric oxide in the coronary microcirculation to
maintain resting coronary flow.
A major determinant ofEDRF release at the level of the coronary resistive vessels
is that of coronary flow itselfwhich acts through shear stress on the endothelial cells.
The myogenic response which may be a component part of coronary autoregulation
(Section 1.4.1) would be uncontrolled ie, inappropriate vasoconstriction, were it not
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Aggregating platelets
Figure 1.5. Endothelium-dependent responses under pathological conditions such as
hypercholesterolaemia and atherosclerosis during platelet aggregation. Normally, EDRF
inhibits platelet aggregation and adhesion as well as platelet-induced vasoconstriction.
Less EDRF is released leading to a imbalance of vascular smooth muscle contraction,
secondary to serotonin and thromboxane A2 acting on smooth muscle independent of
endothelium. In atherosclerosis, both EDRF and prostacyclin production are reduced,
with little synergistic action against platelets. Abbreviations as Figure 1.4, except ATP =
adenosine triphosphate, TBA2 = thromboxane A2, MAO = monoamine oxidase (Modified
from Vanhoutte & Shimokawa, 1989).
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for the release of EDRF in response to the initial increase in flow occurring in
response to the increase in perfusion pressure. Thus, the degree of successful
autoregulation by the coronary resistive vessels is dependent on an intact normally
functioning endothelium and adequate production or release of nitric oxide (Griffith &
Edwards, 1990). It is of interest that the greatest amount of EDRF activity resides in
the pre-arteriolar vessels (>100 |im) which are under the most shear stress (Griffith et
al, 1987). Given the importance of these vessels in distributing perfusion to meet
tissue needs in the context of varying perfusion pressure, the integrity of EDRF
activity would seem to be important in avoiding the disturbance of myocardial
perfusion, occurring as an early manifestation of coronary artery disease (Section
1.4.3.2.2).
The heterogeneous response of the coronary resistive vessels to nitroglycerin is
further evidence for a functional distinction between pre-arteriolar and arteriolar
vessels. Nitroglycerin dilates resistive vessels >100 [im, but not the arterioles
<100|im because of the latter's inability to convert nitroglycerin to its vasoactive
metabolite. This occurs because the arterioles lack sulphydryl-containing compounds
such as cysteine to convert the nitroglycerin to a nitrosothiol, with subsequent
conversion to nitric oxide (Kurz et al, 1991). In this study, it was suggested that
arteriolar vascular smooth muscle cells have a markedly reduced sulphydryl "pool"
compared to larger vessels accounting for this heterogeneous vasodilator response.
1.4.3.2. Endothelial Function and Disease States
Because of the central role played by the endothelium in the control of tissue
perfusion, its function may be affected by the risk factors for cardiovascular disease.
This endothelial dysfunction may be the earliest manifestation of the disease process
and account for many of the abnormalities documented in regional tissue perfusion.
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1. Cardiovascular Risk Factors and Atherosclerosis
Risk factors such as hypercholesterolaemia and hypertension lead to an
impairment of endothelial function as has been shown in many different experimental
models. In a rabbit aorta model, low-density lipoprotein (LDL) inhibits endothelial-
dependent relaxation to acetylcholine (Andrews et al, 1987) as well as prostacyclin
production (Nordoy et al, 1978). Although LDL can impair EDRF activity directly,
the more prolonged effect of oxidised LDL may be on the cell membrane of the
endothelial cell diminishing receptor-mediated EDRF release (Kugiyama et al, 1990).
As this may have the effect of increasing local concentrations of LDL on the intimal
side of the media (Curmi et al, 1990), it is interesting to speculate that this may lead to
the local development of atheroma.
With the development of atheroma, endothelial-dependent relaxation to a variety of
different vasoactive agents is impaired (Verbeuren et al, 1986; Freiman et al, 1986;
Shimokawa et al, 1988). Acetylcholine infusion may even cause paradoxical
vasoconstriction in patients with coronary artery disease and in transplant patients
(Ludmer et al, 1986). In atherosclerosis, these changes may be accounted for mainly
by reduced EDRF release, but also by intimal and media changes, and often release of
an EDCF (Bossaller et al, 1987; Shimokawa et al, 1987). There is now much
evidence to show that the vasodilator responsiveness of the coronary resistive vessels
may be impaired not only by the atherosclerotic process but in the presence of
hypercholesterolaemia alone (Section 1.5).
In experimental models of hypertension, endothelium-dependent relaxation to
acetylcholine, ADP, and serotonin (Lamping & Dole, 1987) is impaired. Moreover,
there may be a relative excess of endothelin over EDRF in the resistive vessels of
hypertensive circulations compared to normal (Liischer et al, 1990). In clinical
studies, impaired endothelial-dependent vasodilatation has been described in the
forearms of patients with essential hypertension (Panza et al, 1990).
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2. Coronary Artery Disease
In experimental models, hypoxia and ischaemia inhibit EDRF production and
release (De Mey & Vanhoutte, 1983) and there is much clinical evidence to show that
endothelial dysfunction may contribute to myocardial ischaemia. Some patients with
localised epicardial coronary artery stenoses may sustain coronary spasm sufficient to
cause myocardial ischaemia (Maseri et al, 1975) and local endothelial dysfunction has
been implicated as the mechanism behind this phenomenon (Kaski et al, 1986).
Coronary spasm will occur at sites of endothelial denudation in response to agents
which normally cause endothelial-dependent vasodilatation but have direct
vasoconstrictor effects on vascular smooth muscle such as acetylcholine (Yasue et al,
1986), histamine (Shimokawa et al, 1983) and serotonin (Brum et al, 1984;
Shimokawa et al, 1987). In the clinical setting, platelet activation will release
endothelial-active agents such as serotonin, ADP and thrombin which may contribute
to this unopposed vasoconstriction in patients with variant angina.
Much more commonly, coronary artery disease is a diffuse process with more
than one discrete lesion affecting some or all of the main epicardial coronary arteries
with atheromatous lesions which are of variable morphology with a variable dynamic
component to each lesion. This complicated process will lead to a variable degree of
endothelial dysfunction in the epicardial coronary artery of interest and endothelial
denudation may exacerbate this situation. It has been demonstrated convincingly that
diseased epicardial coronary arteries will vasoconstrict to infusion of acetylcholine
(Ludmer et al, 1986) and serotonin (McFadden et al, 1991) and that with the latter
agent, the degree of vasoconstriction is greatest in the smallest epicardial arteries. In
porcine coronary arteries, endothelium denuded by gentle balloon injury regenerates
but with a response to endothelial-dependent vasodilators which remains impaired for
a prolonged period of time, and in this porcine model, with release of an excess of an
endothelium-derived constricting factor (Shimokawa et al, 1987). In addition to
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vasoconstriction of epicardial arteries with endothelial dysfunction, the inhibitory
effect of EDRF on platelet adhesion and aggregation is lost (Hogan et al, 1988),
exacerbating the effect of serotonin released from platelets and leading to a reduction in
coronary blood flow by an effect on the microcirculation (Golino et al, 1991).
In summary, the endothelium may undergo a functional change in response to the
physiological environment. This functional change may manifest as altered vasdilator
responsiveness which is only one component of the multifarious role of the
endothelium. Impaired endothelial function will also lead to an increase in leucocyte
adhesion and platelet aggregation and an alteration in the control of vascular smooth
muscle tone. There is a strong relationship between the coronary endothelium and the
atherosclerotic process. It is likely that the alteration in endothelial function which
occurs alters coronary resistive vessel function sufficient to cause change in their role
in coronary autoregulation and vasodilator responsiveness to pharmacological stimi
1.5 Resistive Vessel Dysfunction in Coronary
Artery Disease
Myocardial ischaemia occurs when perfusion pressure is so low at the origin of
maximally dilated arteriolar vessels that increased myocardial oxygen extraction cannot
compensate for the reduced coronary flow. This usually occurs in the presence of a
severe epicardial coronary artery stenosis. However, there are several observations in
experimental models and clinical studies to suggest that myocardial ischaemia may also
be caused by resistive vessel (pre-arteriolar) constriction. In this setting, myocardial
ischaemia on exercise may occur by two mechanisms i) an increase in myocardial
oxygen consumption above the coronary flow reserve and ii) arteriolar vasodilatation
with a reduction in intraluminal distending pressure, insufficient to oppose
extravascular pressure.
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The vasoactive peptides, neuropeptide Y and endothelin have been shown to cause
myocardial ischaemia in humans (Clarke et al, 1987) and conscious dogs (Larkin et al,
1989) respectively, with no demonstrable effect on epicardial coronary arteries.
Myocardial ischaemia may also occur through resistive vessel constriction following
high doses of intracoronary acetylcholine in angiographically normal coronary arteries
(Newman et al, 1990) and with serotonin in patients with coronary artery disease
(McFadden et al, 1991). This latter effect may also be exacerbated by the
vasoconstrictor action of serotonin on intramural penetrating arteries (mean diameter
200 (im) in the presence of a significant proximal stenosis, thus aggravating
subendocardial ischaemia (Bache et al, 1992). After emergency angioplasty,
ischaemia may occur due to microvascular constriction (Wilson et al, 1989) and this
vasoconstriction may be seen in visible distal vessels after an elective procedure
(Fischell et al, 1990). Even in patients with chronic stable angina, it has been shown
that inappropriate resistive vessel constriction may cause or contribute to causing
myocardial ischaemia (Pupita et al, 1990).
For inappropriate resistive vessel constriction to occur in the presence of
myocardial ischaemia, it is implicit that the potent compensatory vasodilator stimulus
of local metabolites is overcome, lending weight to the hypothesis that there is a
distinct functional heterogeneity of resistive vessels (Section 1.4.1.4). Although it
remains a possibility that inappropriate constriction of arteriolar vessels could account
for the resistive vessel constriction, this is most unlikely as it would require an
unrealistic constrictor stimulus in the presence of potent vasodilator metabolites such
as H+ and a low tissue pC>2.
There is increasing evidence to demonstrate that the atherosclerotic process affects
the coronary resistive vessels. In a recent study of the microcirculation using normal
and atherosclerotic monkeys, Chilian et al showed that serotonin (an endothelium-
dependent vasodilator) decreased coronary resistance in normal animals but increased
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large artery and microvascular resistance in atherosclerotic animals (Chilian et al,
1990a). Ergonovine, although elevating microvascular resistance in both animal
groups, increased large artery resistance in the atherosclerotic group. Atherosclerosis
however did not potentiate the response to phenylephrine (an al-adrenergic agonist).
Given that the response to adenosine was no different in the two groups, this implied
that atherosclerosis did not impair vascular smooth muscle responsiveness. In
conclusion, this study demonstrated that the atherosclerotic process was associated
with endothelial dysfunction. As the endothelium modulates microvascular responses
to vasoactive substances (Forstermann et al, 1987), and hypercholesterolaemia has
been shown to impair endothelial-dependent relaxation to ATP and acetylcholine in
larger arteries (Verbeuren et al, 1986), it was suggested that a similar mechanism
could occur in the microcirculation.
To investigate further the mechanism of effect of atherosclerosis on microvascular
function, isolated cannulated coronary arterioles (30-70 (im) from atherosclerotic and
normal pigs were studied using the endothelial-dependent agents, ADP, serotonin and
histamine (Kuo et al, 1992). These agents induced vasodilatation of only 20-30% of
controls, even then only at the highest doses. The response to flow was abolished in
denuded normal arterioles and in those from atherosclerotic animals. However,
administration of L-arginine (the substrate for synthesis of EDRF) restored to normal
the vasodilator response to pharmacological stimulation and to flow. In
hypercholesterolaemic animals, it appears that the availability of L-arginine is the rate-
limiting factor in EDRF production (Rubanyi, 1991), and it is thought that the
oxidised low density lipoprotein (LDL) cholesterol accumulating in the vascular wall
interferes with receptor-mediated release of L-arginine from intracellular stores or the
synthesis of the amino acid (Tanner et al, 1991). Thus, it was concluded that the
abnormality in arteriolar responsiveness developing with large vessel disease involved
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an impairment of the synthesis and/or release of the endothelium-derived relaxing
factor (Kuo et al, 1992).
The atherosclerotic process appears to have a similar effect on coronary vasomotor
tone in man. It has been demonstrated previously that normal epicardial vessels dilate
in response to increasing flow induced by the effect of intracoronary papaverine on the
resistive vessels (Drexler et al, 1989). In the same study however, this flow-
dependent coronary vasodilatation was reduced in atherosclerotic arteries. Zeiher et al
studied the coronary vasomotor responses to three different endothelium-mediated
stimuli; acetylcholine, increasing blood flow, and sympathetic activation by cold
pressor testing in different groups of patients (Zeiher et al, 1991). All three stimuli
elicited epicardial artery dilatation in patients with angiographically normal coronary
arteries and no cardiovascular risk factors. Subjects with normal arteries but
hypercholesterolaemia sustained vasoconstriction to acetylcholine. Patients with a
normal artery but with disease elsewhere showed both vasoconstriction to both
acetylcholine and cold pressor, with preservation of flow-dependent vasodilatation.
Patients with angiographic wall irregularities showed abolition of vasodilatation to all
three stimuli, thus indicating a hierarchy of impairment on endothelial-dependent
vasodilatation in epicardial arteries with progression of the atherosclerotic process.
With respect to the microcirculation, the dilator response to acetylcholine was
markedly reduced in patients with smooth epicardial arteries and
hypercholesterolaemia, compared to the other groups. Patients with smooth arteries
but disease elsewhere also showed a reduced response to acetylcholine, and this was
associated with those patients with raised LDL cholesterol. However, the dilator
response to papaverine (flow-dependent vasodilatation) was lower only in those with
macroscopic disease of the study artery compared to the control group. Cold pressor
testing decreased vascular resistance in normals and those with hypercholesterolaemia,
but it was increased in those with disease (Zeiher et al, 1991).
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In patients with hypercholesterolaemia and minimal irregularities of the epicardial
vessel wall, it is also possible to reverse this impairment in endothelial-dependent
resistive vessel dilatation with L-arginine. Using Doppler catheterisation, Drexler et al
have shown that infusion of L-arginine before intracoronary acetylcholine can restore
the vasodilator response of the myocardial region under study to that in
normocholesterolaemic patients (Drexler et al, 1991). In both patient groups, the
response to papaverine, an endothelium-independent vasodilator, was not impaired
and basal coronary flow was unaffected by L-arginine infusion, implying that it was
during vasodilatation that the deficit in EDRF production was most prominent (Drexler
et al, 1991).
Thus, there is progressive impairment in endothelium-dependent vasodilatation in
patients at different stages of early atherosclerosis. This endothelial abnormality may
precede atherosclerosis ie. in the presence of hypercholesterolaemia, or be an early
marker for the disease process. That this abnormality may alter the vasodilator
responsiveness of the coronary resistive vessels is of central importance to the
hypothesis of discordance between pre-arteriolar and arteriolar resistive vessels. Such
an impairment could be modulated by an increased sensitivity to neural or humoral
vasoconstrictor stimuli (Maseri et al, 1990) and account for insufficient vasodilatation
or inappropriate vasoconstriction of the pre-arteriolar vessels.
1.6 Existing Models of Resistive Vessel
Dysfunction
There is evidence to suggest that there is altered coronary resistive vessel function
in different pathological states which affect the cardiovascular system. In these
conditions however, there are several physiological variables which complicate the
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study of coronary blood flow and make the demonstration of coronary resistive vessel
dysfunction less clear.
1.6.1. Hypertension
Systemic hypertension, by definition, is associated with an increase in the
peripheral arterial resistance. However, even before the development of ventricular
hypertrophy, the alteration in systemic haemodynamics may affect coronary perfusion
pressure and myocardial oxygen demand, both determinants of basal coronary blood
flow. Theoretically, in hypertension however, even with a reduction in maximal
vasodilatation through hypertrophy, the increased perfusion pressure may normalise
the coronary reserve as maximal coronary flow will be comparable for the same
(autoregulated) basal flow.
In the presence of left ventricular hypertrophy irrespective of the primary cause,
the coronary flow reserve may be reduced. In one study, there was a 34% reduction
in the coronary flow reserve with dipyridamole (Strauer, 1979). Maximal
vasodilatation may be reduced by up to 50% in such patients and this marked
reduction in the coronary reserve can lead to chest pain (Opherk et al, 1984). This
reduction in regional myocardial blood flow in patients with left ventricular
hypertrophy has been demonstrated using positron emission tomography (Goldstein &
Haynie, 1990).
In hypertensive ventricles, the normal transmural distribution of coronary flow is
accentuated. In dogs with left ventricular hypertrophy at fast atrial pacing (200
beats-mim1), although flow increased similar to controls, there was a reduction in the
endocardial/epicardial ratio of flow (Mueller et al, 1980). At 250 beats-min-1,
subendocardial coronary flow reserve was exhausted, but with some residual reserve
in the subepicardium (Bache et al, 1981). Thus, resistive vessel function may vary
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across the myocardium in any one region of interest. However, current methods of
measuring coronary blood flow in man cannot discriminate transmural regional flow.
There are several mechanisms whereby the coronary reserve may be reduced in
left ventricular hypertrophy. Increased myocardial demand may increase basal flow
with no effect on maximal vasodilatation. The maximal cross-sectional area of the
resistive vessels does not generally increase in parallel with left ventricular mass such
that flow per gram at maximal vasodilatation may actually diminish (Tomanek et al,
1986). This imbalance is probably most severe when due to a pressure load (Marcus
et al, 1983a). Furthermore, with myocardial and vascular hypertrophy there may also
be a physiological derangement of coronary blood flow regulation contributing to the
reduction in flow reserve (Gradman, 1992). Elevated end-diastolic pressure in left
ventricular hypertrophy may also reduce maximal dilatation through extravascular
compression, particularly in the subendocardium (Ellis & Klocke, 1979). There are
also several additional factors which may determine the degree of impairment of the
coronary reserve such as the duration of hypertrophy and the stage of its development
(Marcus et al, 1981).
In the absence of hypertrophy, resistive vessel dysfunction may occur perhaps
secondary to the high perfusion pressure. Structural changes may occur with
hypertrophy of the vascular smooth muscle with subsequent thickening of the medial
layer, and thus a disproportionate reduction in luminal diameter in response to any
vasoconstrictor stimulus (Vogt et al, 1990). In one study, intravenous ergonovine
caused a increase in coronary resistance in patients with hypertension compared to
controls, which may suggest increased sensitivity of the pre-arteriolar vessels to
circulating vasoconstrictors (Brush et al, 1988). In the human forearm model, the
vasodilator effect of acetylcholine infusion is reduced in hypertensive patients,
although the response to nitroprusside was the same, implying impaired release or
production of EDRF by the forearm resistive vessels (Linder et al, 1990; Panza et al,
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1990). In the human coronary circulation, intracoronary acetylcholine causes marked
vasoconstriction in epicardial arteries of hypertensive patients with normal
vasodilatation to nitroglycerin, although this study did not determine if the abnormality
was at the level of the resistive vessels (Brush et al, 1992).
Hypertension and myocardial hypertrophy serve as model for resistive vessel
dysfunction although it is likely that this is only one factor contributing to the
impairment of coronary flow reserve in the absence of angiographic disease.
1.6.2. Cardiac Transplantation
After successful cardiac transplantation, the incidence of accelerated coronary
artery disease increases, with up to 50% of patients demonstrating significant
epicardial vessel stenoses by 3 years (Uretsky et al, 1987). The small and medium
sized epicardial arteries are also affected by this diffuse process making angiographic
assessment more difficult (Gao et al, 1988). The coronary flow reserve may be
impaired in transplant patients before the development of angiographic disease
however, and with positron emission tomography, it has been shown that this
impairment is due to a higher basal flow occurring because of hypertension and thus
an increased myocardial oxygen demand (Rechavia et al, 1992). However, maximal
vasodilatation to dipyridamole also tended to be lower than in controls. In patients
with angiographically normal arteries, the endothelium-dependent epicardial vessel
dilatation to substance P is preserved (Kushwaha et al, 1991), although epicardial
vessel constriction has been demonstrated to acetylcholine (Fish et al, 1988)
Measuring the resistive vessel response to endothelium-dependent vasodilatation in
transplant patients with early angiographic disease, Treasure et al showed that there
was a sequential reduction each year in the coronary vasodilator response to
acetylcholine when compared to the non-endothelium-dependent vasodilator,
adenosine (Treasure et al, 1992). It was believed that this reflected both a primary
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deterioration in endothelial cell function and underlying vasomotor insensitivity as
graft arteriosclerosis progressed. Using the endothelium-independent vasodilator,
papaverine, it is possible to show an impaired coronary vasodilator response in
transplant patients with minor occlusive disease compared to patients with
angiographically normal arteries or controls (Mullins et al, 1992).
Thus, in cardiac transplant patients with early atherosclerosis there is an
impairment of the coronary flow reserve. However, given the development of diffuse
disease of the distal epicardial vessels (Billingham, 1987), a significant degree of
coronary resistance must move proximally to these vessels and reduce the contribution
of normal or abnormal resistive vessel function to the impaired flow reserve.
1.6.3. Syndrome X
Syndrome X refers to a condition first defined by chest pain and a positive
exercise test in the presence of angiographically normal coronary arteries and the
absence of epicardial arterial spasm (Kemp et al, 1973). This controversial condition
may serve as a model of resistive vessel dysfunction, as an impairment of vasodilator
responsiveness (leading to a reduced coronary flow reserve) has been consistently
observed using pharmacological vasodilatation (Opherk et al, 1981; Bortone et al,
1989; Geltman et al, 1990; Camici et al, 1991a) and atrial pacing (Cannon et al, 1983;
Camici et al, 1991a). Although the nature of the resistive vessel abnormality remains
poorly defined (Cannon et al, 1988), syndrome X may represent be a wider
disturbance of resistive vessel function with altered vasodilator reserve also reported in
the forearm circulation of these patients (Sax et al, 1987). There is evidence to
suggest that endothelial function is altered in syndrome X patients (Motz et al, 1991),
and an association has also been suggested between syndrome X and the presence of
hyperinsulinaemia (Dean et al, 1991). Modulation of the coronary resistive vessels by
the sympathetic nervous system may be also be abnormal as chronic treatment with
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oral doxasosin, the oci-adrenergic antagonist, restores the coronary flow reserve to
normal in the subgroup of patients with a reduced reserve (Camici et al, 1991b).
Whether the resistive vessel abnormality gives rise to myocardial ischaemia in
syndrome X is much more controversial. In one study, patients experiencing typical
pain during pacing after intravenous ergonovine demonstrated a lower flow response
(and higher coronary resistance) than those without pain (Cannon & Epstein, 1988).
In this group with pain at pacing after ergonovine, there was an increase in myocardial
oxygen extraction suggesting an inadequate tissue delivery of oxygen, although only
10% of these patients demonstrated a net lactate production at pacing stress. Although
stress tests may cause chest pain and ECG changes characteristic for myocardial
ischaemia (>0.1 mV ST segment depression), the development of ventricular wall
motion abnormalities on echocardiography during exercise is controversial with
conflicting reports of the presence (Cannon et al, 1985) and absence of such changes
(Nihoyannopoulos et al, 1991). Using coronary sinus catheterisation and
measurement of myocardial substrate extraction, net lactate production at maximal
atrial pacing has not been documented despite ECG evidence of ischaemia (Camici et
al, 1991a). Furthermore, the chest pain of syndrome X is poorly controlled by
standard anti-ischaemic therapy (Cannon et al, 1992). Thus, an impaired coronary
flow reserve and myocardial ischaemia are not synonymous when studying resistive
vessel function.
In theory, a reduced coronary flow reserve could occur in the absence of
myocardial ischaemia if there was a concomitant reduction in cardiac work and thus
reduction in myocardial oxygen demand, or an increased extraction of metabolic
substrate such as oxygen. Given that left ventricular function remains normal at rest
and often after exercise/stress, there is no evidence for a reduction in myocardial
oxygen demand. In addition, at pacing, syndrome X patients achieve the same rate
pressure product as normals without increasing myocardial oxygen extraction, but
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with reduced energy expenditure measured by indirect calorimetry (Camici et al,
1991a).
The problem with syndrome X as a model of resistive vessel dysfunction is that it
is a heterogeneous group of patients dependent on inclusion criteria (Cannon et al,
1992), and consists of more than one pathophysiological entity. Thus, patients may
have low or normal flow reserve (Camici et al, 1992), an altered perception of pain
(Cannon et al, 1990) the presence or absence of left bundle branch block (Opherk et
al, 1989), a normal or hyperdynamic response to exercise (Camici et al, 1991a), or the
presence or absence of regional wall motion abnormalities on exercise (Cannon et al,
1985). For these reasons, although in a large subgroup of cases of syndrome X, there
may be resistive vessel dysfunction occurring secondary to an alteration in sympathetic
drive or as a primary microvascular abnormality, as a pure model of coronary resistive
vessel function, syndrome X remains a controversial subject for investigation.
1.7 Summary
The coronary resistive vessels are a major determinant of coronary blood flow and
myocardial perfusion. There are several physiological parameters which determine the
extent ofmyocardial perfusion under resting conditions and under stress. It has been
hypothesised that resistive vessels may be considered as two groups roughly
according to vessel size; a proximal compartment controlled by coronary flow,
intravascular distending pressure and myogenic tone and modulated by the autonomic
nervous system, and a distal compartment mainly influenced by the perfusion pressure
at origin and the composition of the interstitial fluid, and thus the metabolic state of the
myocardium. Myocardial perfusion and thus coronary resistive vessels are dependent
on the integrity and function of the endothelium. There is increasing experimental and
clinical evidence for inappropriate vasoconstriction or an an inability to vasodilate fully
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in the proximal "pre-arteriolar" coronary resistive vessels. Models exist of abnormal
resistive vessel function in patients with hypertension, after cardiac transplantation,
and in syndrome X. It is possible that both the effect of the early atherosclerotic
process on endothelial function and alterations in autonomic nervous control could
account for this abnormality in patients with coronary artery disease.
The intention of this thesis is to document the presence of abnormal coronary
resistive vessel function in patients with different manifestations of coronary artery
disease using Doppler catheterisation and positron emission tomography and to
determine the prevalence and possible mechanisms of this abnormality.
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CHAPTER 2. THE MEASUREMENT OF
CORONARY BLOOD FLOW
2.1 The Assessment of Coronary Blood Flow
The regulation of coronary blood flow has been studied extensively in animals
using experimental techniques which are highly accurate in terms of both temporal and
spatial resolution. As described in Chapter 1, techniques have also been developed in
animal models to study microvascular flow on the surface of the beating heart. By
comparison, many methods developed to study the human coronary circulation are
relatively crude and more sophisticated techniques are not widely available in clinical
practice. Thus much of what is known about the regulation of the human coronary
circulation has been derived from research done on other mammals. Although there is
much similarity between species under normal conditions, the regulation of the human
coronary circulation in disease is less well understood which accounts for the variety
of techniques employed to measure myocardial perfusion in man.
In the human heart, the ability of the resistance vessels to dilate or to constrict can
only be assessed indirectly from measurement of coronary blood flow. Coronary
blood flow can be measured invasively by Doppler flow catheter and quantitative
angiography (Wilson et al, 1985), or by coronary sinus thermodilution (Ganz et al,
1971). However, these techniques measure blood flow through a single coronary
artery branch and through the coronary sinus or the great cardiac vein, respectively,
and so do not allow the comparison with reference myocardium perfused by normal
vessels in the same patient at rest and during interventions (Marcus et al, 1987).
Myocardial blood flow (MBF) can also be measured non-invasively by positron
emission tomography (PET) (Bergmann et al, 1985). This technique has two
important advantages over the above methods. Firstly, it provides a measure of the
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regional distribution of flow for the entire left ventricular wall and allows comparison
of perfusion in the myocardial region of interest with a region perfused by normal
arteries. Thus, it allows the vasodilator or vasoconstrictor response of the vascular
segment under study to be compared with the effect of the stimulus on adjacent normal
coronary vascular segments. Secondly, being non-invasive, it allows repeated
assessment of the vascular response in tissue.
2.2 Limitation of Arteriographic Techniques
The anatomical significance of epicardial coronary artery disease may be
documented by analysis of coronary arteriograms. However, large intra- and inter-
observer variability exist with visual inspection of arteriograms. Despite the use of
computer-assisted edge-detection methods (Brown et al, 1977) to reduce the error and
inaccuracy of visual assessment (Hoffman, 1984; Klocke, 1987), poor correlations
still exist with post-mortem evaluation of coronary stenoses (Grondin et al, 1974).
Furthermore, there is a poor correlation between anatomical estimate of the severity of
a coronary stenosis and any physiological measurement of the functional significance
of the stenosis (White et al, 1984; Harrison et al, 1984). This is particularly true for
lesions in the range of diameter stenoses 50-90% (Klocke et al, 1987) ie. those of
most interest in determining functional significance.
Many of the problems relating to anatomical assessment occur because of the
limitation of arteriography in reconstructing a three-dimensional lesion. Thus, the
orientation of the vessel to the X-ray planes, stenoses at curvatures of the native vessel
and asymmetrical narrowing lead to inaccuracy. Because the effective resistance at the
site of the stenosis is proportional to the fourth power of the radius, small changes in
radius beyond the resolution of arteriographic assessment may cause larger changes in
resistance, particularly in more severe stenoses. Problems also arise when describing
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the stenosis as a percentage of normal as many adjacent "normal" segments are
affected by diffuse disease leading to an underestimation of stenosis severity. The use
of intravascular ultrasound to document early atherosclerotic changes may indicate
such disease in adjacent segments, but the problem still remains of predicting
functional significance of lesions. There is a complex non-linear relationship between
pressure gradient across a stenosis and flow through the stenosis which becomes
accentuated with the increase in the severity of the stenosis. Because of this, the
effective resistance of even a rigid stenosis (without a dynamic component) increases
with an increase in myocardial oxygen demand ie. flow requirement.
Minimum luminal diameter is an absolute measurement but does not take into
account the large variability in coronary artery diameter in normal subjects. Moreover,
the eccentricity and irregularity of a lesion will determine the transtenotic pressure drop
for a given luminal diameter due to flow separation and shear stress (Sibley et al,
1986; Wilson et al, 1987), causing much variability for the same absolute diameter.
Estimates of the minimal cross-sectional area are complicated by uncertainty over the
predicted reference area at the same point in a non-diseased artery, particularly in
eccentric lesions.
These problems with conventional arteriography are compounded by the variables
which, with epicardial coronary diameter, determine myocardial perfusion such as
mean aortic pressure (perfusion pressure), venous pressure, collateral blood flow,
resistive vessel function in the distal vascular bed and intra-ventricular wall stress
(Kirkeeide et al, 1986). These variables assume even greater importance in the
presence of a significant epicardial stenosis with progressive vasodilatation of the the
vascular bed distal to the obstruction (Klocke, 1987).
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2.3 Maximal Vasodilatation and the Coronary
Vasodilator Reserve
The coronary flow reserve (or the coronary vasodilator reserve) has been
proposed as an objective measurement of the vasodilatory capacity of the coronary
resistive vessels, which regulate myocardial perfusion modulated by neural and
metabolic influences. This was defined as the ratio of maximal coronary blood flow to
basal coronary blood flow, ideally for a given perfusion pressure, by Gould in 1974
(Gould et al, 1974). Its validity has been confirmed and applied using different
techniques such as coronary sinus thermodilution (Ganz et al, 1971), Doppler
catheterisation (Wilson et al, 1985), and positron emission tomography (Bergmann et
al, 1985) using a pharmacological stress such as intravenous dipyridamole or
intracoronary papaverine.
Coronary vasodilator reserve has been widely used as a physiological
measurement of the severity of a coronary artery stenosis, including all of its geometric
characteristics (Kirkeeide et al, 1986). The ultimate effect of a coronary stenosis
depends on the degree to which the increased impedance to flow is compensated for by
vasodilatation at the level of the resistive vessels - the "reserve". Thus, the coronary
vasodilator reserve may be seen in terms of autoregulation: the ability of the coronary
vascular bed to maintain coronary flow at a constant level in the presence of a potential
decrease in coronary perfusion pressure at a constant myocardial oxygen demand
(Klocke, 1987) (Figure 2.1).
The coronary vasodilator reserve has a pharmacological maximum of around 5-6
times in man under conditions of a normal aortic pressure (Gould et al, 1990). It has
been estimated from extensive animal studies that with the development of a 40%
diameter stenosis, the coronary vasodilator reserve starts to diminish such that with a
































Figure 2.1. Steady-state relationship between coronary flow and coronary arterial
pressure in the left ventricle. The solid line describes the normal relationship. At a
constant level of myocardial metabolic demand, coronary blood flow is maintained
constant over a wide range of coronary perfusion pressure, between the boundaries of
maximal vasodilatation and vasoconstriction. The black circles represent the basal
state and maximal blood coronary flow under normal conditions, giving a coronary
vasodilator reserve of 5.0. Pra = right atrial pressure, Pf=o = pressure at zero flow
(the back pressure opposing coronary flow). (Modified from Klocke, 1987)
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Figure 2.2. The relationship between basal coronary blood flow and maximal
coronary blood flow in dogs. With progressive acute epicardial coronary stenosis,
basal flow did not change until the coronary stenosis diameter exceeds 80% stenosis.
Maximal coronary blood flow decreases from the development of a 50% stenosis
(Modified from Gould et al, 1974).
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start to diminish, ie. the point at which autoregulatory vasodilatation is maximal
(Gould et al, 1974).
The coronary vasodilator reserve, whether used to describe the functional
significance of an epicardial stenosis or used as an objective measure of the
vasodilatory capacity of a myocardial region, may be altered by many different factors.
When used to measure functional stenosis severity, because of the non-linear
relationship between trans-stenotic pressure gradient and stenosis severity, a
progressive non-linear reduction in vasodilator reserve is seen (Figure 2.2). There are
three variables which need to be taken into further consideration when measuring the
coronary vasodilator reserve at a given point in time; i) the coronary perfusion
pressure, ii) the basal flow, and iii) the pressure-flow relationship during maximal
vasodilatation.
i) Modest changes in aortic pressure can have a significant effect on maximal flow
because of the steepness of the pressure-flow relationship during maximal
vasodilatation. Alternatively, small dynamic changes at the site of a severe stenosis (or
passive collapse of the stenosis due to distal vaodilatation) leading to a reduction in
perfusion pressure may reduce reserve to a significant degree.
ii) Basal flow varies directly with myocardial oxygen demand (largely dependent
on heart rate, contractility and myocardial wall tension), and as the denominator of
coronary vasodilator reserve, a small increase in basal flow may reduce the derived
value of vasodilator reserve accordingly. The control of basal coronary flow is
determined by coronary autoregulation ie. pressure-dependent changes in vascular
resistance, and tissue metabolism (Chapter 1, Section 1.4) (Figure 2.1).
iii) The pressure-flow relationship at maximal dilatation may be altered by several
factors. Chronic hypertrophy may reduce the slope of this relationship considerably
(Figure 2.3), such that a 30% increase in ventricular mass may lead to a 60% reduction
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Figure 2.3. Mechanisms whereby the coronary vasodilator reserve may be altered.
The basal coronary flow may increase with an increase in myocardial metabolic
demand. Maximal vasodilatation may be reduced by an increase in heart rate or
contractility, increased blood viscosity, and by resistive vessel dysfunction (in this
case from 5.0 to just over 3.0). With hypertrophy, if coronary blood flow is
measured as total flow (ml-mim1), then maximal vasodilatation may be approximate to
control values but with an increase in basal flow because of the increase in muscle
mass. If measured as flow per unit mass (ml-min^-g1) as depicted in the figure, then
maximal vasodilatation is reduced and basal flow per unit mass the same as controls
(Hoffman, 1987). With a reduction in perfusion pressure, usually caused by
epicardial disease, a third variable is introduced. Coronary artery stenoses are the
open circles expressed as % diameter stenoses. The horizontal distance along the
autoregulatory range from control to stenosis is the trans-stenotic pressure gradient,
which has a non-linear relationship with diameter stenosis. Thus, resistive vessel
dysfunction due to epicardial disease may compound an already compromised





















Figure 2.4. The presence of coronary artery disease adds to the complexity of the
coronary vasodilator reserve as a concept. Increasing myocardial oxygen demand eg.
with atrial pacing increases basal flow vertically in control subjects for a given
perfusion pressure. With epicardial disease, the increase in flow leads to an increased
pressure gradient across the lesion, as trans-stenotic gradients vary with flow (as well
as with the degree of stenosis). With greater stenosis severity, the increase in basal
flow is progressively limited, such that in the example, there is little increase in flow
with an 80% stenosis ie. "exhaustion of reserve". With a 90% stenosis, flow is
reduced. This is caused by the shift in the lowermost part of the pressure-flow
relationship to the right. An increased heart rate does this by reducing diastolic filling
time and increasing time-averaged compressive forces, the latter also augmented by
increased contractility and hypertrophy. Increased preload increases Pf=o and Pra-
(Modified from Klocke, 1987).
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in contractility, preload, or heart rate may reduce maximal dilatation. An increase in
left ventricular end-diastolic pressure (LVEDP) reduces maximal vasodilatation, and at
low coronary perfusion pressures, this effect is accentuated such that at a perfusion
pressure of 30 mmHg (= 85% stenosis) an elevation of LVEDP from 10 to 15 mmHg,
would result in a 30% reduction in maximal flow. Tachycardia may reduce maximal
dilatation by reducing diastolic filling time, notwithstanding the increase in myocardial
oxygen demand and thus basal flow. It has also been shown that the effect of heart
rate on maximal dilatation is greatest in the subendocardial layers because of the direct
compressive effect of systolic contraction (Bache & Cobb, 1977). Other factors
affecting coronary vasodilator reserve through an effect on maximal vasodilatation are
blood viscosity and the extent of collateral flow which is difficult to quantify but which
may be recruited by pharmacological agents (Klocke, 1987).
Coronary vasodilator reserve remains highly reproducible in the same subjects
studied several months apart using intracoronary Doppler catheterisation (Section
2.4.2.4), with any differences between study related to changes in heart rate rather
than mean arterial pressure (McGinn et al, 1990). In one study investigating the
haemodynamic determinants of the coronary vasodilator reserve, atrial pacing led to a
rate-related increase in basal flow but with no reduction in maximal flow at a rate of
120 beats-min"1. A similar increase in basal flow was seen with volume expansion (an
increase in preload), but with no effect on maximal flow. Increasing mean arterial
pressure with handgrip caused a proportionate rise in basal and vasodilator flow
(McGinn et al, 1990) and a maintenance or the coronary vasodilator reserve. This
confirms the importance of interpreting coronary vasodilator reserve measurements
talcing into account the haemodynamic conditions at the time of study.
It is often assumed in clinical studies that the coronary vasodilator reserve is a
globally homogeneous measurement with regional differences which occur perhaps as
a consequence of epicardial disease or altered myocardial function. Animal studies
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have suggested that there is marked spatial heterogeneity between different small
regions of myocardium both under basal at maximal conditions (Austin et al, 1990).
Regional coronary vasodilator reserve to adenosine may vary from 1.75 to 21.9 with
no relationship between basal and maximal flow. However, in this study using
microspheres, basal coronary flow and reserve appeared to be locally continuous
perhaps defining functional zones of vascular control and vulnerability to ischaemia
(Austin et al, 1990). With improvement in techniques used to measure myocardial
perfusion in clinical studies, these observations may have implications in determining
the control of regional microvascular function.
2.3.1. The Absolute and Relative Coronary Flow Reserve
Conventionally, with the development of proximal coronary disease to a
significant degree, coronary resistance would be determined by the geometry of the
lesion with a compensatory vasodilatation in the resistive vessels to maintain basal
myocardial perfusion and the increased perfusion in response to increased myocardial
demand (Gould et al, 1974). However, percent diameter stenosis is poorly related to
the functional severity of the coronary obstruction at quantitative angiography (Demer
et al, 1989) or the coronary vasodilator reserve at Doppler catheterisation (White et al,
1984). Cardiac workload (and thus myocardial oxygen consumption) may be affected
by changes in aortic pressure (coronary perfusion pressure) and heart rate leading to
changes in the basal coronary flow and ultimately maximal vasodilatation (Gould et al,
1990). Thus, the absolute coronary vasodilator reserve may be affected by these
determinants independent of stenosis geometry. This may diminish the value derived
under varying physiological conditions and diminish valid comparisons between
different patients. This has lead to the concept of the relative coronary vasodilator
reserve which is the maximal coronary flow in the index artery/region divided by the
maximal coronary flow in the control artery/region. As this ratio cancels out the effect
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of the prevailing physiological conditions on coronary flow in both regions, this
relative value reflects geometric stenosis severity, as long as there is maximal
vasodilatation in the control region.
The ability to measure absolute and relative coronary vasodilator reserve is one of
the major advantages of positron emission tomography. The quantitation of
myocardial blood flow at basal and at maximal vasodilatation in the region of interest
allows calculation of the absolute vasodilator reserve and the comparison with a
control region determines the relative vasodilator reserve, thus providing
complementary information in the same study.
Until the development of positron emission tomography, all methods used to
measure basal and maximal coronary blood flow, and thus the coronary vasodilator
response, were invasive thus interfering with true basal flow either through
instrumentation or injection of contrast, thus leading to an underestimation of this
ratio. It has also been argued that the coronary vasodilator response may appear
diminished due an increased basal flow in certain conditions such as left ventricular
hypertrophy or valvular disease where it is argued that "vascular function" is normal
(Hoffman, 1987).
This argument has led to the proposal that it is maximal myocardial blood flow
alone that determines the functional status of the coronary circulation (Pijls et al,
1990), and that it is independent of other confounding variables. This view however,
ignores the fact that the earliest sign of resistive vessel dysfunction may be a change in
basal myocardial blood flow per se, before maximal flow is affected.
2.3,2. Pharmacological Vasodilatation
Many different stimuli have been used to achieve maximal coronary vasodilatation
in order to assess the coronary vasodilator reserve. Using atrial pacing (Holmberg &
Varnasukas, 1971), and intracoronary hyperosmolar contrast media (Bassan et al,
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1975) or intravenous isoprenaline (Horwitz et al, 1974), values of between 2-2.5 have
been achieved which is well below maximal vasodilatation (Gould et al, 1990). With
maximal exercise, coronary blood flow increases from 2-3.9 times control values
(with a reduction in coronary resistance to 36% of basal) (Holmberg et al, 1971).
However, such an increase in flow may not be maximal as it is possible to increase
flow by another 35% in dogs after maximal exercise with dipyridamole (Barnard et al,
1979). This is evidence of the dissociation between vasodilatation due to an increase
in myocardial demand and that due to a pharmacological stimulus.
The maximal coronary flow possible is probably the hyperaemic flow seen after a
20 second occlusion of an epicardial coronary artery at surgery which leads a coronary
vasodilator reserve of 5.5-6.3 (Marcus et al, 1981). The coronary vasodilator reserves
of 3.0-5.0 seen following pharmacological dilatation with intravenous dipyridamole
(Brown et al, 1981), with the addition of isometric handgrip, give the most easily
obtainable maximal values in the non-invasive environment. The most widely used
pharmacological vasodilators are intravenous dipyridamole and adenosine, and
intracoronary papaverine.
1. Dipyridamole
Dipyridamole is an adenosine deaminase inhibitor and by blocking uptake of
adenosine produced locally by red blood cells, platelets and endothelium, potentiates
the activity of adenosine. Adenosine then acts directly on vascular smooth muscle on
the Pi-purinergic receptor coupled to the adenylate cyclase enzyme. Systemic effects
include a fall in arterial blood pressure and an increase in heart rate. Distal to a
coronary artery stenosis, blood redistributes from the endocardial to the epicardial
layers - transmural coronary "steal" associated with a fall in distal perfusion pressure.
It has been argued that dipyridamole induces less than maximal dilatation in as
many as 25% of normal subjects and thus elicits a lesser coronary vasodilator reserve
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than intracoronary papaverine (3.7 vs. 4.4 respectively) (Rossen et al, 1991). For this
reason, many advocate the use of isometric handgrip to increase systemic vascular
resistance and thus increase aortic pressure and coronary perfusion pressure (Brown et
al, 1981; Rossen et al, 1989). Others advocate using a dose higher than the standard
(0.56 mg-kg-1 over 4 minutes) by adding another 0.28 mg-kg-1 (Picano et al, 1991).
There is also a variability in the time to peak effect of dipyridamole in different patients
(Wilson et al, 1985).
Another limitation with dipyridamole is that it has a longer duration of effect (over
20 minutes) than other vasodilators often making quick serial studies during the same
procedure impossible, although if only being used once eg. at PET scanning, this is
not such a problem. Dipyridamole is well tolerated as a vasodilator although some
patients suffer chest pain, headache and dizziness, it remains the most widely used
vasodilator for perfusion imaging.
2. Adenosine
Adenosine is usually given at a dose of 140 jig-kg^-min"1 and is said to elicit a
similar vasodilator response as intracoronary papaverine (Wilson et al, 1990).
Adenosine and dipyridamole produce similar haemodynamic effects when given by
intravenous infusion. It has been argued that adenosine gives maximal vasodilatation
with less individual variability in response compared to dipyridamole (Wilson et al,
1990). However, more side effects are reported with adenosine requiring
intervention, 9% in one study (Nishimura et al, 1992), and there is the increased
tendency to develop atrio-ventricular node inhibition in a small number of patients,
albeit transient and asymptomatic (Nishimura et al, 1992). It has been proposed that
the effect of adenosine is consistent and near-maximal (Wilson et al, 1990), perhaps
suggesting an advantage over dipyridamole. However, in one prospective study using
PET, no difference in the vasodilator response to either agent was found (4.4±0.9
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ml-min ^g1 with adenosine vs. 4.3±1.3 ml-min^-g1 with dipyridamole), with a
similar range in the individual coronary vasodilator reserve (2.0-8.4 for adenosine vs.
1.5 to 5.8 for dipyridamole) (Chan et al, 1992). To date, no one study has
convincingly shown that adenosine is superior to dipyridamole as an intravenous
coronary vasodilator stimulus.
3. Papaverine
Papaverine is an opiate derivative which is produces direct relaxation of arteriolar
smooth muscle. It has become a widely used vasodilator for measurement of the
coronary vasodilator response using Doppler catheterisation when given intracoronary.
This is because it produces rapid maximal vasodilatation (at 15 seconds) returning to
10% of basal values within 128 seconds (Wilson et al, 1985), compared to over 4
minutes with dipyridamole which has a duration of action of over 30 minutes.
Although maximal vasodilatation may be dose-dependent (ranging from boluses of 6-
12 mg), the hyperaemic period is sufficiently brief to allow repeat measurements.
Given intracoronary, there are only minimal systemic haemodynamic effects (Wilson
et al, 1985). However, in dog studies, although producing equivalent coronary
vasodilatation to intracoronary adenosine, ST segment depression, QT interval
prolongation (and occasional ventricular fibrillation) and lactate production are found
with intracoronary papaverine (Christensen et al, 1991). Furthermore, papaverine
also causes a bizarre double contraction-relaxation effect perhaps by an inhibitory
effect on oxidative phosphorylation or on calcium uptake (Christensen et al, 1991).
For these reasons, current practice has moved towards the use of intravenous
dipyridamole and intracoronary adenosine.
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2.4 Methods of Measuring Myocardial Blood
Flow
It is important to make an early distinction between myocardial blood flow, which
is the perfusion of a finite volume (or mass) of myocardium by a volume of blood per
unit time, and coronary blood flow, which is the volume of blood per unit time
flowing down an epicardial coronary artery. Although in normal subjects the two may
be approximate, it is important to draw a distinction in disease states as with changes
in myocardial mass, the two may become dissociated, particularly as the determinants
of proximal flow and distal perfusion may have changed.
Flow may be measured with three different methods in animal models which are
more accurate than what is generally practicable in human subjects.
2.4.1. Laboratory Methods
2.4.1.1. Electromagnetic Flow Measurement
This method uses the principle of induction where blood acts as a moving conductor in
a magnetic field placed perpendicular to the direction of flow, producing an induced
voltage proportional to the amount of flow. This method is accurate and integrates
flow across the whole vessel but the probes are large and require to be implanted into
the wall of the vessel. Calibration is also difficult with this technique, particularly
when used intra-operatively placed on vein bypass grafts because of poor vessel
contact and changes in distending pressure. This method is no longer used in clinical
practice.
2.4.1.2. Epicardial Ultrasonic Flow Velocity Measurement
Reflection of ultrasound waves emitted from a piezo-electric crystal from moving
red blood cells occur at a given frequency according to the Doppler equation:
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fd = 2fo • vcos a
c
where fd is the frequency shift, fo the frequency of emitted waves, v the velocity of
the red blood cells, a the angle of the ultrasound waves relative to the direction of flow
and c the velocity of ultrasound in blood (c. 1,500 m-s_1)- This method is used in
exposed coronary arteries (Marcus et al, 1981) usually as a circular probe. The
diameter of the vessel should be considered to allow calculation of absolute coronary
flow. Flow at one point is determined at the centre of the flow wave and assumes
laminar flow; thus the calculated flow is proportional to rather than equal to actual
flow.
These two methods correlate very well with each other and have the advantage of
allowing a high frequency response and unlimited measurements.
2.4.1.3. Microspheres
These radio-labelled particles are usually injected into left atrium and are of
sufficient size to become trapped in the coronary capillary network, subsequently
measured using a gamma counter after animal sacrifice. Myocardial flow is expressed
as a ratio to flow taken from a peripheral arterial sample at the same time as injection
(Buckberg et al, 1971). This method allows quantitation of transmural myocardial
perfusion but is limited by a low frequency response, loss of microspheres, few
separate measurements allowable, and radiation exposure.
2,4.2. Clinical Methods
Methods for measuring myocardial and coronary blood flow which are applicable
to man are less accurate, generally not widely available (Marcus et al, 1987), and may
put the patient at a small but additional risk because of the invasive nature of the
method in question. However, in clinical terms, the major derivative is often what
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relative changes there have been in flow or perfusion, rather than absolute
measurements of coronary flow.
2.4.2,1. Coronary Sinus Thermodilution
The principle of thermodilution to measure cardiac output was first developed
using a flotation balloon catheter in the pulmonary artery by Swan and Ganz, and has
also been applied to the measurement of coronary venous blood flow by insertion of a
thermodilution catheter into the coronary sinus (Ganz et al, 1971). Although this
method involves only right heart catheterisation, coronary flow is assessed only in the
territory of the left anterior descending artery. Regional left ventricular flow
measurements are confined to crude separation of great cardiac (anterior) vein flow
(anterior wall and septum) and perfusion draining to the distal coronary sinus. Even
then, the venous drainage of left ventricle is variable with substantial venous
collaterals, meaning in effect that drainage alone from the great cardiac vein is an
accurate representation of left anterior descending (LAD) artery flow under basal
conditions (Rossen et al, 1992). Following LAD occlusion and hyperaemia, great
cardiac vein flow underestimated both the decrease and the increase in flow (Cohen et
al, 1988). A steady state is essential as several seconds are required to measure flow
and thus phasic flow cannot be measured. Inaccuracies arise from inadequate mixing
of indicator and blood along with coronary sinus reflux. In contrast to in vitro studies,
the technique has been poorly validated in the in vivo situation (Mathey et al, 1978;
Pepine et al, 1978). Furthermore, it has been demonstrated that coronary sinus
thermodilution consistently underestimates coronary vasodilator reserve compared to
Doppler catheterisation in the same patients (Rossen et al, 1992).
Substantial alterations in flow of the order of 25-30% are required for accurate
measurement, and in coronary artery disease, reliability markedly diminishes (Marcus
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et al, 1987). For this reason, the technique should only be used in patients with
normal coronary arteries where large changes in coronary flow are expected.
2.4.2.2. Gas Clearance Methods
The principle of this method is similar to that of coronary sinus thermodilution. Inert
gases may be given by inhalation (non-radioactive helium/argon) or intracoronary
injection (133Xe) and an arteriovenous difference occurs across the coronary vascular
bed due to myocardial extraction. Myocardial perfusion may be calculated from the
uptake and washout of gas with the measurement of coronary arterial and venous
samples (Marcus et al, 1987), but similar limitations to the thermodilution method exist
such as the inability to measure rapid changes in flow and the problems of variable
venous drainage. Spatial resolution has been improved with the use of 133Xe although
because of its high fat solubility, only a limited number of studies can be done.
Furthermore, accurate timing of any intervention is required because of the long time
constant of the method and accuracy is reduced at higher flow rates (Maseri et al,
1977). Consequently, these problems have limited the widespread use of this method.
2.4.2.3. Videodensitometry
The changes of contrast density in the myocardium after the intracoronary power-
injection of contrast may be measured and used to calculate coronary flow using the
indicator dilution theory. This principle was first described in in saphenous vein grafts
by Rutishauser and co-workers in 1967 who used the technique with respect to flow
(Rutishauser et al, 1967), but avoided the need to know the exact amount of indicator
injected into the graft, as was necessary for previous methods in the systemic
circulation. In this method, flow may be calculated from the mean transit time of a
contrast bolus through a measured length and diameter of an arterial segment
(Rutishauser et al, 1967). However, when applied to the coronary circulation, the
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method was less accurate because of the complex three-dimensional course of native
arteries with multiple branch points.
Using ECG-triggered subtraction imaging to enhance visualisation of myocardial
contrast passage, myocardial flow in a region of interest may be calculated from the
time-density curve. Analysis of the changes in contrast density and description of this
curve to calculate the mean transit time using digital subtraction angiography has
improved the spatial resolution of this technique (Vogel et al, 1984). In one of the first
validation studies, Hodgson et al compared contrast density/appearance time ratios
with vasodilator reserve measured by an electromagnetic flowmeter and demonstrated
a correlation of R=0.92 (Hodgson et al, 1985). However, 95% confidence limits
ranged from 1.2 to 2.7 at a vasodilator reserve of 2.0, and a similar spread has been
reported by others (Cusma et al, 1987)
The problems with this method are that the contrast agent itself induces a
hyperaemic response (a biphasic effect), even when using non-ionic iso-osmolar
agents such as Iohexol-140. This may be worsened by reflux of contrast into the aorta
and distribution into different branches of the coronary vascular bed. This makes the
accurate measurement of basal myocardial blood flow almost impossible. Contrast
media is a poor vasodilator with a variable dose-response relationship between
patients, and the peak flow effect may be missed; the use of intracoronary papaverine
as a vasodilator has improved the accuracy of the technique (Graham et al, 1991). The
method also requires estimation of the vascular volume between injection site and
myocardial region of interest which changes with alterations in arteriolar resistance,
and thus volume of the resistive vascular bed (Gould et al, 1985; White et al, 1984).
Furthermore, stability of the image for up to 20 seconds ie. absolute breath-holding by
the patient, is essential to allow measurement of the mean transit time from a good
quality time-density curve.
63
Although many of these limitation may be overcome by mathematical assumptions
and rigourous technique including atrial pacing, only accurate measurement of
maximal myocardial blood flow may be achieved (Pijls et al, 1990). As will be
discussed later in this thesis, alterations in basal myocardial blood flow are a common
pathophysiological feature of altered resistive vessel function, and it is for this reason
that positron emission tomography remains the best non-invasive method for the
absolute quantitation of basal and maximal myocardial blood flow.
2.4.2.4. Doppler Catheterisation
The use of an intracoronary Doppler catheter to measure coronary blood flow
velocity was developed at the University of Iowa in the mid-1980s. The catheter
consists of a 20 MHz piezo-crystal mounted at the top of a steerable 3F gauge catheter
which may be inserted into a coronary artery over an angioplasty guide wire (Wilson et
al, 1985; Sibley et al, 1986). This allows selective and repeated measurement of
coronary flow, and like epicardial probes, these catheters have an excellent frequency
response. They have been well validated against other methods (Marcus et al, 1981;
Wilson et al, 1985). However, because of the invasive nature of the procedure, there
is a small risk of injury to the coronary artery under study, a risk which is
compounded by the relatively unstable free-floating tip which can lead to a variable
quality of the recordings. The original method using the suction Doppler
intraoperatively measured only changes in velocity although absolute velocity may be
estimated from the frequency shift using the intracoronary catheter. With the Doppler
technique, the normal coronary vasodilator reserve is 5.0 with no difference reported
with gender, age or study vessel (Marcus, 1983b).
In the presence of epicardial coronary artery disease, the catheter tip may be
inserted distal to the stenosis to achieve reliable measurements. However, this in itself
can lead to increased obstruction at the site of the stenosis, with further disturbance of
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laminar flow, in a situation where the distribution of velocities in a cross-sectional area
is already unknown. Furthermore, with passage of the catheter into smaller vessel
diameters (<2.5 mm2), overestimation of the severity of the flow obstruction will also
occur. The catheter tip may be placed proximal to the lesion (up to 5 mm) to give an
estimate of flow at the point where there is a reduction in flow. However, given that
changes is vessel diameter in this proximal segment may occur with vasodilatation,
this diameter and thus the cross-sectional area of the so-called reference segment
should be included in the estimation of coronary blood flow from coronary flow
velocity. Some avoid this by pre-administration of nitroglycerin, but this obviates
study of changes in vasomotor tone in the artery under investigation (Jost et al, 1990),
and in general, only trivial changes in intracoronary diameter occur after administration
of intracoronary papaverine (Wilson et al, 1986) or intravenous dipyridamole (Brown
et al, 1981). Thus, intracoronary Doppler is widely used by groups studying the
pathophysiological changes in coronary blood flow due to coronary artery disease.
Measurement of the coronary vasodilator reserve using the Doppler catheter
correlates reasonably well with the stenosis severity whether described as percent
diameter stenosis (R=0.82), percent area stenosis (R=0.85), or minimum cross-
sectional area (R=0.79) determined from orthogonal planes (Wilson et al, 1985).
Despite these reasonable correlations in a highly selected group, there was substantial
scatter on individual vasodilator reserve values at any level of stenosis. This
variability underlines the additional factors affecting coronary flow in the presence of
an epicardial stenosis such as angiographically unapparent collateralisation and
resistive vessel function distal to the stenosis.
There have been several developments with the principle ofDoppler catheterisation
such as the Judkins Doppler-tipped catheter which may be used for the measurement
of coronary flow velocity in normal arteries at the right or left coronary ostia. Most
recently, the guide wire Doppler has been developed which obviates the need for a
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Doppler catheter and additional instrumentation (Doucette et al, 1992). Another
advantage of this catheter is that coronary flow velocity may be measured both
proximal and distal to a coronary stenosis without significant interference in the cross-
sectional area of the epicardial stenosis providing it is not a severe lesion. To avoid
intracoronary instrumentation, transoesophageal Doppler echocardiography has been
developed to avoid this problem (Iliceto et al, 1991). The use of Doppler
catheterisation with intravascular ultrasound should allow absolute quantitation of
coronary blood flow in the future.
2.4.2.5. Three-Dimensional Imaging Techniques
These non-invasive techniques include ultrafast computed tomography (CT),
magnetic resonance imaging and positron emission tomography (Chapter 3). The first
two techniques involve the principle of the indicator dilution theory. However, true
validation of ultrafast CT and MRI is in its early stages and both techniques remain
predominately research methodologies. Ultrafast CT has been applied to the
measurement of flow in bypass grafts using similar assumptions as were done with
early densitometric techniques (Section 2.4.2.3), with the advantage of an intravenous
injection of contrast (Rumberger et al, 1986).
None of the previous methods described can study coronary flow in specific
transmural layers and stratify the extent of ischaemia from epicardium to endocardium.
It is hoped that ultrafast CT and magnetic resonance imaging may provide this
information in time. In experimental studies, contrast echocardiography may be used
to define the transmural extent of myocardial infarction by measuring the delay in
contrast enhancement (Kemper et al, 1986), although no absolute transmural
quantitation of flow is possible with this technique. This will becomes possible with
the development of advanced PET cameras with improved spatial resolution, as it is
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currently possible to distinguish epicardial from endocardial flow in patients with
ventricular hypertrophy (Camici et al, 1991c).
2.5 Summary
The coronary vasodilator reserve is an attractive concept and allows not only a
functional assessment of epicardial stenosis severity but also defines the vasodilator
responsiveness of a coronary vascular bed, and thus coronary resistive vessel
function. It is important to separate from the coronary vasodilator reserve, the effects
of other variables such as heart rate, loading conditions, contractility and hypertrophy.
Several methodologies have been developed to measure coronary flow in the clinical
environment, the best validated being intracoronary Doppler catheterisation and
positron emission tomography. The next stage of development of these methods is
their application to the study of cardiac pathophysiology where the contribution of
altered resistive vessel function to changes in the coronary vasodilator reserve may be
defined and therapies developed to modify such abnormalities.
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CHAPTER 3. POSITRON EMISSION
TOMOGRAPHY AND THE ASSESSMENT OF
MYOCARDIAL FUNCTION
3.1 Introduction
Positron emission tomography (PET) is an imaging technique which uses the
detection of radiation from relatively short-lived positron-emitting radioisotopes
delivered in vivo labelled to compounds taken up from the vascular bed as part of
normal cellular function. Localisation of such radiation is sufficiently accurate to
allow data presentation of the object studied, with the intensity of each picture element
proportional to the isotope concentration at that position. As positron-emitting
isotopes can be generated from most elements of the periodic table, organic molecules
may be labelled with radioisotopes such as carbon-11, nitrogen-13, and oxygen-15,
without altering the chemical structure of the compound used. These isotopes have
been applied to the study of (myocardial) tissue function in the normal and the disease
state. In this chapter, the principles and theory behind PET imaging and its application
to the non-invasive measurement of myocardial blood flow and metabolism are
described.
3.2 Basic Principles
Positron emitting radioisotopes are proton-rich with an excess positive charge on
the nucleus and may be generated by linear acceleration in a cyclotron, such as carbon-
11 (half-life = 20.4 minutes), nitrogen-13 (half-life = 9.8 minutes) and oxygen-15
(half-life = 2.1 minutes), or from a generator, such as rubidium-82 (half-life = 78
seconds). Such radioisotopes have short half-lives which permit the use of radiation
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dosages compared to conventional myocardial tracers such as thallium-201, and the
option of the use of different radioisotopes in the same scan. However, because of
their short half-lives, an on-site cyclotron is required for production.
The basic principle of physics on which positron emission tomography depends is
that of annihilation radiation and coincidence detection of this event. Two means of
decay exist for such nuclei: i) capture of an orbital electron by the nucleus, or ii)
emission of a positive election (a positron) from the nucleus. After travelling a short
distance, the positron (which is an anti-electron) collides with an electron in orbit and
they annihilate to produce electromagnetic radiation. This so-called annihilation
radiation of two gamma rays of 511keV are emitted at 180° to each other
simultaneously and can be detected externally by taking advantage of this phenomenon
(Phelps, 1977) (Figure 3.1). Coincidence detection of these two photons on opposite
sides of the study object places the site of annihilation on a line connecting the two
external detectors, which are linked themselves by a coincidence circuit. Thus,
annihilation occurring outside the detector volume is electronically rejected as only one
photon is detected.
To determine the three-dimensional isotope distribution, measurements must be
taken from several directions. Thus, radiation detectors scan across an object to obtain
a count rate profile for a certain slice through the object, and then repeat this for a
number of angles around the cross-section defined by the slice. This allows
reconstruction of an image from isotope concentrations. This reconstruction is
dependent on the physics of positron decay, positron annihilation, gamma-ray
interactions within the object, as well as the geometry and engineering of the system.
There are several methods for reconstructing the data to minimize error from
assumptions made from count detection, which is outwith the scope of this chapter
(Hoffman & Phelps, 1986). Suffice it to say, PET systems are designed to maximise
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Figure 3.1. Emission of a positron ((3+) from the nucleus of a molecule of 15-
oxygen. Collision with an electron (e") leads to annihilation radiation of two 511keV
photons of gamma radiation in always at 180° to each other.
70
the detection of coincidence events (unscattered photons) and minimize background
events from scattered photons and high count rates from outside the filed of view.
Two factors serve to limit the accuracy of annihilation coincidence detection to
identify the site of decay of the positron emitting isotope: the positron range effect and
the non-colinearity effect. The positron range effect describes the fact that the
distance a positron travels before annihilation depends on its energy which, in turn,
depends on the parent nucleus eg. positrons from 18F nuclei have lower energy than
those from 82Rb nuclei. Positrons with lower energy combine with electrons at a
smaller distance from the nucleus, allowing better localisation of decay. Non-
colinearity occurs because of the momentum of the positron as it annihilates with the
electron, causing one of the gamma photons to fall outside the detection volume of the
block detectors. These factors account for the limit to the resolution of the current
scanners.
3.3 The Block Detector Positron Emission
Tomograph
Modern PET systems are designed with regular polygonal or circular rings of
detectors to maximize the detection efficiency per slice. These are isolated by lead or
tungsten as shielding for off-plane activity, but are at the vertex of a fan beam of
sensitivity across the field of view, thus increasing sensitivity. The advantage of the
circular sampling system is that there is no longer a need for the detector banks
(hexagonal or octogonal array of blocks) to rotate to compensate for under-sampling.
High density detector materials have reduced the need for movement of the detector
system, such as a "wobble" about the centre of the field of view to increase sampling,
and thus improve resolution and reduce artefact.
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The scanner used in these studies was the ECAT 931/08-12 (Siemens-CTI Inc.
Knoxville, Tennessee, U.S.A.) (Spinks et al, 1988) As described above, this scanner
uses the principle of annihilation coincidence detection but has 8 rings of detectors
each with 512 detector elements made of bismuth germanate. The detector elements
are coupled to photomultiplier tubes in the ratio of 32 to 4 (Figure 3.2), and
localisation of the detector in which the count is registered occurs through analysis of
the peaks from all 4 photomultiplier tubes. Thus, any one detector is in coincidence
with other detectors in the same and adjacent rings. There is an axial field of view of
10.8 cm consisting of 15 planar slices, 8 direct planes and 7 cross planes. Thus data
acquisition occurs in direct planes between detector pairs in the the same ring, and in
cross planes between detector pairs in adjacent rings of detectors, giving better axial
resolution in the latter case.
The spatial resolution of the PET camera is assessed by the accuracy in localising
a radioactive point source the field of view of the camera (Figure 3.3). This is
determined from the gaussian-shaped profile resulting from the measurement of a
radioactive line source positioned axially in the camera. The width of the count profile
at 50% of the peak count is a commonly used determinant of the spatial resolution.
Using the ECAT 931/08-12, spatial resolution is 8.4 mm at full width halfmaximum
(FWHM) at the centre of the field of view (Spinks et al, 1988).
3.4 Quantitation
The quantity actually measured in PET is the local tissue concentration of positron
emitter. This quantity can be related to a physiological or metabolic process through
the application of an appropriate mathematical model of the process. With a uniform
response from the annihilation coincidence detection system and attenuation correction
(see below), it becomes practical to do this with PET.
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Figure 3.2. External irradiation of the subject with a ring source to generate a
transmission scan. The patient is positioned transaxially at the centre of the ring source
and the block detectors. The detector elements are coupled to photomultiplier tubes in
the ratio of 4 to 1.
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EMISSION
Figure 3.3. Gamma radiation from a positron emitting tracer in the myocardium.
The block detectors are positioned transaxially around the patient, and should they
detect the two annihilation photons simultaneously (in coincidence), then the original
site of the annihilation event can be localised to the volume between the two detectors.
Gamma photons outside this volume may only interact with only one of the detectors
per annihilation. By electronically selecting coincidence events only, and rejecting all
others, all true coincidence events can be localised accurately.
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3.4.1. Calibration
The first step towards quantitation is accurate calibration of the system. This is
done regularly by measurement of a positron emitter in a uniform source in a cylinder
much larger than the spatial resolution of the tomograph. This is followed by
measurement of activity in an aliquot of the solution with a radiation detector, such as
a well counter. Every picture element (or pixel) in the generated image may then be
scaled by this calibration factor to be equal to the activity at that location in the subject
under study. The absolute activity is of less importance, as it is knowledge of the
concentration in the blood and response of the PET system that determines
quantitation. Thus, in cardiac studies, using C150 to produce
[150]carboxyhaemoglobin in red blood cells, after coming to equilibrium, a region of
interest in arterial blood such as left atrium or ventricle may be drawn on the image and
venous samples taken and counted in a well counter. From this measurement, the
response of a calibrated PET system can be calculated for 100% blood volume in the
region of interest.
With C150, the dynamic equilibria existing among the delivery of the activity to
the organ, the physiological washout of the activity of the organ, and the physical
delay of a short-lived isotope allow the formulation of a mathematical model of the
process that requires only one PET image and the amount of activity in several venous
samples to measure the arterial input function. When measuring a more complex
variables, the amount of activity measured in the organ depends on the kinetics of the
metabolic process, the transport properties between the blood and the site of the
process in the cell, and the amount and time course of the delivery of the activity to the
organ.
Initially, direct arterial sampling was used to take a series of blood samples
following delivery of the positron emitter to define the activity and shape of the arterial
input function. However, the PET system may be used to measure the input function
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directly by measuring the amount of activity in the left atrium or ventricle as a function
of time thus relying only on venous sampling.
3.4.2. Image Reconstruction
The scanner collects coincidence data which are reconstructed into images
quantitatively representing the radiotracer distribution in the field of view. This is
done by using filtered back projection which produces such images, the algorithms for
which run on dedicated array processors on a MicroVax II computer. This technique
relies on several assumptions; i) transaxial resolution is constant throughout the field
of view, ii) there is no absorption of gamma photons between coincident detector
pairs, iii) all measured counts are true coincidences (independent of coincidences from
scattered and random photons), and iv) there are no lost counts because of detector
dead-time. The design of the current camera in use ensures that transaxial resolution is
constant, and that both scattered/random coincidences and dead-time losses are
corrected for. Absorption and attenuation of photons by structures in the field of view
account for the main problem in determining accurate image reconstruction.
3.4.3. Attenuation Correction
Annihilation gamma photons from positron emitting radionuclides in the heart
interact with other thoracic structures causing deviation from the original course of
emission. This leads to a reduction in counts detected by the scanner. The attenuation
of gamma photons from a uniformly dense object depends on the thickness of the
object, irrespective of the depth of the source. To allow for this attenuation, the
correction factors are measured directly, given the variation of density of thoracic and
thoracic wall structures. A blank scan across the field of view is acquired with the
exposure of an external ring source of germanium-68 (half-life = 287 days).
Positrons from this external ring annihiliate in the air of the field of view and are
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detected. This need only be done every week of scanner use. The next step of
attenuation correction is the transmission scan which again uses the external ring
source but with the patient positioned in the scan at the beginning of each study
(Figure 3.2). Using the ratio of the counts from each coincident detector pair when
the patient's body is present (transmission scan) and absent (blank scan), the
correction factor for each detector is calculated for the degree of attenuation by
different intrathoracic structures. This accurate process of attenuation correction along
with improved spatial resolution is what sets PET above other radio-imaging
techniques such as single photon emission computed tomography (SPECT).
3.4.4. Cross-calibration of the PET Camera
The PET camera measures counts of activity which by using the methodology
described above leads to the accurate measurement of the true coincidence count rate.
In order to allow quantitation, it is important that the camera is calibrated to permit
calculation of radioactive concentration from count rate. This is done using a
cylindrical phantom of a positron-emitting radionuclide at a known concentration, a
sample of which has also been measured in a sodium iodide crystal well counter. The
activity of the phantom from the camera is measured in counts-sec-1 -voxel"1 (the
volume element equivalent of pixel in the reconstructed image), whereas the well
counter measures radioactivity in p,Ci-ml-1. This known relationship permits
conversion from the count rate to absolute radioactive concentration.
3.4.5. Tracer Kinetic Modelling
The development of different radio-labelled tracers to exploit the advantages
derived from the accuracy, repeatability, and quantitation of PET imaging is as
important as improvements in the technical abilities of the PET scanners themselves.
The definition of a tracer is that of a measurable compound which can follow ("trace")
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a chemical process without markedly disturbing the process itself (Huang & Phelps,
1986). This is facilitated by the use of very low concentrations of PET tracers and the
ability of cameras to perform rapid dynamic imaging to follow the chemical process
under study.
Positron-emitting radionuclides may be incorporated into tracers by rapid
radiochemical procedures and administered by the intravenous route or by inhalation.
These then follow the natural chemical and metabolic pathways of the individual. As
the amount of tracer delivered is known, the myocardial concentration (tissue
response) and arterial concentration (arterial input) are measured as a function of time
with the camera. This arterial input measured in left atrium or left ventricle documents
the supply of tracer to myocardium through the study.
A tracer kinetic model is used to describe the relationship between the tissue
response to the arterial input in mathematical terms, from which a quantitative
assessment of the biological process studied may be derived. Such models are based
on previous experiments with the tracer in both in vitro and in vivo (animal) models.
3.5 Limitations of PET Scanning
With an ideal imaging technique, the value in each pixel of a PET image is equal to
the concentration of a positron-emitting radioisotope at that point in the tissue under
study. However, no technique is free from a degree of error although with particular
interpretation of images allowing for known sources of error, it is possible to
minimize this.
3.5.1. Resolution
The primary limitation in PET is spatial resolution. The term line spread function
(LSF) is used to define the spatial accuracy of a PET camera and refers to a narrow
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line source of positron emitter between a pair of coincidence detectors to give a count
rate profile as a function of position. In cylindrical detectors, the LSF is
approximately gaussian in shape with a full width at half maximum (FWHM) of 40-
50% of the diameter of the detectors at the midpoint of the detectors. Thus, LSF
measurements taken over the central third of the region between coincidence detectors
are remarkably constant, and that region constitutes the most useful field of view for
accurate measurements in PET. When two line sources of activity are exactly 1
FWHM apart, it is not possible to tell that there are two sources, and when they are 2
FWHMs apart the lines should be clearly separated, with the valley between going to
the background level.
The limiting resolution due to the physics of the PET system is of the order of 2-3
mm. Poor resolution can affect quantitative measurements by i) causing difficulty in
interpretation of the anatomy for identification of the structure of interest (a problem
becoming relevant to cardiac PET with the increased interest in documenting
transmural flow accurately), ii) failing to resolve two structures close to each other and
incorrectly attributing activity from one structure to the other, iii) reducing the apparent
isotope concentration in structures that are smaller than about twice the system
resolution, iv) causing overestimation in size of structures smaller than twice the
resolution distance of the PET system, and v) low sensitivity in the detection of small
low contrast lesions.
Resolution may also be lost if the patient moves during any stage if the scan. This
is reduced by placing the patient on a comfortable bed, using a head restraint to
remove axial movement, and employing short scan times.
The partial volume effect which is another limitation of scanner resolution is
discused below (Section 3.6.1).
3.5.2. Accidental and scatter coincidences/
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3.5.2. Accidental and scatter coincidences
Accidental and scatter coincidences are the two primary sources of background
noise in PET. Accidental coincidences occur due to the nature of detection of emitted
gamma rays. To establish that annihilation photons are in coincidence, timing
measurements need to be performed for thousands of combinations of detection pairs.
The detector, a scintillation crystal such as bismuth germanate, absorbs a photon and
generates an electronic pulse (timing signal) of precise width (through emission of
light to a photomultiplier), which is summed with other pulses from other detectors
possibly in coincidence. When in coincidence, the pulses sum to twice the amplitude,
identified by a pulse height discriminator and stored as image data. Because of the
decay time of bismuth germanate (300 nsec), there is an inherent delay between the
annihilation event and the timing signal. The width of the timing signal is chosen so
that most of the signal from true coincidences falls into the electronic coincidence time
window. Inevitably, unrelated photons may also produce timing signals which
overlap - accidental coincidences. These may be corrected for and subtracted from the
total coincidences either by measuring the single event of the individual detectors or
using parallel timing circuitry to delay one of the signals (Hoffman & Phelps, 1986)
(Figure 3.4). Scatter coincidences occur through photons being deflected by the tissue
of the subject, with very little energy lost as a consequence and detected similarly to
true events by the detectors. It is dependent on the cross-sectional geometry of the
patient, the distribution of activity, and the design of the PET system. Although
scatter can be measured in detail using line sources placed in the field of view, an
estimate can usually be made from the edges of the field of view and correction made
accordingly (Hoffman & Phelps, 1986).
Design of the PET system is of utmost importance in minimising these artifacts. A
larger system diameter increases the ratio of true to background events an allows the
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Figure 3.4. Sources of true, accidental, and scatter coincidences. True
coincidences are those which are detected simultaneously in the region between the
two detectors (D), the coincidence field of view (FOV). Accidental coincidences
originate in areas of the subject which is in the direct field of view of one of the
detectors (single FOV within either set of the dashed lines). Such coincidences can
also arise from poor shielding, back scatter, and non-annihilation photons from the
radioisotope. Scatter coincidences originate in a region that is viewed simultaneously
by both detectors (between two sets of dashed lines) (Modified from Hoffman &
Phelps, 1986)
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use of longer lead side shielding. The sources of true, accidental and scatter
coincidences are shown in Figure 3.4.
3.5.3. Dead-time losses
Dead-time losses can be estimated for a particular distribution of activity by taking
a series of PET measurements of that distribution as a function of time until the total
number of events per data acquisition is decaying with the true physical half-life of the
isotope. Extrapolation to earlier times, with the physical half-life of the isotope,
allows calculation of the true data rate. The difference between the true and measured
rates is an estimate of data losses at higher count rates. Dead-time corrections in PET
require simultaneous measurement of the single event rate of each detector and the
coincidence rate.
3.6 Myocardial PET Scanning
The anatomical and physiological nature of the heart impose specific requirements
on the acquisition and analysis of images generated by positron-emitting isotopes.
Because of this, there are several considerations which need to be taken into account in
order to improve image quality and tissue quantitation. It is important to ensure that
the patient under study remains still during imaging so as to achieve optimum time-
activity curves in each region of interest during each individual component of the
study. In addition with multiple studies during the same scan, it is important that
comparability is not lost between studies because of patient movement. To avoid this,
a neon laser beam is used to demonstrate the patient's position in relation to the field of
view, and temporary marks applied to maintain position from scan to scan.
The block detectors are positioned in a circumference around the long axis of the
patient. However, the long axis of the heart is oblique to this such that images when
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reconstructed are transaxial limiting complete evaluation of the left ventricle,
particularly with respect to the inferior wall, cutting a tangential plane through this
region. This problem is less apparent when restricting analysis to mid-ventricular
sections with equally sized regions of interest from all walls of the ventricle. It is now
possible to reslice the reconstructed PET images along the long axis of the heart to
create short axis images from apex to base, without the need for tilting of the imaging
gantry as was previously done in some centres.
Because the position of the heart in relation to the other thoracic structures is
asymmetrical surrounded by tissue of different density, the degree and extent of
photon attenuation by these tissues requires measurement before delivery of tracer,
which has the advantage of conferring quantitation on the technique. This has lead to
the initial transmission scan generated by external irradiation which allows
determination of the attenuation coefficients of the soft tissues and correction for
photon attenuation, as well as defining the thoracic anatomy.
Cardiac and respiratory wall motion are potential causes of image degradation with
problems of motion artifacts causing apparent heterogeneity in myocardial tissue tracer
uptake. PET images may be taken gated to the ECG, although breath-holding is not
practical for most cardiac patients over the periods of time required for data
acquisition. Another advantage of ECG-gating is that apparent changes in regional
tracer concentrations caused by regional wall motion abnormalities and due to the
partial volume effect (Section 3.6.1) may be minimised.
In addition to the potential problems caused by the physical nature of scanning,
there are other considerations in relation to the analysis of images when determining
true tissue concentration of tracer such as the partial volume effect, bidirectional cross
contamination of activity between myocardium and blood, so-called "spillover"
activity, and blood activity in the vascular space ofmyocardium.
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3.6.1. Partial Volume Effect
Tissue concentrations of tracer are underestimated if the object size viz. left
ventricular wall thickness, is less than twice the spatial resolution of the imaging
camera (2 x FWHM), and the image is only partially occupying the sensitive volume
of the detectors viewing that dimension, as after reconstruction, the concentration seen
in the image is proportional to the concentration in the object. This leads to an
underestimation of the isotope concentration in the object. Previously the resolution
was of the order of 15-20 mm, causing underestimations of up to 50% of tissue tracer
concentration. With improved spatial resolution, currently at 6.6 mm, this error has
declined. In order to correct for the partial volume effect, corrections can be derived
from scanning of different-sized phantoms containing a positron-emitting radioisotope
allowing measurement of count recovery (the recovery coefficient) against object size.
In the method employed in this thesis, partial volume may be corrected for by
manipulating the transmission and C150 blood pool images (Figure 3.5). This
involves pixel-by pixel subtraction of a blood density image image from the
transmission image after normalisation of the latter for tissue density (Iida et al, 1991).
This provides a quantitative image of extravascular tissue density (Figure 3.5). Using
phantom studies, this method has been validated over a range of wall thickness of 3-
27 mm (Spinks et al, 1991). The value of extravascular tissue density measurement is
dependent only on cardiac wall motion and the physical dimensions of the heart wall
and is termed the anatomical tissue fraction (ATF; Section 3.9.1).
3.6.2. Spillover and Arterial Activity
The resolution of the scanner determines the amount of spillover of activity from
the ventricular chamber ie. blood pool to the myocardium and vice versa. With the
improvement in resolution with the newer generation of scanners, spillover has
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Figure 3.5. Upper panel) The blood volume or "blood pool" image is generated
from the C150 inhalation scan and is reconstructed over 15 transaxial planes. A left
atrial region of interest may be drawn over several planes to allow measurement of the
arterial input function. Lower panel) The extravascular volume (or density) image is
created by subtracting the blood volume image from the transmission scan, which is
generated by external irradiation of the thorax by a 68-germanium ring source.
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become less of a problem, and may be corrected for by modelling appropriately
(Appendix 1).
In man, the coronary vascular space occupies an average of 10% of myocardial
volume. High activity in this compartment contaminates the data from tissue activity,
particularly early in tracer uptake. However, analysis of data over the whole of the
dynamic image reduces this as a potential source of error (Iida et al, 1988).
3.7 Application of PET to the Measurement of
Myocardial Blood Flow
Positron emission tomography offers the unique opportunity to evaluate
myocardial perfusion in vivo with absolute quantitation, unavailable with other radio-
imaging techniques (Bergmann et al. 1985). With the transverse field of view
obtained with the current PET scanner, it is possible to measure myocardial perfusion
in the whole heart and also measure perfusion in different regions of the left
ventricular wall simultaneously.
Early work investigating the effect of coronary artery stenoses on MBF
distribution used rubidium-82 (Selwyn et al, 1982), and nitrogen-13-labelled ammonia
(13NH3) (Krivokapich et al, 1989), to demonstrate exercise-induced relative defects in
myocardial distribution. However, the accumulation in ischaemic areas may reflect
altered metabolism rather perfusion alone (Bergmann et al, 1985). This has led to the
use of oxygen-15-labelled water (H2150) which is a pure flow marker free from
distortion attributable to the effects of ischaemia or metabolism (Bergmann et al, 1984;
Iida et al, 1988). MBF measurement by H2150 can be performed during vasodilator
stimuli in order to assess the coronary vasomotor response. Quantitation of MBF
during vasodilator or vasoconstrictor stimuli will allow comparison of the vasomotor
response in the myocardial region under study with that of normal regions. Thus, by
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comparing flow between these two regions, the behaviour of flow in the abnormal
area may be referred to that of the normal regions (Walsh et al, 1990).
3.7.1. Myocardial Blood Flow Measured by Positron Emitters
There are three principles of an imaging method for accurately detecting regional
changes in the coronary vasodilator reserve: i) cross-sectional PET to obtain depth-
independent resolution of images, ii) a myocardial perfusion agent extracted by
myocardium in proportion to flow at at levels up to 5 times basal values, and iii) a
potent, consistent vasodilator stimulus to increase coronary flow sufficient to allow
discrimination ofmyocardial flow between different regions (Gould et al, 1991). As
PET perfusion imaging can discriminate a difference of only 15% in maximal flow
between a diseased and control region, this makes it by far the most sensitive and
specific radio-imaging technique for demonstrating the physiological consequences of
a coronary stenosis.
Flow tracers may be extractable particulate, such as labelled albumin microspheres
which need to be delivered direcdy to the left heart, or extractable diffusible, which are
transienty trapped in or cleared from myocardium proportional to flow. Although
many positron-emitting tracers have been developed to allow measurement of
myocardial blood flow, many are impractical because of the need for intracoronary
delivery to achieve sufficient myocardium to background ratios to allow external PET
imaging. The tracers which have been developed for clinical use are 13N-ammonia
(half-life = 9.8 minutes), 82-rubidium (82Rb; half-life = 1.3 minutes) and lsO-water
(half-life = 2.1 minutes).
3.7.1.1. 13N-ammonia
13N-ammonia given as an intravenous injection is cleared rapidly from from
blood, with high myocardial retention giving high quality images. Although initial
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extraction approaches 100%, there is some back diffusion leading to an extraction
fraction of 82%. At higher flows, this declines further leading to a non-linear tissue
response curve (the linear relationship only holds to myocardial blood flows of up to
2.5 ml-min'-g1). 13N-ammonia diffuses across the cell membrane in the NFLf1" form
equilibrating to NH3 which is trapped by the enzyme glutamine synthetase, which
converts glutamic acid to glutamine. Because of the dependence on an enzyme
involved in tissue metabolism, it has been suggested that tracer fixation may be
affected by the underlying metabolic state of the myocardium (Bergmann et al, 1980).
Under most circumstances such as changes in haemodynamics and contractility, the
relationship between myocardial 13N-ammonia net extraction and regional myocardial
blood flow is not significandy affected. However, in chronic myocardial ischaemia, it
may not be possible to make such assumptions.
13N-ammonia clears rapidly from blood and distributes in proportion to regional
myocardial blood flow in myocardium where it becomes trapped for several hours.
Tissue concentrations of 13N are stable within two minutes of injection. However,
tissue concentration of 13N can increase with time because of recirculation of labelled
amino acids leading to error. Furthermore, arterial blood samples are required within
two minutes of injection to allow well counting of 13N activity.
3.7.1.2. 82-rubidium f82Rb)
As rubidium has an extraction fraction of over 50%, it distributes in myocardium
in proportion to blood flow and has been used for qualitative evaluation ofmyocardial
perfusion. As 82Rb is generated from a 82Sr-82Rb generator, it can be used for PET
studies in centres without an on-site cyclotron. With a half-life of 78 seconds, it may
be used for serial studies. To develop a method for quantitation of myocardial blood
flow, two approaches have been used. The equilibrium technique relies on an image
being taken during constant 82Rb infusion, followed by another image after the
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infusion is stopped. These two images allow calculation of the arterial and myocardial
82Rb concentrations and thus the extraction fraction. This method relates the net
regional myocardial uptake of 82Rb for a given flow to the amount given. The bolus
injection technique employs a rapid injection over 10-30 seconds along with sequential
PET image acquisition. Both methods assume a constant extraction fraction, but
extraction decreases non-linearly with higher flows leading to problems with accurate
quantitation at higher blood flows. This has led to the development of a tracer kinetic
model.
3.7.I.3. 15Q-water
150-water is freely diffusible with an extraction fraction approaching 100% which
is unaffected by tissue metabolism. With a half-life of only 123 seconds, serial
studies may be performed. Problems with this tracer originally occurred because of
the high 150 content of the blood pool and the myocardial vascular space. However,
by recording blood pool images during 150-labelled carbon monoxide, it is possible to
subtract blood pool activity from tissue activity (Figure 3.6). 150-water has been
given as an intravenous bolus along with fast PET scanning, although this required
intra-arterial sampling to determine the arterial input function (Iida et al, 1988). By
giving a lsO-labelled carbon dioxide (C15C>2) inhalation which is instantly converted
to 150-water in the lung capillaries, the delivery to the myocardium is achieved
without the need for rapid scanning and high levels of activity. The advantages of this
method of delivery are that C1502 is easy to produce and may be delivered to the PET
laboratory without the need for direct handling by the radiochemist, and may be
controlled by the scanner operator. The slow inhalation, by providing a slow input
function, reduces the artefact seen with bolus injections (Figure 3.7).
The main disadvantage is the high level of activity in the cardiac chambers which
interferes with the myocardial signal, because of the limited resolution of the scanners.
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To correct for this, the Va, representing the arterial blood volume and the spillover
fraction, has been introduced into the model. Myocardial blood flow is calculated by
fitting the arterial input and tissue time-activity curves to a single tissue compartment
tracer kinetic model, which includes corrections for the underestimation of tissue
activity due to the partial volume effect and the spillover of activity from the left
ventricular chamber into the myocardial wall. The model estimates myocardial blood
flow, the fraction of exchangeable tissue, and the Va with the region of interest
measured. The fraction of exchangeable tissue is the fraction of the region of interest
that consists of tissue capable of exchanging water within the time period of the study.
This tissue fraction accounts for different wall thicknesses and thus corrects for
myocardial tracer underestimation because of the partial volume effect, obviating the
need for an independent measurement of wall thickness. Another minor disadvantage
is that image quality is poorer than that seen with 13NH3 or 82Rb because of the
kinetic characteristics of the tracer and the rapid dynamic scanning involved (Figure
3.8). However, the ability to quantify myocardial blood flow, with a correlation
coefficient of 0.91 against microspheres, makes up for this minor disadvantage. The
non-invasive measurement of the arterial input function is also affected the partial
volume and spillover effects, although these effects may be minimised by using the
left atrial chamber which has a recovery of over 90%. A mathematical description of
the application of 150-water delivery to the measurement of myocardial blood flow is
given in Appendix 1.
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Figure 3.6. Upper panel) The dynamic C1502 is acquired over a seven minute
period consisting of i) a 30 second background scan, ii) inhalation of C1502 over 210
seconds, and iii) a period of "washout" of the gas from myocardium over a further
180 seconds. The washout image is created from the last 4 time frames of this
washout period, with subtraction of the blood volume image from the dynamic scan,
to give an image of 150-water perfused tissue. Lower panel) To facilitate drawing
of the regions of interest, the washout images eg. at basal and after vasodilator stress







Figure 3.7. Three-dimensional images of blood volume (red image) in the lateral
and left anterior oblique view (LAO) and myocardial blood flow or more correctly,
washout images (yellow image) superimposed in the LAO view. The blood flow
images are shown at basal and after the vasodilator stress of dipyridamole in a patient
with a left anterior descending artery stenosis. In the latter image, the activity from the
dynamic C1502 scan is corrected to the flow in a remote region of myocardium. In the
anterior region, myocardial blood flow fails to achieve this threshold and a perfusion
defect is evident.
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3.8 Application of PET to the Measurement of
Myocardial Metabolism
PET has been used to study different metabolic processes in myocardium such as
amino acid utilisation and protein turnover, but the main focus of attention has been
the study of energy metabolism. PET also allows detection of the metabolic alterations
caused by ischaemia and the definition of its three-dimensional myocardial
distribution.
The glucose analogue 2-deoxyglucose, in which a hydroxyl group is substituted
by a hydrogen atom on the second carbon atom, shares with glucose the same trans-
sarcolemmal carrier and is a good substrate for the enzyme hexokinase with
production of deoxyglucose-6-phosphate. This is not further metabolised and
accumulates in the cell in proportion to exogenous glucose utilisation and hexokinase
activity (Phelps et al, 1978). Although deoxyglucose uptake parallels glucose
utilisation, it gives no further information regarding the disposal of glucose
intracellularly. Nonetheless, global and regional changes in glucose utilisation under
controlled conditions may be studied using deoxyglucose, labelled with the positron
emitter, fluorine-18 (18F-2-fluoro-2-deoxyglucose, FDG) (MacGregor et al 1977;
Phelps et al, 1978) (Figure 3.8). Until recently, PET-derived glucose uptake
measurements have been qualitative because of the difficulty in estimating a value
known as the lumped constant. This factor relates the kinetic behaviour of FDG to
glucose in the terms of their relative affinity for the trans-sarcolemmal carrier and
hexokinase, and may vary under different physiological conditions. However, it is
possible to quantify myocardial glucose uptake using a graphical method based on the
measurement of fluorine-18 in the blood pool and myocardial regions of interest
(Hicks et al, 1991). Of interest, it has been demonstrated that, even with the
hyperinsulinaemic-euglycaemic clamp to control glucose and insulin levels, there is a








Figure 3.8. Upper panel) Myocardial washout images derived from C1502
inhalation at basal and during dipyridamole stress at a mid-ventricular plane. Lower
panel) FDG images over 8 planes from apex (upper left image) to base (lower right
image) of the heart in a normal subject.
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due to preferential free fatty acid utilisation (Hicks et al, 1991).
FDG imaging has been applied in two main areas; i) the demonstration of regional
myocardial ischaemia in fasted individuals, and ii) the demonstration of reversibly
injured, or viable myocardium in patients with previous myocardial infarction or
reduced left ventricular function.
3.8.1. FDG Imaging and Myocardial Ischaemia
An epicardial coronary artery stenosis reduces the increase in coronary blood flow
available during stress when an increase in myocardial oxygen demand occurs. Most
of our knowledge on myocardial metabolism comes from work on isolated perfused
animal hearts in normoxic and anoxic conditions. A description of normal cardiac
metabolism with particular reference to myocardial carbohydrate metabolism is given in
Appendix 2. Ischaemia is the commonest situation leading to reduced myocardial
oxygen delivery in man, and many different factors determine the duration, severity
and extent of ischaemia (Maseri, 1983). FDG is selectively taken up by myocardial
cells which have been rendered ischaemic, even for a few minutes (Camici et al,
1986). This approach lends itself particularly well to the study of ischaemia caused by
provocation tests that do not increase myocardial work, as this by itself could stimulate
glucose uptake in non-ischaemic myocardial cells.
During myocardial ischaemia, major changes occur in intracellular substrate
metabolism: there is an increased glycogen breakdown and exogenous glucose uptake
which fuel glycolysis (Camici et al, 1989a; Opie et al, 1973) (Figure 3.9).
Accumulation of reduced coenzymes (NADH2) stimulate the conversion of pyruvate to
lactate by lactate dehydrogenase. With mild ischaemia, the transport of glucose into the
cell is accelerated, as is glycolysis. However, the distal products of glycolysis, lactate
and reduced coenzymes, will finally inhibit the enzyme glyceraldehyde 3-phosphate
dehydrogenase lower down the Embden-Meyerhof pathway (Rovetto et al, 1975).
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VASCULAR SPACE CYTOPLASM MITOCHONDRION
SEVERE ISCHAEMIA
Figure 3.9. Upper panel) During stress-induced myocardial ischaemia, there is
a reduced oxidation of free fatty acid with an increased storage of triglyceride.
Glucose utilisation is increased (both from exogenous glucose and from glycogen),
but the extra pyruvate formed cannot be oxidised. Hypoxia stimulates glucose uptake
and phosphofructokinase (PFK) activity is accelerated due to a decrease in adenosine
triphosphate and creatine phosphate and a decrease of citrate. Pyruvate dehydrogenase
is inhibited by increased amounts of NADH (reduced coenzyme nicotinamide
dinucleotide). There is an increased production of alanine with a greater myocardial
glutamate consumption. In addition, due to the accumulation of NADH, there is
activation of the enzyme lactate dehydrogenase, with conversion of pyruvate to lactate
that is then released; at the same time 1 mole ofNADH is reoxidised to NAD. Lower
panel) With severe myocardial ischaemia, glycolysis is inhibited. This because of a
reduced glucose delivery, inhibition of phosphofructokinase by a low intracellular pH
and inhibition of glyceraldehyde-3-phosphodehydrogenase by lactate and NADH.
(Modified from Camici et al, 1989 a,b).
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Although there is an increase in glucose uptake, carbohydrate oxidation is negligible
(Figure 3.9). With the return of myocardial oxygen delivery, lactate is oxidised back
to pyruvate with restoration of glycogen to pre-ischaemic values. The time required to
return to the pre-ischaemic metabolic pattern is prolonged with persisting high glucose
uptake, probably for glycogen re-synthesis, more so in post-ischaemic than normal
myocardium (Camici et al, 1989b). This persistence of high glucose uptake in post-
ischaemic myocardium is the underlying principle which allows the identification of
transiently ischaemic myocardium using FDG with PET.
With severe ischaemia, the rate of exogenous glucose delivery is also reduced
(Figure 3.9). Under these circumstances, the ischaemic myocardium will rely almost
exclusively on intracellular glycogen stores. However, the insufficient "washout" of
accumulated hydrogen ions and the ensuing intracellular acidosis will inhibit
phosphofructokinase, and thus, glycolysis much earlier than with mild ischaemia.
Thus, the uptake and intracellular utilisation of glucose is modulated by the presence
and severity of ischaemia.
3.8.1.1. Chronic Stable Angina
At rest in the fasting state, myocardial FDG uptake is comparably low in normal
controls and in patients with angiographically proven coronary artery disease and
stable exertional angina. After supine exercise (sufficient to induce chest pain and
significant ST segment depression), a marked increase in FDG uptake may be seen in
both normals and patients (Camici et al, 1986).
In patients, FDG uptake in non-ischaemic regions (regions with a normal
increment of coronary flow on exercise) was similar to that in control subjects.
However, FDG uptake was significantly higher in regions with impaired flow during
exercise (defined as perfusion defects at rest). This disparity in FDG uptake was
detected well into the post-exercise phase, after defects of the flow marker 82Rb and
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the ECG had returned to baseline. This increased uptake is thought to be due to
prolonged recovery of metabolic function with a continued preference for glucose in
"post-ischaemic" myocardium, and may reflect increased glycogen synthesis to
replenish glycogen stores that were depleted during ischaemia and increased cardiac
work (Camici et al, 1986). However, the precise time course of this phenomenon and
its possible relation to the severity of the ischaemic episode is still to be elucidated.
Recovery of full contractile function after revascularisation may also be delayed
until tissue glucose metabolism returns to normal. In another study of patients with
stable coronary artery disease using 13NH3 and FDG, it was observed that segmental
wall motion abnormalities did not improve 48 hours after coronary angioplasty despite
improvement in myocardial perfusion (Nienaber et al, 1991). However, wall motion
scores had improved at two months follow-up associated with improvement in blood
flow-FDG mismatch, implying that normalisation of the altered metabolic state is a
prerequisite for contractile recovery. This may be evidence for slow normalisation of a
chronic metabolic adaptation to a persistent reduction in blood flow (Fedele et al,
1988).
3.8.1.2, Unstable Angina
PET scanning with FDG has also been done in patients with severe coronary
artery disease and unstable angina characterized by frequent spontaneous episodes of
ST segment depression at rest. Unlike patients with stable angina pectoris with an
FDG uptake at rest similar to control subjects, patients with unstable angina may have
regional and even global increases in FDG uptake at rest in the absence of perfusion
abnormalities or transient myocardial ischaemia (Araujo et al, 1988). As a control,
glucose utilisation was similar in chest wall skeletal muscle in all groups studied. This
increase in FDG uptake, of up to four-fold, occurred throughout the myocardium
compared to patients with stable angina or control subjects, in the absence of
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ischaemia, and despite similar disease severity at angiography. No relationship was
seen between FDG uptake and recent episodes of chest pain or ST segment
depression. This has led to the concept of a metabolic adaptation to chronic ischaemia
(with preferential glucose utilisation) which is sustained even in the absence of
demonstrable myocardial ischaemia (Fedele et al, 1988). It is of interest that an
increase in glucose utilisation may occur in areas not subtended by a stenotic artery.
This may imply that the metabolic derangement in areas supplied by diseased vessels
imposes a metabolic stress on a normal area such that there is also a move towards an
increased glucose flux, possibly because of a necessary increase in cardiac work, so-
called regional intra-ventricular loading. Alternatively, this may be evidence for
altered metabolism in territories subtended by angiographically normal arteries
(Chapter 7).
3.8.1.3. Myocardial Infarction
Metabolic imaging with positron emission tomography has been of value in
characterising the functional insult of myocardial infarction and the determinants of
recovery. In animal studies using 150-water and 11C-palmitate, after recanalisation
following coronary occlusion, myocardial blood flow is reduced after initial high
reflow. Although oxidative metabolism (nC-palmitate) parallels this early rise and
fall, the subsequent recovery of fatty acid accumulation is much more variable, but
ultimately predictive of viability (Knabb et al, 1987). Despite often rapid
normalisation of myocardial oxygen consumption (! ^-acetate) in infarcted tissue,
there is a delay in recovery ofmyocardial blood flow. However, recovery of regional
wall motion and oxidative metabolism occur in parallel (Buxton et al, 1992). In man,
it has been confirmed that the preservation of oxidative metabolism is a necessary
condition for recovery of regional function (Gropler et al, 1992: Vanoverschelde et al,
1992). These studies using direct measures of cellular oxidative metabolism (UC-
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acetate) substantiate the earlier studies done using FDG and PET as a clinical predictor
ofmyocardial viability.
In contrast to the fasting state, there is regional uptake of FDG in the presence of
cellular metabolism with a concomitant reduction where there is necrotic tissue
consistent with infarction. The PET concept of viability is based on the demonstration
of a maintained or increased glucose metabolism in areas of reduced perfusion
("mismatch"). On the other hand, a concordant reduction of myocardial blood flow
and glucose uptake ("match") indicates the presence of scar without any viable tissue
and predicts no recovery of function (Figure 3.10). In one study, Marshall et al
demonstrated that within the first weeks after myocardial infarction, preserved glucose
metabolism (relative to flow measured with 13NH3) ie. mismatch, identified viable
tissue (Marshall et al, 1983). In another study, early after myocardial infarction,
although it was not possible to differentiate hypoperfused regions with preserved
glucose metabolism from those without residual metabolic viability according to
myocardial perfusion alone, segmental wall motion abnormalities, or left ventricular
ejection fraction (Schwaiger et al, 1986), after 6 weeks, 50% mismatched segments
improved their segmental wall motion compared to no change in the matched group.
Thus, maintenance of metabolic activity in infarcted territory predicts a variable
outcome consistent with the wide variation in residual perfusion, collateralisation and
borderline ischaemia within 72 hours of infarction.
Consistent with the added prognostic value of an open artery after thrombolysis,
PET scanning with FDG has demonstrated increased uptake in 76% of regions
subtended by such an artery, compared to 29% of regions with an occluded artery,
despite significant collateral flow in the majority of these (Schwaiger et al, 1987).
Conversely, reduced or absent FDG uptake in an infarct territory is predictive for no
improvement in ventricular function (Schwaiger et al, 1987; Pierard et al, 1990).
These early studies have led to the use of PET as a means of predicting the success of
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Figure 3.10. Upper panel) MBF washout and FDG images over four adjacent
myocardial planes in a patient with a previous extensive anteroseptal myocardial
infarction. MBF and FDG uptake is extremely low in the septal, anterior an apical
regions, but equally preserved in the lateral and inferoposterior regions - "flow-
metabolism match". Lower panel) MBF washout and FDG images in two
myocardial planes in another patient with a previous anteroseptal myocardial
infarction. MBF is low in the anterior and septal regions but FDG uptake is preserved
in all myocardial regions "flow-metabolism mismatch".
101
revascularisation particularly in patients with poor left ventricular function or in those
patients where conventional radio-imaging techniques may suggest irreversible
myocardial injury (Section 3.9). The subject of PET imaging and the diagnosis of
myocardial hibernation and thus myocardial viability has been covered extensively in
recent reviews (Uren & Camici, 1992; Dilsizian &Bonow, 1993).
Thus, PET imaging can distinguish viable and non-viable myocardium on the
basis of analysis of FDG and myocardial blood flow images after oral glucose loading.
This concept of match and mismatch has been developed to predict the success of
revascularisation and has become the main clinical indication for PET scanning
(Section 3.9).
3.8.2. PET Imaging of Oxidative Metabolism
As described above, in addition to the imaging of glucose uptake using FDG,
other tracers have been developed specifically to study myocardial oxidative
metabolism, most notably 11C-palmitate and 1 ^-acetate. nC-palmitate has been used
to trace the oxidation of free fatty acids which are the principle source of high energy
phosphate generation in fasted individuals. However, kinetic modelling of this and
related tracers has proven difficult making quantitation of oxidative metabolism
impossible. 1 ^-acetate has been developed to trace myocardial oxygen consumption
as it enters the tricarboxylic acid cycle directly (Walsh et al, 1989; Armbrecht et al,
1989). Clearance of this tracer does correlate with oxygen consumption (Brown et al,
1987), but again absolute quantitation has also been difficult because of the early
generation of nCC>2 from aerobic metabolism of acetate. Because of this, there has
been much interest in taking the study of oxidative metabolism one stage stage further
with the development of 15C>2 itself as a direct means of quantifying regional
myocardial oxygen consumption. The development of this latter tracer is outwith the
scope of this thesis.
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3.9 New Developments in the Measurement of
Myocardial Viability
In the clinical environment, most PET scanning is done to demonstrate myocardial
viability in patients with reduced left ventricular function prior to revascularisation.
The use of the mismatch of blood flow to FDG uptake as an index of viability (Section
3.8.1.3) has been used to predict the success of revascularisation. Tillisch et al
studied 17 post-infarction patients where preservation of glucose uptake predicted
recovery of 85% of asynergic segments with flow-metabolism mismatch after
coronary artery bypass grafting. Decreased glucose uptake (flow-metabolism match)
implied irreversibility of hypokinesis in 92% of cases (Tillisch et al, 1986). This was
confirmed by Tamaki et al in another study of 22 patients before and 5-7 weeks after
surgery with a positive predictive accuracy of 78% of flow-metabolism mismatch
(Tamaki et al, 1989). They reported a lower negative predictive accuracy of 78% than
the 92% quoted by Tillisch et al (Tillisch et al, 1986). This difference probably
reflected studying patients in the fasted state with a much lower uptake by normal
myocardium increasing the sensitivity of FDG uptake, but in areas with not sufficient
viability to improve with revascularisation. Recovery of myocardial segments after
coronary angioplasty has also been predicted (Nienaber et al, 1991). In this study,
the degree of flow-metabolism mismatch before angioplasty was directly related to late
improvement in wall motion, thus allowing quantitative prediction of contractile
recovery. Other studies have shown flow-metabolism mismatch in asynergic regions
with fixed thallium-201 defects, indicating that conventional radio-imaging techniques
tend to underestimate the extent of viable myocardium (Brunken et al, 1987).
Furthermore, by quantifying flow and to an extent metabolism, and deriving a ratio of
the two, viability may be defined as occurring in asynergic regions with
metabolismrflow ratios of >1.2 (Bonow et al, 1991; Vanoverschelde et al, 1992).
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Myocardial FDG uptake depends on dietary conditions (whether the patient is fed
or fasting which determines substrate availability), the neurohormonal state, cardiac
workload, and the presence of diabetes mellitus (Camici et al, 1989b; Pierard et al,
1990). Even in the normal heart under fasting conditions, there is variability in
regional myocardial glucose uptake independent of oxidative metabolism or perfusion
with reduction in FDG uptake in the interventricular septum (Gropler et al, 1990).
Even so, in comparison with 1 ^-acetate, this reduction in septal FDG uptake persists
despite a similar metabolic demand to other regions studied (Hicks et al, 1991).
Furthermore, it has been shown recently in an animal model of coronary occlusion and
reperfusion that myocardial deoxyglucose deposition in infarct territories overestimates
the extent ofmyocardial necrosis at histology (Sebree et al, 1991). In addition, it was
shown that deoxyglucose uptake was increased in peri-infarct regions. Detection of
myocardial viability using FDG is dependent on the demonstration of residual FDG
uptake in the area at risk. However, the FDG uptake in infarct regions may occur due
to residual deoxyglucose uptake in persisting ischaemic tissue or inflammatory cells
(Sebree et al, 1991). In addition, the presence of FDG activity in an infarcted region
may result from the limited spatial resolution of PET cameras. This may produce a
spillover of activity from the peri-infarct regions, which have an enhanced FDG
uptake, into the infarcted region on the reconstructed FDG image.
These observations may make assessment of myocardial viability with FDG less
accurate, and are a strong argument for standardisation of study conditions by using
the hyperinsulinaemic-euglycaemic clamp technique (de Fronzo et al, 1979), which
improves the interpretation of FDG images when comparing control and diseased
regions. However, despite such improvements, the search for other measurements of
myocardial viability has continued.
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3.9.1. The Perfusable Tissue Index
In order to measure viability without using FDG and consequent problems with
interpretation, a new measure, the water perfusable tissue index (PTI) which is
independent of tissue metabolism has been developed derived from the analysis of
transmission, blood pool (ClsO) and dynamic (H2150) scans (Yamamoto et al, 1992).
The concept of tissue fraction was first introduced to correct for the underestimation of
myocardial radiotracer concentration caused by cardiac wall motion and the small
transmural myocardial thickness relative to the spatial resolution of PET scanners (the
partial volume effect, Section 3.6.1) (Iida et al, 1988). Tissue fraction is the fractional
volume of a given region of interest occupied by myocardium that is capable of rapidly
exchanging water ie. the H2150-perfusable tissue. It is dependent on the ability of the
tissue to exchange H2150 at a microvascular level as well as wall motion and partial
volume effects. It may be referred to as perfusable tissue fraction (PTF). Using the
anatomical tissue fraction (ATF) defined above it is possible to define the PTI as:
PTF (g(H2150-perfusable tissuej-rrii1 ROI) -s- ATF (g(anatomical tissue)-mi1 ROI)
In normal myocardium, this value should be unity ie. all myocardium should be
perfused by water. Using H2150 as a flow tracer, this technique also allows absolute
quantification of myocardial blood flow, in addition to a measure of myocardial
viability (Figures 3.11 and 3.12).
In an initial study, patients were studied within 2-4 days and 4 months after
successful thrombolysis for myocardial infarction who had asynergic myocardium (at
echocardiography) and a regional reduction in myocardial blood flow (Yamamoto et al,
1992). In the acute phase, the PTI was significantly lower in regions in which there
was no subsequent contractile recovery, although myocardial blood flow was reduced









Figure 3.11. Diagrammatic representation of a myocardial region of interest (ROI)
containing a mixture of 150-water perfusable and non-perfusable tissue. Panel A)
Volume of the ROI. Panel B) Anatomical tissue fraction (ATF) for the ROI
produced by subtraction of the converted C150 emission scan (blood pool) from the
transmission data after normalisation of the latter to tissue density. ATF contains both
perfusable and non-perfusable tissue components. Panel C) lsO-water perfusable
tissue fraction (PTF) for the ROI calculated from the dynamic H2150 study. Note that
the non-perfusable or necrotic region is excluded from this parameter. The 150-water
perfusable tissue index (PTI) is calculated by dividing PTF (C/A) by ATF (B/A) thus
independent of ROI size, and represents the fraction of total anatomical tissue that is
perfusable by water.
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Figure 3.12. The PTI may also be demonstrated as a three-dimensional image
corrected to a lower threshold of 70% water-perfused myocardium (yellow image).
This is superimposed on the blood volume image (red image) in the right anterior
oblique view. The subject has sustained a small anterior myocardial infarction with an
apparent "window" of <70% water perfused tissue ie. non-viable myocardium.
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indicated that within a given region, 70% of the tissue should be capable of rapidly
exchanging water to enable a subsequent improvement in contractile function. In
patients with previous myocardial infarction, PTI demonstrated good agreement with
FDG scanning in predicting reversibility of injury in these patients. Subsequently, this
sensitivity in discriminating reversibly from irreversibly injured myocardium has been
confirmed in a group of 12 patients undergoing coronary bypass surgery and
angioplasty (de Silva et al, 1992). In this study, contractile recovery only occurred in
myocardial regions where PTI was greater than 0.7.
Given that there is a coincident "downregulation" of metabolic activity in
hibernating myocardium, there is a concomitant reduction in tissue oxygen utilisation.
It is possible to directly measure myocardial oxygen consumption non-invasively at
PET using the tracer 15C>2 (Yamamoto et al, 1991). As described above, flow-
metabolism mismatch can demonstrate viability in qualitative terms but with limited
accuracy. By using oxygen utilisation as an absolute measure of regional tissue
metabolism, independent of substrate availability and glycolytic rate, it may be
possible to differentiate hibernating myocardium from non-viable tissue with greater
accuracy. Combining measurement of regional oxygen consumption with the PTI
derived from dynamic H2150 imaging should allow better discrimination of
chronically ischaemic tissue from infarction and the amount of viable tissue in an
infarcted area. The combination of measurement of regional wall motion by gated
PET scanning, myocardial blood flow and the perfusable tissue index with H2150,
and regional myocardial oxygen utilisation with 1502, will provide accurate
assessment ofmyocardial viability, the determination of which is likely to remain the
one major clinical indication for PET scanning in the future.
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3.10 Summary
The basic principles of PET and the design of the tomograph used in our
institution have been described. By incorporating positron-emitting isotopes into
metabolic substrates, it is possible to measure regional myocardial blood flow, and
myocardial oxidative metabolism, and by using radiolabelled ligands, the
pharmacokinetics of myocardial receptor function. The advantage of quantitative
assessment of myocardial perfusion allows the accurate study of the control of
myocardial blood flow under basal conditions and, with the short half-lives of tracers,
the serial study of myocardial blood flow after stress, and thus the assessment of
coronary resistive vessel function. Combined with the demonstration of regional
myocardial ischaemia with FDG, it is now possible to investigate the mechanisms
underlying cardiac disease, with particular reference to atherosclerosis, and coronary
artery disease.
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CHAPTER 4. MODELS FOR THE STUDY OF
RESISTIVE VESSEL DYSFUNCTION IN
CORONARY ARTERY DISEASE
4.1 Introduction
Recent observations in patients have led to the hypothesis that the coronary
vasodilator reserve and thus ischaemic threshold can be substantially altered by
changes in vasomotor tone at the level of the resistive vessels rather than in large
epicardial coronary arteries. There are several models where the role of dynamic
epicardial coronary stenoses can be excluded. By studying different clinical models of
coronary artery disease, it is possible to determine the role of resistive vessel
dysfunction in causing abnormalities of coronary blood flow in these conditions. It is
also possible to determine to what extent they account for other abnormal findings and
their association with other markers of cardiac function. The determination of the
contribution and mechanisms of resistive vessel dysfunction to the coronary artery
disease syndromes, may enable new therapies to be developed which might ameliorate
this abnormality and thereby reduce morbidity.
4.2 Proposed Models in Coronary Artery
Disease
Several models have been selected for study in this thesis, in order to investigate
coronary resistive vessel dysfunction in different manifestations of the process of
coronary artery disease. These have been selected so that resistive vessel function
and its correlate, the coronary vasodilator reserve, may be assessed in regions of
myocardium subtended by diseased and angiographically normal coronary arteries
110
using positron emission tomography. In selected models, Doppler catheterisation
has been used to investigate further the mechanism of abnormalities in coronary
blood flow in epicardial vessels, and coronary sinus catheterisation performed to
quantitate regional myocardial metabolism. The following five studies comprise the
work of this thesis.
In Chapter 5, the first model studied is of patients in whom a flow-limiting
coronary artery stenosis has been relieved by successful percutaneous transluminal
coronary angioplasty. In a previous study following successful angioplasty, the
coronary vasodilator reserve determined using intracoronary papaverine did not return
to normal in 55% of patients immediately following the procedure (Wilson et al,
1988). In the absence of restenosis, the coronary blood flow reserve had returned to
normal at a mean follow up of 7.5 months. The authors suggested that abnormal
resistive vessel function may account for this finding, and that prolonged
vasodilatation resulting from low perfusion pressure distal to the stenosis might cause
a transient inability of the resistive vessels to autoregulate in response to a sudden
restoration of normal perfusion pressure (Wilson et al, 1988). These findings are
consistent with the observation that a positive exercise test may be demonstrated as
early as three days after successful PTCA and remain positive for up to a month before
becoming negative, in the absence of restenosis or coronary artery spasm using non¬
invasive provocation tests (El-Tamimi et al, 1991). In this study, our intention was to
investigate the changes in coronary resistive vessel function which occur immediately
after angioplasty and to determine the time course of any changes in resistive vessel
function.
In Chapter 6, the mechanism underlying this alteration in resistive vessel function
after angioplasty is investigated. Deficient production or release of endothelium-
derived relaxing factor (EDRF), which may be identical to nitric oxide, may occur due
to the effect of the atherosclerotic process on endothelial cell function, and may
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account for an alteration in vasodilator responsiveness (Kuo et al, 1992). Furthermore,
it has been demonstrated in vitro that vasodilatation to exogenous nitrates is enhanced
by the removal of endothelium (Shirasaki & Su, 1985), and by inhibition of nitric
oxide synthesis (Shirasaki & Su, 1985; Moncada et al, 1991), which appears to be
related to an up-regulation of soluble guanylate cyclase (Moncada et al, 1991). If the
impairment of the coronary vasodilator reserve after angioplasty was due to reduced
production of nitric oxide, then there would be an increase in the vasodilator response
with delivery of a high concentration of nitric oxide to the coronary microcirculation.
To test this hypothesis in relation to the reduced coronary vasodilator reserve after
angioplasty, we have infused high intracoronary doses of the nitric oxide donor,
sodium nitroprusside, following intravenous dipyridamole measuring coronary blood
flow with a Doppler catheter.
In Chapter 7, the coronary vasodilator reserve in patients with stable single vessel
coronary artery disease is investigated as a potential model of resistive vessel
dysfunction. Transient myocardial ischaemia in one myocardial region may also lead
to an increase in left ventricular dimensions associated with a regional increase in
contractility in other remote non-ischaemic regions in animal models (Naccarella et al,
1984; Smalling et al, 1986; Buda et al, 1990) and this may be associated with a
regional alteration in myocardial metabolism, such as an increase in glucose and free
fatty acid utilisation, and in oxygen consumption (Liedtke et al, 1982). However, it is
not known whether patients with recurrent myocardial ischaemia, without evidence of
previous infarction or regional wall motion abnormality, may develop alterations in
coronary resistive vessel function in the remote regions subtended by angiographically
normal coronary arteries as an early abnormality, perhaps due to the atherosclerotic
process, as described by Drexler (Drexler et al, 1991) and Zeiher (Zeiher et al, 1991).
Thus, resistive vessel dysfunction may occur not only in regions subtended by
coronary arteries with proximal disease, but also in regions subtended by normal
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arteries in patients with coronary artery disease. To examine coronary resistive vessel
function in remote myocardium subtended by angiographically normal arteries, a
group of these patients was studied in order to measure both regional coronary
vasodilator reserve and metabolic substrate handling in both the region subtended by
the stenosis-related artery and a remote region subtended by a normal coronary artery.
In Chapter 8, a model of acute resistive vessel dysfunction is studied where an
additional factor such as altered sympathetic nervous system activity is present,
limiting further the vasodilator responsiveness of myocardium. This may occur after
myocardial infarction with an increase in sympathetic activation over several days even
in the absence of significant left ventricular dysfunction. By studying patients with
single vessel disease sustaining an uncomplicated myocardial infarction, it is possible
to document any changes in resistive vessel function in both the infarcted and remote
region in the acute and convalescent phases of infarction. In an animal model of
myocardial infarction, a reduced coronary vasodilator reserve has been shown in
remote myocardium due to both an increase in basal flow and to reduced
vasodilatation, in part attributed to reactive myocyte hypertrophy in the remote
myocardium and an increase in end-diastolic pressure (Karam et al, 1990), but
associated with reduced basal nitric oxide release several weeks after infarction
(Drexler et al, 1992). The mechanism for this reduction in vasodilator responsiveness
could perhaps be due to functionally less active endothelium in the resistive vessels,
seen after endothelial injury (Shimokawa et al, 1987). In the clinical model of
infarction that we have chosen to study, using a PET-derived index of myocardial
viability, the perfusable tissue index, it is possible to correlate acute resistive vessel
dysfunction with residual viability and regional wall motion using ventriculography .
In Chapter 9, the final model of resistive vessel dysfunction is represented by
patients with a blocked coronary artery subtending a non-infarcted territory perfused
by collateral vessels from angiographically normal coronary arteries. A recent study
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of 11 patients with a single coronary occlusion and collaterals showed that frequent
episodes of ST segment depression occurred at heart rates considerably lower than
those associated with ST segment depression on exercise testing, and episodes of
sinus tachycardia greatly exceeding the rates associated with ST segment depression
occurred without such changes (Pupita et al, 1990). The authors suggested that
reduced collateral blood flow accounted for these observations and it is possible that
constriction of the vessels feeding the collaterals or of the collaterals themselves, or
constriction of the (resistive) vessels receiving the collaterals could account for this.
As this could account for myocardial ischaemia often documented in these patients, we
studied the effect of reflex a-adrenergic stimulation using the cold pressor stress on
regional myocardial blood flow and glucose uptake in a group of these patients.
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CHAPTER 5. DELAYED RECOVERY OF
CORONARY RESISTIVE VESSEL FUNCTION
AFTER CORONARY ANGIOPLASTY
5.1 Abstract
The time course of abnormal coronary resistive vessel function in the impairment
of the coronary vasodilator reserve was studied after successful coronary angioplasty,
using Doppler catheterisation and sequential dynamic positron emission tomography.
The coronary vasodilator reserve may be impaired immediately after coronary
angioplasty, despite successful dilatation of a flow-limiting stenosis. Twelve male
patients (mean age 52±10 years) with single vessel coronary artery disease and normal
left ventricular function were studied. The coronary vasodilator reserve to intravenous
dipyridamole (0.5 mg.kg"1 over 4 minutes) was determined from intracoronary
Doppler measurement of coronary flow velocity, before and after successful
angioplasty. Basal and maximal myocardial blood flow in the angioplasty region and
a normal region were determined in 9 patients using positron emission tomography
(PET) with H2150, at 1 day (PETi), 7 days (PET2), and 3 months (PET3) after
angioplasty. The coronary vasodilator reserve, measured by Doppler catheterisation,
was similar before and immediately after angioplasty, 1.6310.40 and 1.6210.55
respectively (p=NS). After angioplasty, in 7 of 9 patients without restenosis, basal
myocardial blood flow at PETi, PET2, and PET3, was 0.9810.16, 0.9410.09, and
0.9910.13 ml.min lg"1 respectively, in the remote region, and 1.1910.23 (p<0.01 vs.
remote region), 1.1710.19 (p<0.01 vs. remote region), and 1.1010.08 ml.mnrlg-1
(p=NS vs. remote region) respectively, in the angioplasty region. Myocardial blood
flow after dipyridamole at PETi, PET2, and PET3 was 3.0410.68, 3.0010.71, and
3.0010.60 ml.mnr'.g1 respectively, in the remote region, and 2.1110.80 (p<0.01
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vs. remote region), 2.28±0.73 (p=NS vs. remote region), and 3.06±0.86 ml.minhg
1 (p=NS vs. remote region) respectively, in the angioplasty region. The coronary
vasodilator reserve at PETi, PET2, and PET3 was 3.15±0.85, 3.18±0.68, and
3.08±0.75 respectively, in the remote region, and 1.80±0.68 (p<0.01 vs. remote
region), 1.94±0.49 (p<0.01 vs. remote region), and 2.77±0.74 (p=NS vs. remote
region) respectively, in the angioplasty region.
In conclusion, after successful angioplasty, basal myocardial blood flow is
increased for at least 7 days in the angioplasty region, with a reduction in the
dipyridamole-induced increase in maximal myocardial blood flow for at least 24 hours
following the procedure. Thus, the coronary vasodilator reserve is impaired for at
least 7 days after angioplasty, indicating that there is abnormal resistive vessel function
in the coronary vascular bed distal to a coronary artery stenosis which persists for
between 7 days and 3 months.
5.2 Introduction
Animal studies indicate that dilatation of the coronary resistive vessels can allow
coronary blood flow to increase 3-4 times above resting values, even in the presence
of a 70% diameter stenosis (Gould et al, 1975). However, in patients with coronary
artery disease, the behaviour of resistive vessels may be abnormal, and the ischaemic
threshold can be altered by changes in vasomotor tone at the level of the resistive
vessels rather than in the large epicardial coronary arteries (Pupita et al, 1990).
Determination of the contribution of resistive vessel dysfunction to myocardial blood
flow limitation is, however, problematic since in the presence of a flow-limiting
coronary artery stenosis, it is impossible to separate the effects of altered vasomotion
at the site of a stenosis from those of the resistive vessels on modulation of the residual
coronary blood flow (Epstein & Talbot, 1981; Maseri et al, 1991).
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In order to resolve the difficulty in establishing to what extent coronary blood flow
can be modulated by resistive vessel dysfunction, it is necessary to evaluate coronary
and regional myocardial blood flow in a clinical model of coronary artery disease
which allows exclusion of the effect of a flow-limiting epicardial stenosis, such as
following successful percutaneous transluminal coronary angioplasty (PTCA). In
addition, as the coronary vasodilator reserve may vary among patients, it is essential to
compare, in each case, the behaviour of the vascular bed distal to the stenosis with that
of a remote myocardial territory. We used positron emission tomography (PET) to
compare the results of Doppler catheterisation of a myocardial region previously
subtended by a coronary artery stenosis with a remote region subtended by an
angiographically normal artery, and to follow the coronary vasodilator reserve to
dipyridamole, non-invasively. We report the changes in basal myocardial blood flow
and the myocardial blood flow response to dipyridamole following PTCA, together
with the time course of these changes from 1 day up to 3 months after the procedure in
diseased and remote myocardial regions.
5.3 Methods
5.3.1. Patient Population
Twelve male patients (mean age 52+10 years, range 39-72) with chronic stable
angina were studied. All patients had a positive exercise test. Patients who had
suffered a previous myocardial infarction or unstable angina pectoris were excluded.
All had proximal left anterior descending coronary artery disease and were undergoing
routine PTCA. The left circumflex and right coronary arteries were angiographically
normal. Doppler catheterisation was used to evaluate basal and post-dipyridamole
coronary blood flow velocity before and immediately after PTCA in 12 patients; in 9 of
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these patients, PET was used to evaluate regional basal and post-dipyridamole
myocardial blood flow 1 day, 7 days and 3 months after PTCA.
5.3.2. Study Protocol
The protocol was approved by the Research Ethics Committee of Hammersmith
Hospital and all patients gave informed and written consent.
All anti-anginal medication (except sublingual nitroglycerin) was discontinued at
least 48 hours prior to initial exercise testing and angioplasty, and 72 hours prior to
PET scanning. No patient took nitroglycerin within 12 hours of any part of the
protocol. Treadmill exercise testing was performed according to the modified Bruce
protocol the day before angioplasty. PTCA was performed as clinically indicated.
Coronary blood flow velocity and the coronary vasodilator reserve (defined as post-
dipyridamole coronary flow velocity/basal coronary flow velocity) (Klocke, 1987),
was measured before and after PTCA, as described below. PET scanning with
measurement of the myocardial blood flow (MBF) and coronary vasodilator reserve
was undertaken 1 day after PTCA (PETi) in 9 patients (3 patients declined to continue
in the study after PTCA). Repeat exercise testing and PET scanning was done at 7±1
days (PET2) and 100±20 days (PET3) after PTCA, according to the same protocol as
before. In all 9 patients, repeat coronary angiography was performed at 110±25 days.
5.3.2.1. Coronary Blood Flow Velocity Measurement bv Doppler Catheterisation
Coronary angiography was performed as clinically indicated in order to best
demonstrate the lesion morphology. On completion, an 8-French gauge guiding
catheter was inserted into the left coronary ostium. A 0.010 or 0.012 in. "Hi-Torque"
guide wire (Advanced Cardiovascular Systems Inc., Santa Clara, Ca.) was advanced
across the coronary lesion in the usual fashion. Providing there was no evidence of
myocardial ischaemia (chest pain or ECG changes), a 3-French gauge Doppler flow
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catheter (Model No. DC 201; Millar Instruments Inc., Houston, Tx., U.S.A.) with a
20 MHz pulsed Doppler crystal, referenced to zero and calibrated, was advanced over
the guide wire. The tip of the Doppler catheter was positioned up to 5 mm proximal to
the stenosis (Wilson et al, 1985). The Doppler velocimeter range control was adjusted
to obtain an optimal audio signal and both phasic and mean tracing of maximal resting
coronary blood flow velocity.
Coronary flow velocity, heart rate and systemic arterial pressure were measured
continuously. Resistive vessel dilatation was induced by dipyridamole (0.5 mg.kg"1
intravenously over 4 minutes). In 7 patients, coronary flow velocity was measured
before PTCA. PTCA was then performed entirely as clinically indicated using an
A.C.S. RX balloon angioplasty catheter (Advanced Cardiovascular Systems Inc.,
Santa Clara, Ca., U.S.A). Following the procedure, the angioplasty catheter was
removed leaving the guide wire in situ. The Doppler flow catheter was re-positioned
as described above. Repeat measurements of basal and maximal coronary blood flow
velocity after dipyridamole were performed as described above in all 12 patients.
5.3.2.2. Quantitative Coronary Arteriography
Coronary arteriograms were analysed by an automated edge contour detection
computer analysis system (Cardiovascular Angiographic Analysis System [CAAS],
Pie Medical Equipment BV, Maastricht, The Netherlands) (Reiber et al, 1984). The
luminal diameter of the coronary stenosis in the projection showing maximum
severity, and of the proximal reference segment, were measured at end-diastole with
care taken to select a view free from overlapping vessels. This was done under basal
conditions and at the peak effect on coronary flow velocity of dipyridamole both
before and after angioplasty. The diameter of the stem of the Judkins coronary
catheter was used for calibration in order to obtain measurements in absolute units
(mm). Correction was made for radiographic pincushion distortion. Stenosis severity
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was also expressed as percentage reduction of the internal luminal diameter relative to
the angiographically normal proximal coronary segment, the reference segment.
Restenosis was defined using the same criteria as Beatt et al (Beatt et al, 1992): a
reduction in the residual lumen diameter of >0.72 mm and >50% diameter stenosis.
The coronary vascular resistance index was calculated as the quotient of mean
arterial pressure and coronary blood flow velocity, and expressed as units (Kern et al,
1989).
5.3.2.3. Regional Myocardial Blood Flow Measurement with PET
Regional myocardial blood flow (MBF) was measured using 15-oxygen (150) and
dynamic PET (Araujo et al, 1991). This was performed at three time points after
coronary angioplasty in 9 patients: i) within 24 hours, ii) 7±1 days, and iii) 100+20
days. All PET scans were recorded with an ECAT 931-08/12 scanner (CTI Inc.,
Knoxville, Tn., U.S.A.). The scanner consists of 8 contiguous rings of bismuth
germanate detectors which allows 15 cross-sectional images of the heart to be
visualised simultaneously in a 10.5 cm axial field of view. All emission scans were
reconstructed with a Hanning filter which had a cut-off frequency of half maximum.
This resulted in a transaxial resolution of 8.4+0.7 mm FWHM (full width at half
maximum) for the emission data at the centre of the field of view (Spinks et al, 1988).
Thus, it was possible to record simultaneously myocardial and blood tracer
concentrations of the whole heart (Chapter 3, Section 3.4).
1. Scanning procedure. Patients abstained from drinking tea or coffee on the
morning of the scan and all had been off anti-anginal medication for at least 72 hours.
After PTCA, patients were treated with intravenous nitrate until 12 hours prior to the
scan.
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Patients were positioned in the scanner and a 5 minute rectilinear transmission
scan was recorded to allow positioning of the left ventricle in the centre of the field of
view. This was done by exposing a circular ring source using 2 mCi of germanium-
68. Another transmission scan was then recorded for 20 minutes which was used to
correct all emission scans for tissue attenuation. The patient's position with respect to
the camera was determined by a cross-shaped low power laser beam and pen marks on
the patient's skin. Following transmission, radioactive gases were continuously
delivered by an MC face-mask. Blood pool scans were performed with lsO-labelled
carbon monoxide (ClsO). This tracer, which forms 150-carboxyhaemoglobin, was
continuously delivered at at a flow rate of SOOml-min"1 (3 MBq-ml"1) for 4 minutes,
and a 6 minute single frame scan was recorded starting one minute after the end of gas
delivery. Venous blood samples were taken before and after gas delivery. The C150
concentration was measured with a sodium iodide well counter cross-calibrated with
the scanner. After a 10 minute period to allow for decay, a continuous inhalation of
C1502 was given for 3.5 minutes (4 MBq.ml"1 at a flow rate of 500 ml-min"1). The
C1502 is converted immediately by the enzyme carbonic anhydrase in the lung
capillaries to lsO-labelled water (H2150), which is delivered to pulmonary venous
blood (Clark & Buckingham, 1975). A sequence of 24 scans started with C1502
delivery, consisting of 6 scans of 5, 10, 20, and 30 seconds. This produced a build¬
up scan over 3.5 minutes and a washout scan over 3 minutes. Basal MBF was
measured in all patients. After 10 minutes to allow for decay, the myocardial blood
flow was measured following an intravenous infusion of dipyridamole (0.5 mg-kg"1
over 4 minutes). The delivery of C1502 started two minutes after the end of this
infusion. A standard 12 lead electrocardiogram was recorded every minute during the
dipyridamole infusion and for up to 8 minutes after the infusion. Blood pressure was
measured every minute by a cuff sphygmomanometer during the same period of time.
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2. Analysis of PET data. The sinograms were corrected for attenuation and
reconstructed on a Microvax II computer (Digital Equipment Corporation, Marlboro,
Ma.) using dedicated array processors and standard reconstruction algorithms (Araujo
et al, 1991; Spinks et al, 1988). Images were transferred to a SUN 3/60 work-station
for further analysis using Analyze™ (Mayo Foundation, Rochester, Mn.,U.S.A.) and
Pro-Matlab™ (The Mathworks Inc., South Natick, Ma., U.S.A.) software packages.
A blood volume image was created using the C15C>2 data, by dividing the raw
image by the product of the average venous blood radioactivity and the density of
whole blood (1.06 g-mb1)- Either 4 or 5 transaxial regions of interest were drawn
within the left atrium which were projected onto the dynamic lsO-water images to
generate time-activity curves for each region. The average was used as arterial input
function. Images of extravascular volume were created by subtracting blood volume
from transmission images after the latter were normalized for tissue density (1.04
g-ml"1). In addition, the blood volume images were subtracted from the integrated
time frames of the washout phase of the 150-water studies. The images of
extravascular volume and extravascular 150-water were used to delineate 4 regions of
myocardium (anterior, lateral, infero-posterior and septal) over 5-7 transaxial planes,
and data averaged prior to the modelling of myocardial perfusion (Figure 5.1). The
regions of interest were superimposed onto the kinetic time frames recorded during the
C1502 inhalation and washout. This generated myocardial tissue time-activity curves
for each region, which together with arterial time-activity curves, were fitted to a single
tissue compartment tracer kinetic model to give values for regional MBF (in ml-min-
hg-1) (Araujo et al, 1991).
In all patients, the anterior region was designated as the PTCA region and the
infero-posterior region was designated as the remote region. Basal MBF and MBF
after dipyridamole were determined in both regions. The coronary vasodilator reserve
was defined as post-dipyridamole MBF/ basal MBF (Klocke, 1987).
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Anterior Right ventricle
Figure 5.1. A schematic of the standard regions of interest drawn on the left
ventricular extravascular density image and transposed to the washout image. The
anterior region was drawn from the intersection of right ventricular free wall with
septum. The demarcation between lateral and inferoposterior regions was drawn at the
level of the posterior papillary muscle.
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5.3.3. Statistical Analysis
All values are expressed as mean±SD. Data from Doppler catheterisation before
and after angioplasty was analysed using the paired Students t test. Two-way analysis
of variance (ANOVA) was used to compare data derived from PET scanning at the
different time intervals. Specific comparisons were done using the paired Students t
test corrected for multiple comparisons with the Boneferroni inequality adjustment
(Wallenstein et al, 1980). Linear regression analysis was used to examine the
relationship between coronary artery dimensions and the the coronary vasodilator
reserve measured by Doppler. MBF values in the regions of interest in each individual
plane for each scan were derived and the coefficient of variation within and between
groups measured by one-way ANOVA. A p value <0.05 was considered statistically
significant.
5.4 Results
Doppler catheterisation was performed in 7 patients before PTCA, and in all 12
patients after PTCA (Table 5.2). PET scanning was done 1 day after PTCA in 9
patients (3 patients declined to continue in the study after PTCA). Seven (7±1) days
and 3 months (100±20 days) after PTCA, the same 9 patients underwent repeat
exercise testing and PET scanning, according to the same protocol as before (Tables
5.4 and 5.5). In all 9 patients, repeat coronary angiography was done 110±25 days
after the initial PTCA. Two patients who had developed recurrent angina and who had






All patients underwent treadmill exercise testing at least 48 hours off all anti¬
anginal medication before PTCA (Figure 5.2). Nine patients agreed to continue in the
study after PTCA. Before PTCA, the rate-pressure product (RPP) was 9,160±2,880
mrnHg-min-1 at rest, 18,310±7,820 mmHg-min-1 at O.lmV ST segment depression,
and of 20,750±7,670 mmHg.min"1 at peak exercise. Seven days post-PTCA, all 9
patients performed negative tests; the RPP at peak exercise was 29,410±7,920
mmHg-min"1 (p<0.05 vs. peak RPP pre-PTCA). In the 7 patients with no restenosis,
the RPP at peak exercise was 20,960±7,830 mmHg-min-1 pre-PTCA, and
29,550±8,690 mrnHg-min"1 at 7 days (p<0.05 vs. peak RPP pre-PTCA) (Figure 5.2).
All 9 patients underwent exercise testing approximately 3 months (100±20 days) after
PTCA. The exercise tests were negative in 6 patients and positive in 3 patients. Of
these 3 patients, 2 had restenosis: 1 asymptomatic patient without restenosis (patient 3)
reached O.lmV ST segment depression at a RPP of 25,830 mmHg.mhr1 (compared to
8370 mmHg-min-1 pre-PTCA), unassociated with symptoms of chest pain. Thus, the
RPP at peak exercise in the 7 patients without restenosis was 29,560±9,310
mmHg-min-1 (Figure 5.2).
In the 2 cases with restenosis at 3 months, both had negative tests at 7 days.
Patient 8 had an RPP to O.lmV ST segment depression of 18,600 mmHg.min"1 at 3
months (cf. 9,960 mmHg-min-1 pre-PTCA), and patient 9 had an RPP to O.lmV ST
segment depression of 21,450 mmHg-min-1 at 3 months (cf. 21,250 mmHg-min-1 pre-
PTCA) (Figure 5.2).
5.4.2. Quantitative Coronary Arteriography/
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5.4.2. Quantitative Coronary Arteriography
(Table 5.1)
The results of quantitative coronary arteriography are shown in Table 5.1. There
was an increase in luminal diameter at the site of stenosis from 0.64±0.28 mm to
1.86±0.48 mm (p<0.0001) immediately after PTCA, corresponding to a reduction in
percentage luminal stenosis severity from 73.1±10.3% to 26.2±7.2% (p<0.0001).
Pre-PTCA, at the peak effect of dipyridamole, there was no significant change in
diameter at the stenosis or of the reference segment, 0.74±0.27 and 2.29±0.38 mm,
respectively. Post-PTCA, there was no significant change in diameter at the stenosis,
1.86+0.48 and 1.84±0.46 mm, or of the reference segment, 2.50±0.50 and
2.54±0.39 mm, from basal to post-dipyridamole, respectively.
At follow-up arteriography, there was no evidence of restenosis in 7 patients, with
a lumen diameter at the site of stenosis of 1.80±0.23 mm (p=NS vs. post-PTCA
stenosis diameter) and a reference diameter of 2.61±0.36 mm (p=NS vs. post-PTCA
reference diameter). In 2 cases, there was evidence of restenosis: a residual lumen
diameter of 0.46 mm (reference diameter of 3.11 mm) in patient 8 and complete
occlusion at the site of previous PTCA in patient 9. In patient 9, there was no clinical
or ECG evidence ofmyocardial infarction.
5.4.3. Coronary Flow Velocity with Doppler Catheterisation
(Table 5.2, Figures 5.3 and 5.4)
Seven patients underwent Doppler catheterisation before PTCA (Table 5.2). Heart
rate increased from 64±8 beats-min4 at basal to 82±5 beats-min4 at the peak effect of
dipyridamole (p<0.01), with no significant reduction in systolic (149±18 to 140±15
mmHg), diastolic (92±9 to 87±10 mmHg) or mean (111±11 to 106±11 mmHg)
arterial pressure. Coronary flow velocity increased from a basal value of 7.5±3.9
cm-s4, to 11.3+3.6 cm-s4 (p<0.01) after dipyridamole, with a coronary vasodilator
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Stenosis (mm) 0.64±0.28 0.74+0.27
Reference (mm) 2.30±0.37 2.29+0.38
% stenosis 73.1±10.3% 67.6+8.9%
After angioplasty
Stenosis (mm) 1.86±0.48 * 1.84+0.46 *
Reference (mm) 2.50±0.50 2.54+0.39
% stenosis 26.2+7.2% * 27.8+13.1% *
Follow-up
arteriography!
Stenosis (mm) 1.80±0.23 -
Reference (mm) 2.61±0.36 -
% stenosis 29.6±16.0% -
* pcO.OOOl vs. value before PTCA. t Data are from the 7
patients without restenosis among the 9 patients who underwent
follow-up arteriography.
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reserve of 1.63±0.40 (Figure 5.3). The coronary vascular resistance index fell from
17.5±6.4 units at basal to 10.1±3.2 units (p<0.01) with dipyridamole (Figure 5.4).
Twelve patients underwent Doppler catheterisation after PTCA (Table 5.2). Heart
rate increased from 66±13 beats-mim1 at basal to 81±18 beats-min-1 at the peak effect
of dipyridamole (pcO.OOl), with no significant reduction in systolic (135±21 mmHg
to 130±20 mmHg), diastolic (94±10 to 87±12 mmHg) or mean (100±12 to 96±15
mmHg) arterial pressure. The basal coronary flow velocity was 9.2±5.0 cm-s"1 and
the maximal coronary flow velocity after dipyridamole was 13.8+5.7 cm-s-1 (pcO.OOl
vs. basal). The coronary vascular resistance index fell from 13.2±5.2 units at basal to
7.8±2.8 units with dipyridamole (p<0.01 vs. basal), with a coronary vasodilator
reserve of 1.62±0.48. With linear regression analysis, no relationship was
demonstrated between residual stenosis diameter after angioplasty and the coronary
vasodilator reserve.
Coronary flow velocity and coronary vascular resistance index were compared in
the 7 patients who were studied before and after PTCA. In these 7 patients, the mean
time between the start of each dipyridamole infusion was 55.6±10.6 minutes. There
were no significant differences in systolic, diastolic or mean arterial pressures at basal
or at peak dipyridamole before or after PTCA. Post-PTCA, the basal coronary blood
flow velocity was significantly increased to 9.9±6.2 cm-s1 compared with pre-PTCA
(p<0.05 vs. pre-PTCA basal), although that after dipyridamole, 14.5±6.9 cm-s-1, was
not significantly changed (p=NS vs. pre-PTCA peak dipyridamole) (Figure 5.3).
Post-PTCA, the coronary vasodilator reserve was 1.62±0.55 (p=NS vs. pre-PTCA).
The basal coronary vascular resistance index was significantly lower post-PTCA,
13.6±6.2 units (p<0.05 vs. pre-PTCA basal), although the value after dipyridamole,
8.3±3.1 units, was similar to that pre-PTCA (p=NS vs. pre-PTCA peak dipyridamole)
(Figure 5.4).
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Table 5.2. Doppler Coronary Flow Velocity Before and After
Angioplasty












1 4.3 9.2 2,14 4.0 11.0 2.75
2 15.5 15.5 1.00 22.0 27.0 1.23
3 - - - 12.0 15.0 1.25
4 - - - 6 7.5 1.25
5 7.0 12.0 1.71 7.5 9.0 1.20
6 4.6 6.8 1.48 6.0 8.8 1.47
7 5.9 12.2 2.07 7.4 14.3 1.93
8 - - - 10.0 17.8 1.78
9 - - - 7.0 11.2 1.6
10 - - - 5.6 12.5 2.23
11 5.8 7.6 1.31 8.0 10.8 1.35
12 9.2 15.8 1.72 14.6 20.8 1.42
Mean
1SD
7.5±3.9 11.3±3.6 * 1.63±0.41 9.2±5.0 § 13.815.7 t 1.6210.48









Figure 5.3. Bar graphs showing coronary flow velocity at basal and at peak
dipyridamole (Dip) before PTCA (n=7) and after PTCA (n=7). (* p<0.05 vs. pre-





Figure 5.4. Bar graphs showing coronary vascular resistance index at basal and at
peak dipyridamole (Dip) before PTCA (n=7) and after PTCA (n=7). (* p<0.05 vs.
pre-PTCA, ** p<0.01 vs. Basal).
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5.4.4. Regional Myocardial Blood Flow with PET
(Tables 5.3 to 5.5, Figures 55 and 5.6)
Heart rate, systolic and diastolic blood pressure, and rate-pressure product at basal
and after dipyridamole at each PET study are shown in Table 5.3. There were no
significant differences in these haemodynamic parameters comparing all three studies.
Individual myocardial blood flow (MBF) at basal and after dipyridamole and the
coronary vasodilator reserve at 1 day, 7 days and 3 months are shown in Tables 5.4
and 5.5.
One day after PTCA, in the 7 of 9 patients without restenosis at three months,
MBF at rest was significantly higher in the PTCA region, 1.19±0.23 ml-min^g"1,
compared to the remote region, 0.98±0.16 ml-min^-g1 (p<0.01) (Figure 5.5). This
increase in basal MBF was still present at 7 days after PTCA, 1.17±0.19 ml-min^g"1
in the PTCA region compared with 0.94±0.09 ml-min ^g1 in the remote region
(p<0.01). Three months after PTCA, there was no significant difference between
basal MBF in the PTCA and remote regions (1.10±0.08 and 0.99±0.13 ml-min^-g1,
respectively) (Table 5.4 and Figure 5.5).
The dipyridamole-induced increase in MBF in the PTCA region at 1 day,
2.11±0.80 ml-min^-g"1, was lower than the remote region, 3.04±0.68 ml-min'-g"1
(p<0.01). At 7 days, although the MBF response to dipyridamole was still lower in
the PTCA region compared to the remote region (2.28±0.73 and 3.00±0.71 ml-mhr
Lg4, respectively), this was not a significant difference. At 3 months after PTCA, the
MBF response to dipyridamole was similar in the PTCA region and the remote region
(3.06±0.86 and 3.00±60 ml-min^-g"1, respectively) (Table 5.4 and Figure 5.5).
One day after PTCA, the coronary vasodilator reserve was significantly lower in
the PTCA region, 1.80±0.68, compared with the remote region, 3.15±0.85 (p<0.01)
(Figure 5.6). This difference was present 7 days after PTCA; 1.94±0.49 in the PTCA
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Study
HeartRate (beats-min*1)
Systolic Blood Pressure (mmHg)
Diastolic Blood Pressure (mmHg)
Rate-Pressure Product (mmHg-min-1)
HeartRate (beats-min-1)
Systolic Blood Pressure (mmHg)
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PTCA, the coronary vasodilator reserve was similar in the two regions; 2.77±0.74
and 3.08±0.75 (p=NS) in the PTCA and remote regions, respectively.
In the 2 patients with restenosis at 3 months, there was an impaired coronary
vasodilator reserve in the PTCA region (1.28 in patient 8 and 1.90 in patient 9)
compared to the mean value of 2.77±0.74in the 7 patients without restenosis. Of
interest, in the remote region, the coronary vasodilator reserve was also impaired (1.08
in patient 8 and 1.83 in patient 9) compared to the mean value of 3.08±0.75 in the 7
patients without restenosis (Tables 5.4 and 5.5).
To assess variability in the MBF measurements in the PTCA and remote regions in
individual planes at each scan, the coefficient of variation was measured. At basal, the
coefficient of variation in the PTCA region was 21.3±9.7%, 23.1+12.6%, and
22.3±9.4% (all p=NS), and in the remote region was 24.9±10.6%, 30.4±9.8% and
28.7±3.7% (all p=NS) at PETi, PET2, and PET3, respectively. After dipyridamole,
the coefficient of variation in the PTCA region was 23.8±8.7%, 25.9±10.8%, and
24.7±12.2% (all p=NS), and in the remote region was 30.5+10.0%, 33.8+5.5% and
36.1±10.1% (all p=NS) at PETi, PET2, and PET3, respectively. These coefficients
of variation are similar to that reported previously (Araujo et al, 1991).
5.5 Discussion
This study shows that immediately following successful coronary angioplasty,
despite a marked and significant reduction in stenosis severity, maximal coronary
blood flow velocity following dipyridamole was similar to that observed before
angioplasty, and the coronary vasodilator reserve remained unchanged. Basal
coronary blood flow velocity in the region subtended by the stenosed artery before
angioplasty was similar to that reported in normals (Wilson et al, 1985), and increased
immediately after the angioplasty. Measurement of basal myocardial blood flow
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showed that the increase persisted for at least 7 days in the angioplasty region after
PTCA, compared with the remote region, but by three months, it had returned to
normal. The maximal myocardial blood flow response to dipyridamole in the
angioplasty region was lower than that in the remote region 24 hours after angioplasty,
consistent with the observations made immediately post-PTCA with the Doppler
catheter, but by 7 days it had returned towards normal values. Thus, the coronary
vasodilator reserve in the region subtended by the previously stenosed coronary artery
is impaired for the first 24 hours after angioplasty due to an increase in basal coronary
blood flow and a reduction in the maximal vasodilator response. At 7 days, it is still
impaired due to an increase in basal coronary blood flow although the maximal blood
flow response to dipyridamole has returned towards normal.
Persistent Reduction in the Coronary Vasodilator Response after
Angioplasty
We were able to document a reduced coronary vasodilator reserve both by Doppler
catheterisation and by PET. The PET study allowed us to show that the coronary
vasodilator reserve was significantly lower in the angioplasty region than in the remote
region for at least one week after successful angioplasty. The dipyridamole infusion
induced an increase in myocardial blood flow and a coronary vasodilator reserve in the
remote region similar to that previously described in patients with chronic stable angina
and single vessel coronary artery disease, although lower than the value usually
reported in normal subjects (Araujo et al, 1991). We (Uren et al, 1993b) and others
(Sambuceti et al, 1991; Beanlands et al, 1992), have shown that the coronary
vasodilator reserve to dipyridamole is lower in myocardium supplied by
angiographically normal arteries in patients with single vessel coronary artery disease
and normal left ventricles, compared with patients without coronary artery disease
(Chapter 7). The value that we found in the remote region in the present study is
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similar to that reported before in patients with single vessel disease (Araujo et al,
1991).
Alleviation of the flow-limiting coronary artery stenosis would be expected to
permit a larger coronary blood flow when resistive vessel dilatation is induced. Our
findings thus indicate that there was a clear failure of the resistive vessels to dilate in
response to dipyridamole within the first 24 hours. Furthermore, post-PTCA, there
may have been residual effects of the first dose of dipyridamole on myocardial blood
flow and this might be expected to augment the response to the second dose of
dipyridamole. Thus, a possible explanation for the higher basal blood flow post-
PTCA is that it was caused by the residual effects of the first dose of dipyridamole.
This seems an unlikely explanation however since basal myocardial blood flow
measured by PET revealed a higher value in the PTCA region compared with the
remote region for at least the first 7 days post-PTCA. A more striking finding was that
the maximal increase in blood flow velocity in response to dipyridamole post-PTCA
was not increased compared to pre-PTCA, clearly indicating a failure of resistive
vessel dilatation.
Comparison with Other Studies
Several groups have described an impaired coronary vasodilator reserve after
PTCA (Kern et al, 1989; Wilson et al, 1988; Zijlstra et al, 1988; Nanto et al, 1992).
Wilson et al. (Wilson et al, 1988) reported that the coronary vasodilator reserve to
papaverine, measured by Doppler catheter, was impaired immediately after angioplasty
in 55% of patients, and that in these patients, it had returned to normal by a mean
follow-up period of 7.5 months. Zijlstra et al (Zijlstra et al, 1988) reported that the
coronary vasodilator reserve to papaverine was similarly impaired in all their patients
immediately after PTCA. Neither of these studies reported either basal or peak
coronary blood flow or velocity, but only the coronary vasodilator reserve. Kem et al.
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(Kern et al, 1989) and Nanto et al. (Nanto et al, 1992) reported an impaired coronary
vasodilator reserve immediately post-PTCA due to both an increase in basal coronary
blood flow and a decreased maximal coronary blood flow response to papaverine and
atrial pacing respectively. These reports are consistent with our study; basal coronary
blood flow was increased immediately post-PTCA and thereafter for at least 7 days,
and the maximal coronary blood flow response to dipyridamole was impaired
immediately post-PTCA and for at least the first 24 hours. The coronary vasodilator
reserve was therefore reduced for at least the first 7 days post-PTCA. Laarman et al
(Laarman et al, 1991) reported no change in the coronary vasodilator reserve to
papaverine using digital subtraction angiography immediately after PTCA and, as in
our study, no correlation was shown between residual stenosis diameter and the
impaired coronary vasodilator reserve.
Walsh et al (Walsh et al, 1990) used PET to measure the coronary vasodilator
reserve after angioplasty, and reported that it returned to normal in all patients
following the procedure, but this study was limited since individual patients were
studied at different time intervals after angioplasty, ranging from 1 to 18 days (a mean
of 11 days) with no serial studies. It is thus likely that any alterations in basal or
maximal myocardial blood flow, contributing to an abnormal coronary vasodilator
reserve, within the first week were missed. Nevertheless, these data are consistent
with our study since we have shown that the coronary vasodilator reserve returns to
normal between 7 days and 3 months. Using thallium-201 stress imaging, this delay
in the recovery of perfusion has also been reported in patients persisting between 4 and
18 days after PTCA (Manyari et al, 1988).
A reduction in "perfusion defects" within 72 hours of angioplasty implying an
early recovery of myocardial perfusion has been reported using PET (Nienaber et al,
1991), but this was a qualitative analysis with no quantification of myocardial blood
flow or measurement of the vasodilator reserve, and hence it does not define the
142
vasodilator abnormalities present in the angioplasty region relative to a remote region.
Studies by Lassar et al (Lassar et al, 1984) and Hodgson et al (Hodgson et al, 1987)
both reported that the coronary blood flow reserve measured in dilated vessels
immediately after angioplasty was similar to that measured in normal coronary arteries.
However, these studies less reliable since the xenon-133 techniques tend to
overestimate coronary flow, and because the stimulus for coronary vasodilatation
(iodinated contrast medium or small doses of papaverine) may have been variable.
Mechanisms for the Alteration in Resistive Vessel Function after
Angioplasty
Several vascular beds including the coronary circulation autoregulate arteriolar
resistance according to perfusion pressure (Rouleau et al, 1979). The effects of a
prolonged reduction in perfusion pressure (resulting from an epicardial coronary artery
stenosis) on resistive vessel autoregulation are not well documented. It is possible that
prolonged resistive vessel dilatation resulting from a low perfusion pressure distal to
the stenosis might cause a transient inability of these vessels to autoregulate in
response to a sudden restoration of a normal perfusion pressure (Fischell et al, 1990).
If, after the abrupt restoration of a normal coronary perfusion pressure by successful
PTCA, the resistive vessels failed to vasoconstrict, then an increase in basal
myocardial blood flow and a fall in the maximal myocardial blood flow/basal
myocardial blood flow ratio, ie. the coronary vasodilator reserve, would be expected,
as was observed in this study.
Alternatively, basal myocardial blood flow may have been elevated due to the
release of vasoactive agents at the time of angioplasty, eg. from platelets activated by
and adherent to the site of dilatation, the injured vessel wall, or even the myocardial
cells themselves, perhaps as a result of transient ischaemia. This is a less likely
explanation since the increase in basal myocardial blood flow persisted for at least 7
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days and factors directly related to the procedure would be expected to resolve by that
time. It is more probable that resistive vessel function is abnormal before angioplasty
due to the altered autoregulatory mechanisms to compensate for the stenosis as
discussed above.
The maximal myocardial blood flow response to dipyridamole was also reduced
immediately after angioplasty. The mechanism underlying this response is uncertain
and several can be considered. Vasoconstrictor substances released by platelets at the
angioplasty site may limit maximal vasodilatation (McFadden et al, 1991).
Embolisation of the distal coronary circulation with platelet aggregates or fragments of
thrombus might result in transient alterations in coronary blood flow which later
regress (Falk, 1985). One animal study has shown that microembolisation of the
coronary circulation increased resting coronary blood flow and decreased the maximal
hyperaemic coronary blood flow response (Hori et al, 1986). Other factors related to
the presence of a severe stenosis such as recurrent ischaemia before and during
angioplasty might have produced transient changes in the maximal coronary
vasodilator response. Although it has been suggested that short term administration of
calcium channel blockers can reduce vasodilator capacity (Dymek & Bache, 1984),
which were avoided in our study, Wilson et al found no difference in the coronary
vasodilator reserve in patients being treated with nitrates, (3-blockers and calcium
channel blockers compared with those off anti-anginal medication (Wilson et al,
1988).
Potential Limitations
Intravenous dipyridamole was selected as the vasodilator of choice so that data
derived from Doppler catheterisation could be compared with PET at an equivalent
vasodilator stress. Although the vasodilator response may vary amongst individuals
leading to a degree of scatter in the absolute value of vasodilator blood flow, the
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advantage of positron emission tomography is that all regions of of left ventricular
myocardium may be studied simultaneously thus allowing each patient to act as his
own control.
The problem of whether maximal vasodilatation has occurred or not still remains
however. The standard dose of dipyridamole given intravenously has been 0.56
mg-kg"1 over 4 minutes in previous studies (Chapter 2, Section 2.3.2.1), but there is
no pharmacological rationale for this arbitrary dose, it having been derived originally
by extrapolation from a total dose used. Although one may question whether or not
maximal vasodilatation occurred in all patients, the fact remains that in relative terms,
myocardial blood flow and the coronary vasodilator reserve was shown to be
significantly different when comparing two regions at the same time in the same
individual, and thus in the study population.
Clinical Implications
Two important clinical implications arise out of this study, i) A satisfactory
angiographic result does not indicate the immediate return of the behaviour of the
coronary circulation to normal. However, in the absence of restenosis, basal
myocardial blood flow, the myocardial blood flow response to dipyridamole, and
thus, the coronary vasodilator reserve will return to normal over a variable period, of
at least one week. This observation may account for the finding of a positive exercise
test several days after angioplasty in the absence of restenosis (El-Tamimi et al, 1990).
Thus, exercise tests and other non-invasive stress tests will be more reliable in
detecting restenosis if performed at least one week after angioplasty. Conversely,
measurement of the coronary vasodilator reserve after angioplasty cannot be used to
assess the adequacy of the procedure since it may take several days before it has
normalised, ii) Resistive vessel function may be altered in patients with coronary
artery disease. Immediately after removal of the stenosis by angioplasty, there is no
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improvement in coronary vasodilator reserve suggesting that resistive vessel
dysfunction in patients with coronary artery disease may contribute to the development
ofmyocardial ischaemia.
Conclusions
After successful angioplasty, basal myocardial blood flow is increased for at least
7 days in the myocardial region subtended by the previously stenosed artery. The
dipyridamole-induced increase in maximal myocardial blood flow is also impaired for
at least 24 hours after the procedure. The coronary vasodilator reserve in the
angioplasty region is therefore impaired for at least 7 days after angioplasty. Thus,
there is abnormal resistive vessel function in the coronary vascular bed distal to a
coronary artery stenosis which persists for between 7 days and 3 months following
the procedure.
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CHAPTER 6. NITRIC OXIDE PRODUCTION AND
ALTERED CORONARY RESISTIVE VESSEL
FUNCTION AFTER CORONARY ANGIOPLASTY
6.1 Abstract
The coronary vasodilator response to dipyridamole is impaired immediately after
successful coronary angioplasty due to an alteration in resistive vessel dilatation.
Impaired production or release of nitric oxide in the resistive vessels may account for
this alteration. As the vasodilator response to exogenous nitrates is enhanced by the
removal of endothelium and by inhibition of nitric oxide synthesis, after angioplasty
we have infused large doses of sodium nitroprusside, a nitric oxide donor, following
dipyridamole to test this hypothesis. The coronary vasodilator reserve (maximal/basal
coronary blood flow) to intravenous dipyridamole was measured by Doppler
catheterisation after angioplasty in 10 male patients (mean age 53±10 years) with
single vessel coronary artery disease. At the peak effect of dipyridamole, incremental
doses of sodium nitroprusside (4-50 (ig-min-1) were given intracoronary until systolic
blood pressure fell by >5 mmHg. After successful angioplasty, mean coronary blood
flow increased from 32.4+13.2 to 53.4±23.3 ml-mim1 at the peak dipyridamole effect
(p<0.05 vs. basal), giving a coronary vasodilator reserve of 1.77±0.64. At the dose
of nitroprusside before a fall in systolic and mean arterial pressure, mean coronary
blood flow was 49.5±20.4 ml-mim1 (p=NS vs. dipyridamole). Immediately after the
systolic pressure fall, mean coronary blood flow was 52.2±18.0 ml-min"1 (p=NS vs.
peak dipyridamole, and nitroprusside before systolic pressure fall).
Immediately after successful angioplasty, the maximal coronary blood flow
velocity increase to dipyridamole was markedly impaired. Intracoronary sodium
nitroprusside in doses sufficient to cause ultimately a fall in blood pressure did not
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augment the dipyridamole-induced increase in coronary blood flow velocity. Thus,
reduced production or release of nitric oxide in the coronary circulation does not seem
to be responsible for the impaired coronary vasodilator reserve after angioplasty.
6.2 Introduction
A large number of patients have a positive exercise test after successful coronary
angioplasty. In one study, 41% of patients had a positive exercise test after 6 months
despite a mean residual stenosis of only 54% (Parisi et al, 1992) and other studies
have reported similar findings after angioplasty (Massa et al, 1989; Schroeder et al,
1989). Since such a stenosis would not be expected to significantly reduce the
coronary vasodilator reserve in its own right (Gould et al, 1974), it is likely that this
occurs because of resistive vessel dysfunction (Pupita et al, 1990). Intracoronary
Doppler flow measurements in the stenosis-related artery after angioplasty from
several groups have shown a reduced response to intravenous dipyridamole (Kern et
al, 1989; Zijlstra et al, 1988; Uren et al, 1993a) and to intracoronary papaverine
(Wilson et al, 1988). Furthermore, as we demonstrated in chapter 5, positron
emission tomography has confirmed that the reduced vasodilator response to
dipyridamole in myocardium subtended by the angioplasty vessel persists for up to 24
hours after the procedure (Uren et al, 1993a).
The mechanisms leading to this reduced coronary vasodilator reserve in the
vascular territory subtended by a successfully dilated coronary artery are not well
understood. Endothelial dysfunction and denudation at the lesion site due to balloon
dilatation which leads to a loss of control of vasomotor tone has been implicated in
early stenosis vasoconstriction and even abrupt closure following angioplasty (Lazzam
et al, 1992). A defective production or release of endothelium-derived relaxing factor
(EDRF, which may be identical to nitric oxide (Palmer et al, 1987) leading to an
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enhanced vasomotor tone in coronary resistive vessels has been proposed as a possible
explanation for the reduced vasodilator response in patients with coronary artery
disease (Kuo et al, 1992). It has been demonstrated in vitro that vasodilatation to
exogenous nitrates is enhanced by defective EDRF production either by endothelium
removal (Shirasaki & Su, 1985), or by nitric oxide synthesis inhibition (Shirasaki &
Su, 1985; Moncada et al, 1991), which appears to be related to an up-regulation of
soluble guanylate cyclase (Moncada et al, 1991). If the impairment of the vasodilator
response after angioplasty was due to reduced production of nitric oxide, then there
would be an increase in the vasodilator response with delivery of a high concentration
of nitric oxide to the coronary microcirculation. In order to test this hypothesis, we
infused intracoronary high doses of sodium nitroprusside, a nitric oxide donor
(Feelisch et al, 1987), after intravenous dipyridamole, into the index vessel after
successful angioplasty. In some of the patients, we also performed the same study




Ten male patients (mean age 53±10 years, range 40-72) with chronic stable angina
were studied. All had a positive exercise test and normal left ventricular function, and
patients who had suffered a previous myocardial infarction or unstable angina pectoris
were excluded. All had proximal left anterior descending coronary artery disease and
were undergoing routine coronary angioplasty. The left circumflex and right coronary




The protocol was approved by the Research Ethics Committee of our institution
and all patients gave informed and written consent.
All anti-anginal medication (except sublingual nitroglycerin) was discontinued at
least 48 hours prior to cardiac catheterisation and angioplasty. No patient took
nitroglycerin within 12 hours of the study. All patients were taking aspirin 300 mg
daily. Intravenous heparin (10,000 units) was given immediately prior to the study.
Angioplasty was performed as clinically indicated. Coronary blood flow velocity and
coronary vasodilator reserve (defined as post-dipyridamole coronary flow/basal
coronary flow) was measured in 5 patients before, and in all 10 patients after
angioplasty as described below.
6.3.2.1 Cardiac Catheterisation and Doppler Flow Velocity Measurement
Coronary angiography was performed as clinically indicated in order to best
demonstrate the lesion morphology. On completion, an 8-French gauge guiding
catheter (Cordis Ltd., Brentford, Middlesex) was inserted into the left coronary
ostium. A 0.010 or 0.012 in. "Hi-Torque" guide wire (Advanced Cardiovascular
Systems Inc., Santa Clara, Calif., USA) was advanced across the coronary lesion.
Prior to angioplasty, in 5 of the patients in whom there was no evidence ofmyocardial
ischaemia (chest pain or electrocardiogram changes), a 3-French gauge Doppler flow
catheter (Model No. DC 201; Millar Instruments Inc. Houston, Texas, USA) with a
20 MHz pulsed Doppler crystal, referenced to zero and calibrated, was advanced over
the guide wire. The tip of the Doppler catheter was positioned up to 5 mm proximal to
the stenosis (Wilson et al, 1985). The Doppler velocimeter range control was adjusted
to obtain an optimal audio signal and both phasic and mean tracing ofmaximal resting
coronary blood flow velocity.
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Heart rate, systemic arterial pressure (right iliac artery) and coronary blood flow
velocity were measured continuously throughout the procedure. Coronary resistive
vessel dilatation was induced with intravenous dipyridamole 0.5 mg-kg"1 over 4
minutes. At the peak mean coronary flow velocity following the infusion of
dipyridamole, an intracoronary infusion of sodium nitroprusside was given in
incremental doses of 4, 8, 16, 32 and 50 p-g-min-1 each for 1 minute. The sodium
nitroprusside infusion was stopped as soon as systolic blood pressure fell by >5
mmHg. Coronary arteriograms were obtained under basal conditions, at the peak
coronary blood flow velocity following dipyridamole, and during sodium
nitroprusside infusion immediately following a >5 mmHg drop in systolic blood
pressure. Angioplasty was then performed entirely as clinically indicated (ACS RX
balloon angioplasty catheter; Advanced Cardiovascular Systems Inc., Santa Clara,
Calif., USA). Following successful angioplasty, the balloon catheter was removed
leaving the guide wire in situ. The Doppler flow catheter was positioned as described
above in all 10 patients. Measurement of coronary blood flow velocity after
intravenous dipyridamole and during intracoronary nitroprusside were obtained as
described above, together with coronary arteriography at the same time intervals.
Patients in whom it was necessary to give nitrates during the angioplasty were
excluded from further study.
6.3.2.2. Quantitative Coronary Arteriography
Coronary arteriograms were analyzed by an automated edge contour detection
computer analysis system (Cardiovascular Angiographic Analysis System [CAAS],
Pie Medical Equipment B.V., Maastricht, The Netherlands) (Reiber et al, 1984). This
method which involves detection of the boundaries of the relevant coronary artery
segment from the optically magnified and video digitalised region of interest is
described in Chapter 5 (Section 5.3.2.2). In this study, stenosis severity was also
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expressed as percentage reduction of the internal lumen diameter relative to the
angiographically normal proximal coronary segment, the reference segment.
6.3.2.3. Data Analysis
Heart rate, coronary flow velocity, and systemic blood pressure were measured
continuously during the study. Data were analysed at i) basal, ii) the peak effect of
dipyridamole, iii) the sodium nitroprusside dose before a reduction in systolic
pressure, and iv) the sodium nitroprusside dose after a >5 mmHg reduction in systolic
pressure. Mean coronary blood flow was calculated from the product of the coronary
flow velocity (cm-s-1) and the cross-sectional area of artery at the tip of the Doppler
catheter (cm2) and expressed in ml-min1. Coronary resistance was calculated as the
quotient of mean arterial pressure to mean coronary blood flow and expressed in
mmHg-min-ml1.
6.3.3. Statistical Analysis
All data are expressed as mean±SD. Student's t test was used to compare any pair
of mean group values. Simultaneous comparison of more than two mean values was
performed using one-way analysis of variance (ANOVA), and Fisher's least
significant difference method was subsequently applied to localize the source of the
difference. A p value <0.05 was considered statistically significant.
6.4 Results
6.4.1. Quantitative Coronary Arteriography
(Table 6.1)
The results of quantitative angiography are shown in Table 6.1. In all 10 patients,
diameter at the site of the stenosis was increased from 0.62±0.30 to 1.92±0.50 mm
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(p<0.0001) by angioplasty. The reference artery segment was 2.33+0.39 and
2.55±0.53 mm before and after angioplasty (p=NS), respectively. Thus, there was a
reduction in percentage lumen stenosis severity from 74.8±10.4 to 25.4±7.6%
(p<0.0001).
All 10 patients were studied after angioplasty. Dipyridamole had no effect on
residual stenosis diameter, although sodium nitroprusside did cause mild dilatation.
Dipyridamole did not change significantly the reference artery diameter, although
sodium nitroprusside dilated the reference segment. In the 5 patients studied before
angioplasty, changes in coronary calibre were not statistically significant (Table 6.1).
6.4.2. Doppler Flow Velocity Measurement After Angioplasty
(Table 6.2 and Figures 6.1 and 6.2)
All 10 patients underwent Doppler catheterisation after angioplasty (Table 6.2).
Heart rate increased at the peak effect of dipyridamole, with no significant reduction in
systolic, diastolic, or mean arterial pressure. There was an significant increase in
mean coronary blood flow after dipyridamole, from 32.4±13.2 to 53.4±23.3 ml-min-1
(p<0.05 vs. basal) (Figure 6.1), with a reduction in coronary resistance, from
3.95±2.54 to 2.20±1.10 mmHg-min-mf1 (p<0.05 vs. basal) (Figure 6.2). The
coronary vasodilator reserve was 1.77±0.67. Sodium nitroprusside, at a dose just
before a fall in blood pressure, did not change significantly the mean coronary blood
flow, 49.5±20.4 ml-min"1, or coronary resistance, 2.19±1.14 mmHg-min-mf1 (both
p=NS vs. dipyridamole) (Figures 6.1 and 6.2). At the peak systemic effect of sodium
nitroprusside, there was a fall in systolic, diastolic and mean arterial blood pressure,
but there was no further change in mean coronary blood flow, 52.2±18.0 ml-min-1, or
coronary resistance, 1.90±0.88 mmHg-min-mf1 (both p=NS vs. dipyridamole)
(Figures 6.1 and 6.2). The coronary vasodilator reserve before and after the reduction
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* p<0.05 vs. Dipyridamole, f p<0.05 vs. Basal; $ p<0.0001 vs. before
angioplasty, at quantitative coronary arteriography before and after coronary
angioplasty under basal conditions, at the peak effect of dipyridamole, and at the
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Figure 6.1. Individual coronary blood flows under basal conditions, at peak
dipyridamole (Dip), before the sodium nitroprusside-induced fall in systolic blood
pressure (SNPpre), and after the sodium nitroprusside-induced fall in systolic blood





















Basal Dip SNPpre SNPpost
Figure 6.2. Individual coronary resistances under basal conditions, at peak
dipyridamole (Dip), before the sodium nitroprusside-induced fall in systolic blood
pressure (SNPpre), and after the sodium nitroprusside-induced fall in systolic blood
pressure (SNPpost) after angioplasty. * p<0.05, ** p<0.01 vs. Basal.
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Heart Rate (beats-min1) 68±13 83±18* 81±18* 82+17*
Systolic Blood Pressure (mmHg) 136±22 130+21 134+23 123±20*
Diastolic Blood Pressure (mmHg) 85+13 80+16 73±12 72±14*
Mean Arterial Pressure (mmHg) 101±13 97+17 92+16* 89±15*
Coronary Blood Flow (ml-mur1) 32.4±13.2 53.4±23.3* 49.5±20.4* 52.2±18.0*
Coronary Resistance
(mrnHg-min-ml"1)
3.95±2.54 2.20±1.10* 2.19±1.14* 1.90+0.88*
Coronary Vasodilator Reserve - 1.77±0.67 1.68±0.67 1.78+0.65
* p<0.05 vs. Basal. SNPpre = sodium nitroprusside dose before the systolic blood
pressure drop, SNPpost = sodium nitroprusside dose after the systolic blood pressure
drop.
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* p<0.05,f<0.01vs.Ba al;§p . 5,#<0.01beforeangioplasty.SNPpre=sodiumnitroprussidedosef rthsy tol cl d pressuredrop,SNPpost=sodiumnitr pru sideoseafterthsy olicbl dpre redro .
of systolic blood pressure with sodium nitroprusside was 1.68±0.67 and 1.78±0.65
(both p=NS vs. dipyridamole).
Comparison of haemodynamic and coronary flow parameters in the 5
patients studied before and after angioplasty. The 5 patients studied before
and after angioplasty were compared (Table 6.3). The haemodynamic responses to
dipyridamole and sodium nitroprusside were similar before and after angioplasty in the
5 patients. Coronary angioplasty lead to a significant increase in basal mean coronary
blood flow, although there was no significant change in the mean coronary blood flow
after dipyridamole or during the sodium nitroprusside infusion. Thus, there was no
difference in the coronary vasodilator reserve at basal, peak dipyridamole, and during
nitroprusside before and after angioplasty. However, after angioplasty, the basal
coronary resistance was lower at basal, peak dipyridamole, and during nitroprusside
infusion compared to before angioplasty.
6.5 Discussion
This study confirms that the maximal coronary vasodilator response to
dipyridamole was markedly impaired immediately after successful coronary
angioplasty, with a value similar to that before angioplasty. This impairment is
unlikely to be due to a defect in nitric oxide production in the resistive vessels since
large doses of sodium nitroprusside, a nitric oxide donor, sufficient to reduce systemic
blood pressure, had no further effect on the maximal coronary blood flow response.
In the absence of resistive vessel dysfunction, removal of a flow-limiting stenosis
would be expected to restore normal maximal coronary blood flow (Wilson et al,
1988). As the residual stenosis severity was around 25% in this study, it is unlikely
that the residual epicardial lesion had a flow-limiting effect on the coronary vasodilator
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reserve (Gould et al, 1974). Our study thus indicates that there was a clear failure of
the resistive vessels to dilate in response to dipyridamole after angioplasty.
Furthermore, sodium nitroprusside did not normalise the coronary blood flow
response to dipyridamole (although it did have a mild vasodilating effect both at the
site of the stenosis and on the segment of epicardial coronary artery proximal to the
stenosis site, indicative of a local action in the coronary circulation). Thus, reduced
production or activity of nitric oxide in the coronary circulation does not seem to be
responsible for the impaired vasodilator reserve after coronary angioplasty.
Nitric Oxide and Resistive Vessel Function in Atherosclerosis
There is evidence to suggest that the atherosclerotic process in large epicardial
coronary arteries impairs their ability to dilate in response to increasing blood flow,
and that this may be due to endothelial cell dysfunction (Cox et al, 1989). This loss of
endothelial responsiveness to blood flow and also to acetylcholine occurs before the
development of flow-limiting epicardial coronary artery stenoses (McLenachan et al,
1991). In the coronary resistive vessels, although overt atherosclerosis does not
develop, endothelial cell dysfunction may occur (Kuo et al, 1992). In an experimental
primate model, Sellke et al showed that impaired resistive vessel dilatation to
endothelial-dependent vasodilators and constriction to acetylcholine occurs, although
sodium nitroprusside induced vasodilatation of a similar magnitude in the microvessels
from both atherosclerotic and control animals (Sellke et al, 1990). Furthermore, in
man, Zeiher et al reported that impaired resistive vessel dilatation to acetylcholine
occurs in myocardium subtended by an angiographically normal coronary artery in
patients with disease in other arteries, despite a normal vasodilator response to
papaverine (Zeiher et al, 1991). These studies indicate a preserved ability of vascular
smooth muscle in resistive vessels to vasodilate, despite endothelial cell dysfunction.
The alteration of resistive vessel function in response to endothelium-dependent
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vasodilatation in these circumstances may involve a deficiency in the production or
release of nitric oxide, as it is possible to restore maximal endothelium-dependent
vasodilatation in resistive vessels from atherosclerotic animals by incubation with L-
arginine (Kuo et al, 1992), the substrate for nitric oxide synthesis (Palmer et al, 1988).
Again, in this study, the vasodilator response to sodium nitroprusside was similar on
comparing either endothelium-denuded or atherosclerotic vessels with normal controls,
implying preserved vascular smooth muscle responsiveness (Kuo et al, 1992).
Abnormal Resistive Vessel Function After Angioplasty
Whether the process leading to impaired resistive vessel vasodilatation arises
acutely as a direct consequence of the angioplasty procedure itself, or occurs as a
chronic adaptation to a flow-limiting epicardial stenosis, is unknown. Brief reversible
myocardial ischaemia in an animal model can lead to a persistent impairment of
vasodilator responsiveness (for at least 4 hours), independent of the degree of reduced
myocardial contractility - so-called "microvascular stunning" (Nicklas & Gips, 1989;
Bolli et al, 1990). Vasoconstrictor substances, such as serotonin released by platelets
at the angioplasty site, cause diffuse constriction of the distal coronary arteries limiting
maximal vasodilatation (McFadden et al, 1991). Additionally, embolisation of the
distal coronary circulation with platelet aggregates or clot debris may both increase
resting coronary blood flow and decrease the maximal hyperaemic coronary blood
flow response (Hori et al, 1986).
The effect of chronic reduction in perfusion pressure (resulting from the epicardial
coronary artery stenosis) on resistive vessel autoregulation is another possible cause of
altered vasoreactivity. Vasoconstriction occurs in epicardial coronary arteries distal to
a stenosis after successful angioplasty, and is proportional to the severity of the
previous stenosis (Fischell et al, 1990). Coronary resistive vessels may also adapt
structurally to a persistently low perfusion pressure, and one animal study has shown
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that after several weeks a proximal epicardial coronary stenosis causes a reduction in
the ratio of wall area to lumen diameter in the microvessels, associated with changes in
membrane proteins on histochemical analysis (Mills et al, 1991).
Our study indicates that reduced nitric oxide production or release at the level of
the coronary resistive vessels is not the cause of the impaired coronary vasodilator
reserve after angioplasty. There is now evidence that other non-nitric oxide dependent
endothelium-derived relaxing factors exist, and that these play a major role in the
vasodilator responsiveness of the coronary microcirculation (Vanhoutte &
Shimokawa, 1991). Thus, the impairment in the coronary vasodilator reserve may
occur as a result of an alteration in production of such factors in the coronary
microcirculation and our data do not exclude such hypotheses.
Conclusions
Immediately after successful angioplasty, the maximal mean coronary blood flow
increase to dipyridamole was markedly impaired, with a coronary vasodilator reserve
similar to that seen before angioplasty. Administration of intracoronary sodium
nitroprusside in doses sufficient to cause mild dilatation of epicardial coronary arteries
and a fall in systemic blood pressure did not augment the dipyridamole-induced
increase in mean coronary blood flow after angioplasty. Thus, reduced nitric oxide
production or release in the coronary circulation is not the cause of the impaired
coronary vasodilator reserve seen after coronary angioplasty.
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CHAPTER 7. ALTERED CORONARY RESISTIVE
VESSEL FUNCTION AND REGIONAL
METABOLISM IN MYOCARDIUM SUBTENDED
BY NORMAL ARTERIES IN CORONARY ARTERY
DISEASE
7.1 Abstract
There is evidence that following a myocardial infarction, structural and functional
changes occur in the remote myocardium which is often subtended by non-diseased
vessels. However, it is not known whether any changes occur in regions subtended
by angiographically normal arteries remote from a zone of ischaemic, but non-infarcted
myocardium in humans. The objective of this study was to investigate coronary
vasodilator reserve and myocardial metabolism in regions subtended by
angiographically normal arteries in patients with stable angina pectoris and coronary
disease elsewhere. Regional coronary vasodilator reserve was measured using
positron emission tomography in 12 patients with single vessel disease and 13
controls. In a second group of 10 patients and 6 controls, simultaneous arterial and
great cardiac vein catheterisation was done at rest and during atrial pacing to measure
myocardial metabolism in regions subtended by a diseased artery (left anterior
descending artery) or by an angiographically normal artery (left anterior descending
artery in patients with right or circumflex disease). Coronary vasodilator reserve was
1.80±0.24 in regions subtended by a stenosis and 2.73±0.25 in remote regions
(p<0.01 vs. stenosis region). Both values were lower than that in the controls
(4.0710.21; p<0.01). In the second group, no differences in myocardial metabolism
were present at rest. During pacing, there was net lactate production in the diseased
region, -18127% (p<0.05 vs. both remote and control), compared to net extraction in
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the remote region, 38±17%, and control, 26+11%. Glucose and alanine extraction
were increased both in the diseased region (8±6% and 6±6%), and in the remote
region (6±3% and 4±3%), compared to control (2±3% and -1± 3%, p<0.05 vs. both
diseased and remote).
In conclusion, in patients with stable angina and single vessel disease, the
coronary vasodilator reserve is reduced in regions subtended by angiographically
normal arteries. In addition, such regions have different glucose and alanine handling
during pacing in the absence of lactate production.
7.2 Introduction
There is increasing evidence that following a myocardial infarction, structural and
functional changes occur in the remote non-infarcted regions of the left ventricle,
which are often subtended by non-diseased vessels, a process termed ventricular
remodelling. Non-infarcted myocardium is subjected to increased wall stress to
compensate for the loss of contractile tissue. This leads to lengthening and
hypertrophy of the non-infarcted myocytes which, with time, may progress to
dilatation and failure of the left ventricle (Pfeffer & Braunwald, 1990). Transient
myocardial ischaemia may also lead to an increase in left ventricular dimensions
associated with regional hyperfunction in remote non-ischaemic areas, both in animals
(Naccarella et al, 1984; Smalling et al, 1986; Buda et al 1990), and in man (Jaarsma et
al, 1986; Serruys et al, 1986). However, it is not known whether patients with
recurrent myocardial ischaemia, but without evidence of previous infarction, may
develop alterations of cardiac function in the remote regions subtended by
angiographically normal coronary arteries.
The aim of this study was to assess whether alterations ofmyocardial blood flow
and metabolism can be demonstrated in areas of myocardium subtended by
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Twenty two patients with coronary artery disease and normal left ventricular
function were studied. Coronary and left ventricular angiograms were analysed by an
automated edge contour detection computer analysis system to derive coronary artery
stenosis severity and global and regional left ventricular function. None of the patients
had a clinical history or ECG evidence of previous myocardial infarction. There was
no evidence of valvular or primary cardiac disease in any of the patients. In addition,
there was no history of diabetes mellitus or systemic hypertension in any patient.
In 12 patients (Group 1), regional myocardial blood flow and coronary
vasodilator reserve were assessed by positron emission tomography. In the other 10
patients (Group 2), myocardial metabolism was measured by simultaneous arterial and
great cardiac vein catheterisation at rest and during pacing stress.
i) Group 1
(Table 7.1)
Twelve patients (10 male, mean age 60 years, range 47-76) with significant
(>70% diameter stenosis) single vessel coronary artery disease were studied. The
remaining coronary arteries in these patients were angiographically normal (Table 7.1).
All patients had chronic stable angina pectoris and >0.1 mV ST segment depression
on the ECG during exercise. Data from these patients were compared with a group of
13 normal male subjects (mean age 32 years, range 21-43).
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Figure 7.1. Coronary venous angiogram (lateral view) obtained following a
selective injection of contrast into the left anterior descending coronary artery, which
illustrates the course of the great cardiac vein (GCV). The GCV arises in the anterior
myocardial wall and runs posteriorly and cranially in the interventricular groove, and
then in the atrio-ventricular groove before draining into the coronary sinus which in
turn drains into the right atrium.
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ii) Group 2
Ten additional patients underwent simultaneous arterial and great cardiac vein
(GCV) catheterisation (Figure 7.1) at rest and during maximal atrial pacing, following
a routine angiographic study. Five patients (Group 2a: mean age 54 years, range 46-
65) had significant left anterior descending artery (LAD) disease, and 5 patients
(Group 2b: mean age 52 years, range 42-62) had significant right coronary (RCA)
and/or left circumflex (LCX) artery disease. All patients in group 2b had an
angiographically normal LAD (Table 7.2). Since the GCV generally drains blood
from the distribution territory of the LAD, measurements in patients with significant
disease of the LAD should reflect metabolism in a potentially ischaemic territory
(Figure 7.2, panels A and B). In contrast, in patients with significant RCA/LCX
disease and a normal LAD, measurements from the GCV should reflect metabolism in
myocardium remote from the ischaemic zone (Figure 7.2, panels A, C, D). Metabolic
data in groups 2a and 2b were compared with those from a control group of 6 normal
subjects (mean age 47 years, range 39-57), which have been described previously
(Camici et al, 1989a).
7.3.2. Study Protocols and Data Analysis
7.3.2.1. Quantitative Coronary Arteriography and Left Ventriculography
Selective right and left coronary arteriography in multiple views was performed
with the Judkins technique. Coronary arteriograms were analysed by an automated
edge contour detection computer analysis system (Cardiovascular Angiographic
Analysis System [CAAS], Pie Medical Equipment BV, Masstricht, The Netherlands)
(Reiber et al, 1984) (Chapter 5, Section 5.3.2.2). Stenosis severity was expressed as
percentage reduction of the internal luminal diameter relative to the estimated diameter
interpolated from the diameters at the proximal and distal boundaries of the stenosis
(Reiber et al, 1984). Collaterals were graded according to the method of Rentrop et al
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Figure 7.2. Panel A) Antero-posterior view of heart demonstrating a temporary
pacing wire in the right atrium, the thermodilution catheter with its tip well advanced
into the great cardiac vein, and a pigtail catheter in the left ventricular chamber. Panel
B) Right anterior oblique view of the left coronary system with a severe proximal
stenosis in the left anterior descending artery (group 2a patient). Panel C) Right
anterior oblique view of an angiographically normal left anterior descending artery
(group 2b patient). Panel D) Left anterior oblique view of the right coronary artery
with a proximal stenosis at the right upper heart border (group 2b patient).
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(Rentrop et al, 1985); where 0=none, l=filling of side branches without visualisation
of the epicardial segment, 2=partial filling of the epicardial segment via collateral
channels, and 3=eomplete filling of the epicardial segment.
Global and regional left ventricular function was measured from the 30° right
anterior oblique left ventricular cine-angiogram with an automated hard-wired
endocardial contour detector linked to a microcomputer (Serruys et al, 1986). This
was done under basal conditions in all patients and at maximal pacing in group 2
patients and controls (in one patient of group 2b, it was not possible to repeat left
ventriculography at maximal pacing for technical reasons). End-systolic and end-
diastolic contours were drawn to exclude the inferior papillary muscle. Systolic
regional wall displacement is determined along a system of 20 coordinates based on
the pattern of actual endocardial wall motion in normal individuals (Slager et al, 1979).
When normalized for end-diastolic volume, the systolic segmental volume change can
be considered as a variable of regional pump function, and thus can express
quantitatively, the contribution of a particular segment to global ejection fraction.
Regional contribution was described in 5 territories: antero-basal, antero-lateral,
apical, inferior, and postero-basal (Serruys et al, 1986). In patients with anterior
and/or antero-lateral ischaemia, the postero-basal and inferior regions were defined as
remote from the ischaemic region, and in those with inferior ischaemia, the anterobasal
and anterolateral regions were considered remote.
7.3.2.2. Positron Emission Tomography
Patients abstained from drinking tea or coffee on the morning of the scan and all
had been off anti-anginal medication (except for sublingual nitrates) for at least 72
hours. No nitrates were taken for at least two hours before the study.
All PET scans were performed with an ECAT 931-08/12 camera (CTI Inc.,
Knoxville, Tennessee, USA). Regional myocardial blood flow (MBF, ml.mhrkg-1)
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was measured in Group 1 subjects using oxygen-15-labelled water (H2150) as a flow
tracer using the previously validated C15C>2 inhalation technique (Araujo et al, 1991).
Measurements were made at rest and 2 minutes after intravenous administration of
dipyridamole (0.56 mg-kg-1 over 4 minutes). Systemic blood pressure and heart rate
were monitored throughout the study. A 12 lead ECG was recorded every minute
during the dipyridamole infusion and for up to 10 minutes after the end of infusion.
In patients with LAD disease, the anterior region was designated as the stenosis-
related region and the inferior-posterior region as the remote region of interest. In
patients with RCA/LCX disease, the inferior-posterior region was designated as the
stenosis-related region and the anterior region as the remote region of interest. MBF
was measured under baseline conditions and after an i.v. infusion of dipyridamole
(0.56 mg-kg1 over 4 minutes). The coronary vasodilator reserve was defined as the
quotient of post-dipyridamole MBF to basal MBF. Since no statistically significant
differences among the flow rates in the four major myocardial regions (anterior, septal,
lateral and inferior-posterior) could be demonstrated in the control subjects, data from
patients of group 1 were compared with the average MBF in the controls.
1.3.2.3. Invasive Measurement of Myocardial Substrate Metabolism
Patients had been off anti-anginal medication (except for sublingual nitrates) for at
least 72 hours, and were studied after an overnight fast. Studies were performed
following routine coronary arteriography. At least 30 minutes were allowed between
coronary angiography and the beginning of the study in order to minimize any possible
interference of the contrast medium with myocardial metabolism (Wisneski et al,
1982). An 8-F multi-thermistor thermodilution, pacing catheter was introduced
through either the right femoral vein or left antecubital vein and advanced through the
coronary sinus into the GCV for sampling and measurement of flow in the distribution
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territory of the LAD (Ganz et al, 1971; Pepine et al, 1978). A 7-F pigtail catheter was
positioned in the left ventricle. The ECG was continuously monitored.
Subjects performed up to 4 pacing steps of 4 minutes duration each, with heart
rate increments of 15 beats-min1 for the first three steps, and up to maximal achievable
heart rate (exacerbation of symptoms and/or occurrence of atrio-ventricular conduction
disturbances) on the last step (no atropine was used). During maximal pacing, at least
two minutes were allowed to achieve a steady condition before the arterial and GCV
blood samples were obtained, and pressures and GCV flow measured. Paired arterial
and GCV blood samples were drawn under basal conditions (samples taken in
duplicate) and at maximal pacing for the assay of glucose, free fatty acids (FFA),
lactate, pyruvate, alanine, 6-hydroxybutyrate, glycerol, triglycerides and blood gases
as previously reported (Camici et al, 1989a).
Myocardial oxygen consumption (MVO2) was calculated as the product of GCV
flow and the arterial-GCV blood O2 concentration difference; myocardial carbon
dioxide production (MVCO2) was calculated similarly, and the respiratory quotient
(RQ) calculated as MVCO2/MVO2 as previously reported (Camici et al, 1989b). Net
rates of carbohydrate and lipid oxidation and myocardial energy expenditure were
calculated from gas exchange measurements using standard calorimetric equations
(Ferrannini et al, 1988). Thus, net carbohydrate oxidation (jamol-min1) =
0.57-MVCO2- 0.40-MV02and net lipid oxidation (iimol-min"1) = 0.146-(MVO2-
MVCO2), assuming protein oxidation in the heart is negligible. Using the caloric
equivalents of glucose and fat (respectively 673 and 2,398 cal-mmol"1), myocardial
energy expenditure = 0.08-MVC>2 + 0.034-MVC02- The fractional extraction (E) of
substrates was calculated as follows: ([substrate]arterjai - [substratej^cv +
jsubstrateJai-teriai) x 100. This fractional extraction is the capacity of the myocardium
to extract a substrate from the coronary circulation independent of the arterial
concentration of the substrate or the coronary blood flow. Total carbohydrate uptake
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was calculated as the algebraic sum of the net exchange of glucose and three-carbon
compounds (lactate, pyruvate, and alanine, expressed as glucose equivalents).
Coronary resistance was calculated as the quotient of mean arterial pressure to GCV
flow. The precise details of the procedures used in this invasive metabolic study have
been reported elsewhere (Camici et al, 1989a).
The PET scanning protocol and the protocol for intra-cardiac pacing and coronary
sinus catheterisation was approved by the Research Ethics Committee of Hammersmith
Hospital. All patients gave informed and written consent.
7.3.3. Statistical Analysis
All data are expressed as mean±SD. Student's t test was used to compare any pair
of mean group values. Simultaneous comparison of more than two mean values was
performed using one-way analysis of variance (ANOVA) for repeated measures, and
Fisher's least significant different method was subsequently applied to localize the
source of the difference (Godfrey, 1985). A p value <0.05 was considered
statistically significant
7.4 Results
Results from the PET and catheter studies are presented separately for ischaemic
and remote myocardium as defined in Methods.
7.4.1. Ischaemic Regions
i) Regional Myocardial Blood Flow bv PET
(Table 7.3; Figures 7.3 and 7.4)
Global left ventricular function under basal conditions was normal in all patients in
group 1 (Table 7.3). There was a comparable increase in heart rate from basal to peak
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dipyridamole in patients and controls, (64±10 to 87±14 beats-min1, and 67±10 to
92±14 beats-min'1, respectively). Similarly, the increase in the rate-pressure product
from basal to peak dipyridamole was comparable in patients and controls,
(8,550±1830 to 11,760±2250 mmHg-min-1, and 7,640±1630 to 10,480+1660
mmHg-min4, respectively). Systolic blood pressure at basal and peak dipyridamole
was higher in patients compared to controls, (132±19 to 137+18 mmHg, and 115±11
to 115±11 mmHg; p<0.05 and p<0.01 vs. basal, respectively). In the ischaemic
region, resting MBF was 0.96±0.20 ml-min+g1, and increased to 1.73±0.91 ml-min-
'•g4 after dipyridamole (Figure 7.3), giving a coronary vasodilator reserve of
1.80±0.82 (Figure 7.4).
ii) Myocardial Metabolism
(Tables 7.4, 75, and 7.6)
There was a reduction in left ventricular ejection fraction from basal to maximal
pacing, from 81.8±10.0 to 61.9±6.9% (p<0.01) in the group 2a patients, and from
72.4±7.6 to 57.2±5.5% (p<0.05) in the group 2b patients (Table 7.4), while the
ejection fraction was not significantly changed by pacing in the control group from
71.0±7.1 to 66.0±4.9% (p=NS). In group 2a, resting haemodynamic parameters
were comparable to those in controls, except for a higher systolic blood pressure
(148±17 vs. 124±16 mmHg, p<0.05) (Table 7.5). At rest, myocardial substrate
utilisation in patients was similar to that in the controls (Table 7.6). All the patients in
group 2a developed chest pain, >0.1 mV ST segment depression and wall motion
abnormalities on left ventriculography at maximal pacing (Table 7.4). This occurred at
lower heart rates than in the controls (126±21 vs. 159±23 beats.min"1 respectively,
p<0.05) (Table 7.5). The percent increment in GCV flow during atrial pacing was
less in group 2a than in the controls, although this difference did not achieve statistical

































Figure 7.3. The myocardial blood flow at basal (open symbols) and after
intravenous dipyridamole (black symbols) in the ischaemic region and remote region

























Figure 7.4. The coronary vasodilator reserve (defined as the ratio of post-
dipyridamole myocardial blood flow to basal myocardial blood flow) in the ischaemic
region and remote region of patients with single vessel coronary artery disease (group
1), and in normal control subjects.
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pacing are summarized in Table 7.6. The group 2a patients developed metabolic
changes characteristic of myocardial ischaemia, i.e. increased glucose extraction with
net lactate release. The respiratory quotient (RQ) at maximal pacing in the ischaemic
territory was not different from the respective basal value (0.72±0.03 at basal vs.
0.73±0.18 at pacing), whereas in normal subjects, RQ values increased during pacing
(0.72±0.10 at basal vs. 0.84±0.15 at pacing, p<0.05) indicating increased oxidation
of carbohydrate fuel.
7.4.2. Remote Regions
i) Regional Myocardial Blood Flow by PET
(Figures 7.3 and 7.4)
Resting MBF in the remote region, 1.06±0.19 ml-min '-g1, was significantly
higher than that in the normal subjects (p<0.05) (Figure 7.3). Correcting for rate-
pressure product which is a rough approximation ofmyocardial oxygen consumption
(the main determinant of basal MBF), there was no significant difference in basal
MBF. Following dipyridamole infusion, MBF in the remote regions increased to
2.89+0.93 ml-min-'-g-1, which was greater than in the ischaemic territory (p<0.01)
(Figure 7.3), but lower than that in normals, 3.65±0.94 ml-min '-g1, (p<0.05).
Thus, although coronary vasodilator reserve in the remote regions, 2.73±0.89, was
greater than in the ischaemic territory (p<0.01 vs. ischaemic region), it was
significantly lower than that in the normal subjects, 4.07±0.98 (p<0.01 vs remote
region) (Figure 7.4).
ii) Myocardial Metabolism
(Tables 7.4, 75 and 7.6)
At baseline, haemodynamic parameters and myocardial substrate utilisation were
similar to those in the controls (Tables 7.4 and 7.5). All the group 2b patients
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developed chest pain, >0.1 mV ST segment depression and regional wall motion
abnormalities in the inferior and/or postero-basal wall (Table 7.4), at a maximal pacing
rate that was lower than in the controls (131±19 vs. 159±23 beats-min1), although
this did not reach statistical significance (Table 7.5). GCV flow to the remote region
increased by 59±31% which was significantly lower than the flow increment in the
controls (133±66%, p<0.05 vs. group 2b). The metabolic data at maximal pacing are
shown in Table 7.6. The extraction of glucose and alanine was significantly higher
than in the controls (p<0.05), but there were no differences in lactate extraction, the
RQ and total carbohydrate or lipid oxidation.
7.5 Discussion
This study demonstrates that, as expected, the coronary vasodilator reserve was
severely reduced in regions supplied by stenotic or occluded coronary arteries.
Similarly, metabolic evidence of ischaemia was found at pacing stress in comparable
regions in our second patient group. In addition, a reduced coronary vasodilator
reserve and changes in myocardial metabolism during stress were found in myocardial
regions subtended by angiographically normal arteries. These results suggest that,
even in the absence of previous infarction, regions remote from ischaemic areas may
be altered functionally.
The reduction of the coronary vasodilator reserve in the remote non-ischaemic
regions was due to the combination of a higher basal myocardial blood flow and a
reduced vasodilator response following dipyridamole infusion, compared with
controls. The higher basal myocardial blood flow in the remote region was associated
with a higher resting rate-pressure product, and after correction for the rate-pressure
product, there was no significant difference in basal myocardial blood flow when
comparing control and remote regions. In agreement with our findings, a reduced
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coronary vasodilator reserve after dipyridamole in remote areas supplied by
angiographically normal arteries in patients without previous infarction, has recently
been reported by others (Sambuceti et al, 1991; Beanlands et al, 1992).
Metabolism in the remote myocardium was characterized by an increased
utilisation of carbohydrate fuel at maximal stress similar to that in the ischaemic region
(Camici et al, 1991). This is consistent with previous work which demonstrated an
increase in myocardial 18F-fluoro-deoxyglucose uptake in regions subtended by non-
stenotic arteries in patients with coronary artery disease and angina (Araujo et al,
1988). However, while carbohydrates are used anaerobically in the ischaemic region,
as proven by the net lactate release, they are mainly oxidised in the remote regions
similarly to normal controls.
Mechanisms for Alterations in Remote Metabolism and Vasodilatation
The changes that occur in the remote non-ischaemic areas could be due to different
mechanisms which are not necessarily mutually exclusive. The metabolic pattern seen
in remote non-ischaemic areas is in agreement with previous observations by Liedtke
et al (Liedtke et al, 1982), who reported increased glucose utilisation in areas adjacent
to ischaemic myocardium in isolated pig hearts. This could be due to the increased
workload on the remote regions to compensate for the depressed contractile function in
the ischaemic zones (Liedtke et al, 1982). In this respect, it is of note that equicaloric
replacement of lipid oxidation by carbohydrate oxidation saves 0.17 (imol-min4 of
oxygen consumption per joule of energy produced, giving greater energy production
for the same oxygen consumption (Ferrannini, 1988). This hypothesis is consistent
with previous experimental studies which demonstrate that acute coronary occlusion
results in enhanced contractile function in the remote non-ischaemic zone (Naccarella
et al, 1984; Smalling et al, 1986; Buda et al 1990). This might be a consequence of a
compensatory contractile response of the remote non-ischaemic regions for the
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temporary dysfunction in the regions subtended by stenosed arteries during episodes
of ischaemia. This could occur through increased activity of the sympathetic nervous
system, which is known to affect contractility as well as carbohydrate metabolism
(Camici et al, 1989a). In addition, the increased sympathetic drive could lead to a-
adrenergic coronary vasoconstriction (Heusch, 1990) with a reduction in the coronary
vasodilator reserve.
There are other possible explanations for these findings. The impairment in
coronary vasodilator reserve may be a more chronic adaptation to the increased load on
the remote regions with structural remodelling of the coronary vasculature as has been
described in arterial hypertension (Marcus et al, 1983; Folkow, 1990). Finally, the
impairment in coronary vasodilator reserve may also be an early manifestation of
microvascular endothelial dysfunction in the presence of angiographically undetectable
coronary atherosclerosis (Chapter 1, Section 1.5). As described above, the
atherosclerotic process causes early abnormalities in coronary microvessels manifest
as impaired endothelial-dependent vasodilatation to acetylcholine in an
angiographically smooth artery in patients with disease elsewhere (Zeiher et al, 1991).
There is evidence in an animal model (Kuo et al, 1992) and in man (Drexler et al,
1991) that L-arginine infusion may restore the vasodilator response implying deficient
EDRF production or release as the cause of this abnormality. These findings could
also explain the impaired coronary vasodilator reserve described in this study.
The latter explanation is not necessarily mutually exclusive from an increase in
sympathetic activation. Recent work in the beating dog heart model has shown that
coronary microvascular vasoconstriction by both ai- and 0C2-adrenergic activation
may be increased by inhibition of nitric oxide synthesis (Jones et al, 1993) (Chapter 1,
Section 1.4.2.1), implying that nitric oxide release modulated resting coronary
microvascular tone, opposing the constrictor action of catecholamines. It may be that
with vasodilatation either through pharmacological means, pacing stress or exercise,
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this imbalance persists such that EDRF release is either insufficient or the
responsiveness of the vascular smooth muscle is reduced such that a-adrenergic
vasoconstriction predominates to diminish maximal vasodilatation, and an unopposed
increase in P-adrenergic activation acts to stimulate myocyte carbohydrate uptake.
This hypothesis could unify the impaired vasodilator response and altered metabolism
seen in this study.
Potential Limitations
Some important considerations may limit the conclusions that can be derived from
this preliminary study. Firstly, the control subjects studied by dynamic PET were
significantly younger, compared to the patient group, and it could be argued that
coronary vasodilator reserve is reduced with age. However, in a recent study by
Geltman et al (Geltman et al, 1990) using 15H20 and PET, the coronary vasodilator
reserve to intravenous dipyridamole (0.56 mg-kg"1), measured in 9 patients of mean
age 54 years (range 40-73) with normal or minimally diseased coronary arteries, was
4.4±0.4. This was not significantly different from a coronary vasodilator reserve of
3.8±0.3 measured in 16 normal controls of mean age 25 years (range 20-35). Similar
values of coronary vasodilator reserve to dipyridamole have been recently reported in
control subjects ranging from 18 to 84 years of age by Chan et al (Chan et al, 1992).
Any reduction in coronary vasodilator reserve which does occur with age tends to
occur after the age of 60 years, with an increasing exponential reduction in normal
subjects in their 8th (70-79 years) and 9th (80-89 years) decades (Uren et al,
unpublished observations). Furthermore, in our study, a significantly reduced
increment in great cardiac vein flow during pacing was also seen in the group 2b
patients when compared with control subjects of similar age. One potential limitation
is that the PET scanning and invasive studies were performed in two different patient
groups, although their clinical characteristics were very similar. It is unlikely that the
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use of different study groups significantly prejudiced results as the principal findings
of the study relate most to the comparison of normal and abnormal myocardial regions
with patients thus acting as their own controls.
A potential source of error relates to the accuracy in defining a myocardial region
of interest as truly representative of the area under study. The complicating variable
here would be the inclusion of "watershed" areas of normal myocardium
contaminating the data from the study region. However, in addition to great care being
taken to define the myocardial region carefully in relation to the coronary anatomy
derived at angiography, such an error would only occur to diminish the difference
between the study region and remote myocardium. An error of potentially greater
concern is the reverse contamination of remote myocardium by ischaemic or otherwise
abnormal myocardium. To avoid this problem, sampling was done high in the great
cardiac vein to avoid contamination from venous drainage from ischaemic regions (in
the patients with "normal" left anterior descending arteries). In all PET studies
reported in this thesis, the remote region of interest was always diametrically opposite
the study region.
This problem of what is normal persists despite careful data sampling and
analysis. Intravascular ultrasound has shown that arteries that appear smooth at
coronary angiography may already have evidence of intramural atherosclerosis before
the development of intraluminal plaque (St. Goar et al, 1992). This does not invalidate
the observations made above given that this recent technique characterises the state of
the epicardial artery alone, irrespective of resistive vessel function. However, it does
mean that an angiographically normal epicardial artery, when disease is manifest in
another vessel at angiography, probably has subclinical epicardial disease as well.
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Conclusions
The coronary vasodilator reserve is reduced in remote non-ischaemic regions of
myocardium in patients with angina and stable single vessel coronary artery disease,
which correcting for rate-pressure product is predominately due to a reduction in the
vasodilator response to dipyridamole. Increased glucose and alanine extraction also
occurs in these remote regions under pacing stress in the absence of objective evidence
of myocardial ischaemia, such as lactate production. These alterations in remote
regions, if confirmed, may have important implications for the management of patients
with coronary artery disease. In particular, it is possible that some of the beneficial
effects of drugs such as beta blockers and calcium antagonists may be explained by
some effect on myocardial blood flow and metabolism remote from the site of transient
ischemia. Thus, preservation of coronary vasodilator reserve and myocardial
metabolism in remote myocardium may be seen as an additional goal in the treatment
of patients with coronary artery disease.
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CHAPTER 8. ALTERED CORONARY RESISTIVE
VESSEL FUNCTION IN INFARCTED AND
REMOTE MYOCARDIUM AFTER MYOCARDIAL
INFARCTION
8.1 Abstract
Coronary resistive vessel function may be impaired in patients with coronary
artery disease, even in regions subtended by an angiographically normal artery.
Thirteen patients of mean age 62±11 years were studied after thrombolysis for
myocardial infarction (11 had patent infarct-related arteries and were included in a
complementary study described below). Using positron emission tomography (PET)
with H2150, regional myocardial blood flow (MBF) and the coronary vasodilator
reserve to intravenous dipyridamole (0.5 mg-kg'1 over 4 minutes) in infarct and
remote regions was assessed, 8±3 days after infarction (n=13; PETi) and 6±2 months
after infarction (n=9; PET2). At PET^ basal myocardial blood flow (MBF) was
0.81±0.22 ml-min '-g"1 and peak MBF was 0.91±0.51 ml-min'+g"1 in the infarct
region, giving a coronary vasodilator reserve of 1.12+0.50. Basal MBF was
1.09±0.32 ml-min-g"1 (p<0.05 vs. infarct region) and peak MBF was 1.70±0.72
ml-min^-g1 at peak (p<0.01 vs. infarct region) in the remote region, giving a
coronary vasodilator reserve of 1.53±0.36 in the remote region (p<0.05 vs. infarct
region). The coronary vasodilator reserve in remote myocardium was significantly
less than that of remote regions, subtended by a normal artery, in a control group of
patients with single vessel coronary artery disease, 3.17±0.72 (p<0.01). At PET2,
basal MBF was 0.82±0.21 ml-mkU-g"1 and peak MBF was 1.20±0.45 ml-min'-g"1 in
the infarct region (p<0.01), and 1.0910.18 ml-min+g"1 at basal and 2.3810.89
ml-min+g"1 at peak (p<0.01 vs. infarct region, p<0.05 vs. remote region at PETi) in
the remote region. Thus, the coronary vasodilator reserve was 1.4210.37 in the
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infarct region and 2.19±0.69 in the remote region (p<0.01 vs. infarct region, p<0.05
vs. remote region at PETi), a value which remained lower than in controls (p<0.05).
With the addition of four other patients, a total of 15 patients (mean age 61±12
years) with patent infarct-related arteries underwent PET scanning early after
infarction. Regional MBF and the perfusable tissue index (PTI), a measure of
myocardial viability, was measured. The PTI correlated directly with the MBF
response to dipyridamole (R=0.58, p<0.05) and negatively with the time to
thrombolysis (R=-0.60, p<0.05). No relationship was seen between the coronary
vasodilator reserve in the infarct region and the residual coronary stenosis.
In conclusion, there is marked impairment of the coronary vasodilator reserve in
the infarct region early after infarction with a small recovery by 6 months. This
impaired response to dipyridamole is directly proportional to the viability of the tissue
in the infarct region. The coronary vasodilator reserve to dipyridamole is acutely
decreased in regions remote from the site of infarction compared to remote regions in
stable patients with single vessel disease. This impairment in the coronary vasodilator
reserve improves by 6 months after infarction, but remains lower than in stable
patients.
8.2 Introduction
Coronary blood flow in viable myocardium subtended by infarct-related arteries
may remain severely impaired despite successful recanalisation (Kloner et al, 1974;
Willerson et al, 1975; Jeremy et al, 1990). This observation could be explained by
resistive vessel dysfunction occurring in infarcted tissue as a consequence of acute
ischaemia, but particularly at reperfusion because of neutrophil and platelet
accumulation with progressive impairment of post-ischaemic flow (Ambrosio et al,
1989) and marked microvascular endothelial dysfunction due to oxygen free radical
190
production at reperfusion (Quillen et al, 1990). These processes could account for the
wide variability described in the coronary blood flow and the coronary vasodilator
reserve in the infarcted region (Kloner et al, 1974; Schofer et al, 1985).
Recent studies have indicated that in patients with chronic stable angina, basal
coronary blood flow and the coronary vasodilator reserve may also be altered in
regions of myocardium perfused by angiographically normal arteries distant from the
region of ischaemia (Uren et al, 1993b; Sambuceti et al, 1991; Beanlands et al, 1992),
probably as a result of resistive vessel dysfunction due to atherosclerosis, as
suggested by several studies (Cox et al, 1989; McLenachan et al, 1991; Sellke et al,
1990; Zeiher et al, 1991). It is possible that coronary resistive vessel dysfunction may
be accentuated in the remote region subtended by an angiographically normal artery
after acute myocardial infarction.
To study coronary resistive vessel function in patients after acute myocardial
infarction, we used dynamic positron emission tomography to measure regional
myocardial perfusion and the coronary vasodilator reserve in infarct regions, and
remote regions of myocardium subtended by angiographically normal arteries after
thrombolysis for transmural myocardial infarction, both in the first few days after
myocardial infarction and at several months follow-up. In addition, the relationship
between the coronary vasodilator reserve and myocardial viability, described by the




A total number of 17 patients with single vessel disease were studied after
myocardial infarction. Patients with multiple vessel disease or those who developed
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recurrent myocardial ischaemia at rest, acute heart failure or required inotropic support
were excluded from the study. Thirteen consecutive patients (mean age 62±11 years,
range 40-77; 10 male) with single vessel disease were studied initially, in whom all
had left ventriculography after myocardial infarction. Of this group, 11 of 13 patients
had a patent infarct-related artery defined as TIMI grade 2 or 3 (Table 8.1) (TIMI
group, 1985). The infarct-related artery was the left anterior descending (LAD) in 8
patients, a dominant right coronary artery (RCA) in 4 patients and a dominant left
circumflex artery (LCX) in 1 patient. All other arteries were angiographically normal.
All patients received intravenous streptokinase (1.5 MU) and soluble aspirin 300 mg,
4.2±2.4 hours (range 2.0-7.8) after the onset of chest pain (Results, Table 8.1).
Ten male patients (mean age 52±9 years, range 44-72) with chronic stable angina
due to single vessel (LAD) coronary artery disease were studied as a control group.
All had normal left ventricular function and no evidence of previous myocardial
infarction. All other arteries were angiographically normal.
In addition, to study the relationship between the severity of the residual coronary
stenosis, coronary vasodilator reserve and myocardial viability in the infarct zone, an
additional four patients (3 male) of mean age 58±13 years, who had coronary
arteriography alone (without left ventriculography) after infarction with the
demonstration of a single open infarct-related artery were studied (Section 8.5.7).
These data were combined with that of the 11 patients with open-infarct related arteries
from the initial study group to study the relationship between coronary stenosis
severity and myocardial blood flow (Section 8.4, Table 8.1).
8.3.2. Study Protocol
The protocol was approved by the Research Ethics Committee of Hammersmith
Hospital and all patients gave informed and written consent.
i) Myocardial Infarction Patients.
None of the 13 patients studied had been given either B-blockers or calcium
antagonists after myocardial infarction. PET scanning was performed 8±3 days
(range 4-13 days) after myocardial infarction (PETi) and cardiac catheterisation was
done 27±35 days (range 7-122 days) after myocardial infarction. Patients underwent
repeat PET scanning (PET2) 6±2 months after myocardial infarction. Prior to PET2,
any anti-anginal medication (except sublingual nitroglycerin) was discontinued for at
least 72 hours. No patient took nitroglycerin within 12 hours of any part of the
protocol, and all abstained from drinking tea or coffee on the morning of the PET
scan. Treadmill exercise testing was performed according to the modified Bruce
protocol.
Of the additional 4 patients studied, PET scanning was performed 4 days (range
3-6) after myocardial infarction and coronary arteriography was done 3 days (range 1-
6) after myocardial infarction. The same restrictions in abstinence from medication
applied to this group also.
iil Controls
The control group were enrolled from the routine cardiac catheterisation list.
Discontinuation of anti-anginal medication and abstinence from theophylline-
containing compounds was observed as had been done for the study patients.
8.3.2,1. Cardiac Catheterisation and Quantitative Coronary Arteriography
Coronary arteriography was performed as clinically indicated in order to best
demonstrate the lesion morphology. Coronary arteriograms were analysed by an
automated edge contour detection computer analysis system (Cardiovascular
Angiographic Analysis System [CAAS], Pie Medical Equipment BV, Maastricht, The
Netherlands) (Reiber et al, 1984). This method is briefly described in Chapter 5
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(Section 5.3.2.2). Stenosis severity was expressed as percentage reduction of the
internal luminal diameter (or area) relative to the estimated diameter interpolated from
the diameters at the proximal and distal boundaries of the stenosis, as well as the
absolute minimal luminal diameter and area (Reiber et al, 1984). Infarct artery
patency was defined according to the TIMI grading of re-canalisation after myocardial
infarction (TIMI group, 1985).
Global and regional left ventricular function was measured from the 30° right
anterior oblique left ventricular cine-angiogram excluding the posterior papillary
muscle with an automated hard-wired endocardial contour detector linked to a
microcomputer (Serruys et al, 1986; Slager et al, 1979). Regional contribution was
described in 5 territories; antero-basal, antero-lateral, apical, inferior, and postero-basal
(Serruys et al, 1986). In patients with anterior or antero-lateral infarction, the postero¬
basal and inferior regions were considered remote; in patients with inferior infarction,
the antero-basal and antero-lateral regions were considered remote from the infarct
region.
8.3.2.2. Positron Emission Tomography
All PET scans were performed with an ECAT 931-08/12 camera (CTI Inc.,
Knoxville, Tennessee, USA). Regional myocardial blood flow (MBF, in ml.min fg-
9 was measured in patients and controls using oxygen-15-labelled water (H2lsO) as a
flow tracer using the previously validated C15C>2 inhalation technique (Araujo et al,
1991). Measurements were made at rest and 2 minutes after intravenous
administration of dipyridamole (0.5 mg-kg1 over 4 minutes). Heart rate, systemic
blood pressure and a 12 lead ECG were recorded every minute during the
dipyridamole infusion and for up to 10 minutes after the end of infusion. Images were
created and analysed as previously described (Araujo et al, 1991; Spinks et al, 1988).
194
In patients with the LAD as the infarct-related artery, the anterior region was
designated as the infarct region and the infero-posterior region as remote. In patients
with the RCA or LCX as the infarct-related artery, the infero-posterior region was
designated as the infarct region and the anterior region as remote. Basal myocardial
blood flow (MBF) and peak MBF after dipyridamole were determined. The coronary
vasodilator reserve was defined as the ratio of peak MBF to basal MBF. In the control
subjects, the infero-posterior region was defined as the remote region as all had single
vessel LAD disease.
To exclude the effect of changes in mean arterial pressure (and thus perfusion
pressure) on coronary flow, regional coronary vascular resistance was calculated as
mean arterial pressure+MBF both under basal conditions and after dipyridamole, and
expressed as mmHg-min-g-mk1.
8.3.3. Statistical Analysis
All data are expressed as mean±SD. Paired Student's t tests were used to
compare mean group values. Simultaneous comparison ofmore than two mean values
was performed using one-way analysis of variance (ANOVA), and Fisher's least
significant difference method was subsequently applied to localize the source of the
difference (Godfrey et al, 1985). Correlations between parameters were examined
using simple linear regression. A p value <0.05 was considered statistically
significant.
8.4 Results
8.4.1. Clinical Characteristics of Myocardial Infarction/
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8.4.1. Clinical Characteristics of Myocardial Infarction
(Table 8.1)
All patients developed pathological Q waves on 12 lead ECG within 24 hours of
the onset of chest pain. Peak creatine kinase level was 2,733+1,914 IU-1"1. At
exercise testing at 8±3 days after infarction, 6 of 13 patients had a positive exercise
test (defined as >0.1 mV ST segment depression). At the time of the repeat PET
study, 7 of 9 patients had a positive exercise test.
8.4.2. Regional Left Ventricular Function
(Table 8.2)
The mean left ventricular ejection fraction was 56.1±9.8% and mean left
ventricular end-diastolic pressure was 17±4 mmHg at left ventriculography. At
regional left ventricular analysis (Section 8.3), only one segment in the remote regions
demonstrated an increased regional contribution to left ventricular function away from
the designated region of myocardial infarction (patient 1, anterolateral). An additional
segment with increased regional contribution to global function (patient 9, anterobasal)
was demonstrated in a patient with the LAD as the infarct-related artery, although this
patient had no regional impairment of contractile function (Table 8.2).
8.4.3. Quantitative Coronary Arteriography
(Table 8.3)
Eleven of 13 patients had successful recanalisation of the infarct-related artery
(TIMI grade 3 in 10 patients) with a mean residual stenosis of minimum luminal
diameter of 0.72±0.37 mm, equivalent to a minimum luminal area of 0.60+0.53 mm2.
Compared with the interpolated reference diameter of 2.75±0.55 mm (an interpolated
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Table 8.1. Patient Characteristics









1 50/M III RCA 484 3.5 - 0
2 60/M ni, aVF LCX 5,200 4.0 + 0
3 71/F III, aVF RCA 6,102 2.8 + 0
4 76/M II, III, aVF RCA 573 2.0 + +
5 40/M V2-5 LAD 2,885 8.5 - -
6 52/M Vl-3 LAD 1,452 2.8 - +
7 55/M Vl-3 LAD 3,020 3.3 + +
8 59/M Vl-5 LAD 4,260 2.5 - +
9 61/M Vl-3 LAD 549 2.5 + +
10 65/F Vl-5 LAD 4,148 6.5 - 0
11 67/M Vl-4 LAD 1,265 2.5 - -
12 70/M Vl-3 LAD 1,422 6.2 - +
13 78/M VI, 2 LAD 4,170 7.8 + +
Mean±SD 62±11 2,733±1,914 4.2±2.4
14 69/M I, aVL, Vl-6 LAD 2,302 2.4 0 0
15 67/F Vl-3 LAD 6,100 1.8 0 0
16 55/M H, III, aVF RCA 2,900 3.3 + 0
17 40/M H, III, aVF LCX 593 1.8 - 0
CK = creatine kinase, ETT = exercise treadmill test (+ = positive, - = negative, 0 = no
test), LAD = left anterior descending artery, LCX = dominant left circumflex artery, RCA
= dominant right coronary artery.
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reference area of 6.23±2.72 mm2), this gave a residual diameter stenosis of
76.3±13.8%, equivalent to an area stenosis of 92.2±6.9%.
8.4.4. Haemodynamic Parameters at PET Scanning
(Table 8.4)
At PETi, heart rate increased from 66±12 to 80±15 beats-min1 (p<0.01), systolic
blood pressure increased from 108±15 to 114±14 mmHg (p<0.01), and thus, rate-
pressure product increased from 7,145±1,712 to 9,108±2,313 mmHg-min"1 (p<0.01)
from basal to peak dipyridamole (Table 4). There were no significant differences in
any haemodynamic parameters comparing the control group to the patients at PETi
and PET2.
However, at basal in the 9 patients undergoing repeat study, systolic blood
pressure (103±13 and 120+21 mmHg; p<0.01), mean arterial pressure (77±10 and
87±9 mmHg; p<0.05), and rate-pressure product (6,663±1,428 and 7,715±1,146
mmHg-min"1; p<0.05) were lower at PETi compared to PET2, respectively.
Similarly, after dipyridamole, systolic blood pressure (110±13 and 130+21 mmHg;
p<0.05), mean arterial pressure (80±10 and 93±8 mmHg; p<0.05), and rate-pressure
product (8,779±2,335 and 10,311±1,572 mmHg-min"1; p<0.05) were also lower at
PET 1 compared to PET2, respectively.
8.4.5. Regional Myocardial Blood Flow
(Figures 8.1, 8.2 and 8.3)
Regional myocardial blood flow in the controls and the patients at PET 1 and at
PET2 are shown in Figure 8.1. After a mean of 8 days, in the 13 patients studied,
basal MBF was 0.81±0.22 ml-min+g"1 and peak MBF was 0.91±0.51 ml-min '-g"1 in
the infarct region, and 1.09±0.32 ml-min-g'at basal (p<0.05 vs. infarct region) and






































































































Figure 8.1. The myocardial blood flow at basal and at peak dipyridamole (Dip) in
the infarct region and the remote region in the patients at PETi (n=13) (upper panel),
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the coronary vasodilator reserve was 1.12±0.50 in the infarct region and 1.53±0.36 in
the remote region (p<0.05 vs. infarct region) (Figure 8.2). In the control group, mean
basal MBF was 1.00±0.16 ml-min '-g"1 and the mean peak MBF was 3.08±0.53
ml-min'kg"1 (p<0.01). Thus, the mean coronary vasodilator reserve in the remote
region of the patients was reduced compared to the remote region in the control group,
3.17+0.72 (p<0.01 vs. remote region at PETi) (Figure 8.2).
In the 9 patients who underwent repeat PET scanning, basal MBF was 0.82±0.21
ml-min+g"1 and peak MBF was 1.20+0.45 ml-min'kg"1 in the infarct region (p<0.01),
and 1.09±0.18 ml-min'kg"1 at basal and 2.38±0.89 ml-min'g"1 at peak (p<0.01 vs.
infarct region, p<0.05 vs. remote region at PETi) in the remote region (Figure 8.1).
Thus, the coronary vasodilator reserve was 1.42+0.37 in the infarct region and
2.19+0.69 in the remote region (p<0.01 vs. infarct region, p<0.05 vs. remote region
at PETi) (Figure 8.2). Comparing both PET scans, in the infarct region, there was no
improvement in basal MBF (Figure 8.3).
There was no change in the mean basal MBF at 6 months, which was still
significantly lower than that in the remote region. Although the response to
dipyridamole did show some improvement with time, this did not reach statistical
significance (Figure 8.3). In the remote regions, the peak MBF was higher at PET2
compared to PETi, without significant change in the basal MBF (Figures 8.2 and
8.3). However, despite this improvement, the peak MBF was lower comparing the
remote region to the controls, and thus, the coronary vasodilator reserve remained
lower in the remote region of the infarct patients compared to controls at PET2 (Figure
8.2).
8.4.6. Regional Coronary Vascular Resistance
At PETi, the coronary resistance in the infarct regions was 110.3+48.7
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(p=NS). In the remote region, it fell significantly (pcO.Ol) from 76.1±16.7
mmHg-min-g-ml1 (p<0.05 vs. infarct region) at basal to 55.1±18.4 mmHg-min-g-mh
1 (p<0.01 vs. infarct region) after dipyridamole.
At PET2, the coronary resistance in the infarct region was 116.9±45.8
mmHg-min-g-ml'1 at basal and 107.8±104.4 mmHg-min-g-ml"1 after dipyridamole
(p=NS). In the remote region, it fell significantly (p<0.01) from 83.3+21.0
mmHg-min-g-ml"1 at basal to 43.7+14.8 mmHg-min-g-ml-1 after dipyridamole
(p<0.05 vs. the remote region at PETi). At PET2, the coronary resistance at basal
and after dipyridamole in the infarct region were not significantly different from the
values in the same region at PETj. The coronary resistance in the remote region in the
controls was 90.4+6.7 mmHg-min-g-ml-1 at basal (p=NS vs. the remote region of the
infarct patients at PET] and PET2) and 30.4+6.9 mmHg-min-g-ml-1 after
dipyridamole (p<0.01 vs. the remote region of the infarct patients at PETi; p<0.05 vs.
the remote region of the infarct patients at PET2). Thus, at PET2, the coronary
resistance in the remote region at basal was not significantly different from that value
in the same region at PETj, although after dipyridamole the coronary resistance was
significantly lower, compared with PETj.
8.4.7. Correlates of the Coronary Vasodilator Reserve and the
Perfusable Tissue Index
(Figures 8.4, 8.5, and 8.6)
In this study, 15 patients with an open infarct-related artery (TIMI grade 2/3)
underwent PET scanning and coronary arteriography shortly after myocardial
infarction (Table 8.1 and 8.2). The relationships between residual coronary stenosis
severity, myocardial blood flow, and the perfusable tissue index was examined.
In the infarct region, no relationship was seen between i) the minimum luminal
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Figure 8.5. The relationship between perfusable tissue index in the infarct region
and myocardial blood flow at basal in the infarct region (upper panel), and with
myocardial blood flow after dipyridamole in the infarct region (lower panel), in the 15
patients with open infarct-related arteries after thrombolytic therapy.
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R=-0.60, p<0.05






Figure 8.6. The relationship between perfusable tissue index in the infarct region
and the time from onset of chest pain to initiation of thrombolysis (upper panel). In the
lower panel, the relationship between basal myocardial blood flow in the infarct region
and in remote myocardium is shown in the 15 patients with open infarct-related
arteries after thrombolytic therapy.
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stenosis and basal MBF, peak MBF after dipyridamole, or the coronary vasodilator
reserve (Figure 8.4). However, in the infarct region, there was a weak but significant
relationship between both basal MBF (R=0.56, p<0.05) and peak MBF (R=0.58,
p<0.05) and the perfusable tissue index (Figure 8.5). This indicates that a relationship
exists between the ability of residual myocardium to exchange water and basal
myocardial oxygen consumption (=basal myocardial blood flow). The residual
vasodilator response to dipyridamole is also dependent on the extent of myocardial
tissue still able to exchange water after infarction.
The relationship between the infarct region and the remote region were compared.
The basal MBF in the infarct region correlated inversely with basal MBF in the remote
region (R=-0.54, p<0.05) (Figure 8.6). No such correlation was demonstrated
between the peak MBF after dipyridamole in the infarct region and that in the remote
region. Nor was any relationship seen between the coronary vasodilator reserve in
the infarct region and i) coronary vasodilator reserve in the remote region, ii) creatine
kinase peak, and iii) time to thrombolysis, nor between the creatine kinase peak and
either the coronary vasodilator reserve or the reduction in coronary resistance in the
remote region. However, the perfusable tissue index was closely related to the time to
thrombolysis with a negative correlation demonstrated between the two variables (R=
-0.60, p<0.05) (Figure 8.6).
8.5 Discussion
This study shows that the basal myocardial blood flow was 34% lower in the
infarct region compared with a remote region 8 days after acute myocardial infarction,
and that the vasodilator response to dipyridamole was markedly reduced, not only in
the infarct region but also to a lesser degree in the remote region. After 6 months, the
basal myocardial blood flow in the infarct region was unchanged with a 46% increase
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in the myocardial flow to dipyridamole. However, the coronary vasodilator reserve
still remained significantly lower than the remote region. After 6 months, the basal
myocardial blood flow in the remote region was unchanged and although there was
some improvement in the coronary vasodilator reserve, it remained significantly lower
than in the controls.
Myocardial Blood Flow in the Infarct Region
At the first PET scan, the lower values of basal myocardial in the infarct region are
consistent with myocardial injury and severe resistive vessel dysfunction. There was
no change in the mean basal myocardial blood flow at 6 months, which was still
significantly lower than that in the remote region. Whether there was recovery of
contractile function in the infarct region at follow-up, and thus evidence ofmyocardial
stunning (Braunwald & Kloner, 1983; Bolli, 1992) in the patients with basal
myocardial flows within the normal range, is not known. The persistent reduction in
basal flow would therefore appear to represent irreversible myocardial and resistive
vessel injury.
The vasodilator response to dipyridamole was markedly reduced and improved to
a small degree at 6 months. Two explanations may account for this. First, there may
be a partial recovery in resistive vessel function in areas of viable myocardium within
the infarct zone contributing to vasodilatation after dipyridamole but remaining a small
percentage of overall vasodilator potential. This recovery may occur with resolution
of interstitial oedema restricting microvascular luminal dimensions (Willerson et al,
1972) and of neutrophil plugging in post-ischaemic capillaries (Engler et al, 1983;
Chatelain et al, 1987). The reflex increase in sympathetic activation after infarction
may also acutely impair resistive vessel dilatation (Schwartz & Stone, 1977) (see
below). Alternatively, any small improvement in the response to dipyridamole could
simply reflect the higher mean arterial pressure, and thus, coronary perfusion pressure
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at repeat scanning compared to the initial study. However, coronary resistances after
dipyridamole at both scans were not significantly different in the infarcted region,
making this a less likely explanation.
A relationship was seen between both myocardial blood flow at rest and after
vasodilatation and the amount of water-perfusable tissue in the infarct region which is
a measure of the viability of the residual tissue (Yamamoto et al, 1992; de Silva et al,
1992) (Chapter 3.9). This confirms an inter-relationship between myocyte cellular
function and the integrity of the coronary microvascular bed after myocardial
infarction. The longer delay there is to initiation of thrombolytic therapy and
subsequent recanalisation, the greater the reduction in tissue viability. This finding is
consistent with the benefit in survival established from large multi-centre trials of
intravenous thrombolysis (ISIS-2, 1990).
An inverse relationship was demonstrated between basal myocardial blood flow in
the remote region and that in the infarct region. Whether this reflects a regional steal
phenomenon (so-called "reverse steal" from ischaemic to remote region), an
intracardiac neural reflex, or altered regional intraventricular loading (Smalling et al,
1986) is unknown. In this respect, it has been demonstrated in an animal model that
preconditioning of myocardium in one region by intermittent occlusicn-reperfusion,
may reduce infarct size when another artery in remote myocardium is subsequently
occluded (Przyklenk et al, 1993). This so-called "remote preconditioning" occurred
independent of collateral blood flow, haemodynamic parameters or area at risk. This
could be further evidence for an increase in both a- and (3-adrenergic sympathetic
activation with catecholamine release mediating a preconditioning response, as
described with neuronal noradrenaline release in the isolated rat heart (Locke-Winter et
al, 1991). Alternatively, a protective factor such as adenosine may pass in collaterals
or diffuse from capillary or post-capillary anastomoses to the region at risk. In this
study, the inverse relationship between basal flow in infarct and remote myocardium
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may be the first demonstration in man of "reverse steal". However, whether it is of
importance in determining the extent of myocardial stunning or of outcome after
infarction is unknown.
Myocardial Blood Flow in the Remote Region
The basal myocardial blood flow did not change significantly in the period
between the two PET scans, and was similar to that measured in remote region of
controls. At 8 days after infarction, the flow response to dipyridamole was
significantly lower than that measured in the remote region of the control patients and
did not correlate with the coronary vasodilator reserve in the infarct region, the
enzymatic size of the infarction, or the time to thrombolysis. At the time of the second
PET scan, the myocardial blood flow response, and thus the coronary vasodilator
reserve was significantly greater, but it still remained significantly lower than in
controls.
The reduced coronary vasodilator reserve in the remote region after infarction may
be part of a generalized impairment of coronary vasodilatation observed by different
groups using different methods in myocardial regions subtended by angiographically
normal coronary arteries with disease elsewhere, compared with controls (Uren et al,
1993b; Sambuceti et al, 1991; Beanlands et al, 1992). In support of these findings,
clinical and experimental studies have demonstrated that in the coronary circulation
impaired endothelial-dependent dilatation to increased blood flow and to the
endothelium-dependent vasodilator, acetylcholine, occurs before obstructive coronary
artery disease develops (Cox et al, 1989; McLenachan et al, 1991; Sellke et al, 1990;
Zeiher et al, 1991). This may be due to reduced production or release of nitric oxide
(Sellke et al, 1990), as infusion of L-arginine, the precursor of nitric oxide, restores
the impaired coronary blood flow response (Kuo et al, 1992). In an animal model of
myocardial infarction, a reduced coronary vasodilator reserve has been shown in
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remote myocardium due to both an increase in basal flow and to reduced
vasodilatation, and this in part has been attributed to reactive myocyte hypertrophy in
the non-infarcted myocardium (Karam et al, 1990). Furthermore, it has been shown
that basal release of nitric oxide is impaired in post-infarction reactive hypertrophy
several weeks after infarction (Drexler et al, 1992), perhaps due to functionally less
active endothelium in the resistive vessels, as described after endothelial injury
(Shimokawa et al, 1987). However, whether this mechanism accounts for the
persistent reduction in the vasodilator response of the remote myocardium in this study
is unknown.
In patients with acute myocardial infarction, these alterations may be accentuated
by several mechanisms. First, following myocardial infarction there is a marked
increase in sympathetic activity, which lasts for several days, associated with an
increase in circulating catecholamine concentrations and activation of the renin-
angiotensin-aldosterone system (McAlpine et al, 1988), the degree of which depends
mainly on infarct size (McAlpine et al, 1988; Karlsberg et al, 1981). It is possible that
the reduction in the coronary vasodilator reserve to dipyridamole in the remote regions
could occur as a consequence of increased sympathetic activity following infarction
(Minisi & Thames, 1991; Naccarella et al, 1984); in particular, increased a-adrenergic
activity may cause a blunting of the vascular smooth muscle response to dipyridamole
(Heusch, 1990), reducing the coronary vasodilator reserve at early scanning. Second,
the coronary vasodilator reserve may have been affected by differences in blood
pressure at the time of the two PET scans. The rate-pressure product was slightly but
significantly lower at the first scan, because of a lower systolic blood pressure
response to dipyridamole. When the resistive vessels are maximally dilated, the
myocardial blood flow is proportional to the perfusion pressure providing the
myocardial oxygen demand remains unchanged, ie. when blood pressure rises,
myocardial blood flow will increase and the converse is true. However, this seems an
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unlikely explanation for our findings since despite the small haemodynamic
differences between the two scans, the coronary resistance in the remote regions after
dipyridamole was significantly lower at repeat scanning, providing evidence of a
change in resistive vessel function in the remote region in the period between the two
scans. Third, following myocardial infarction, there is an acute increase in left
ventricular diastolic pressure and, although this may fall over subsequent days to
weeks (McKay et al, 1986), an acute rise in left ventricular diastolic pressures could
impair the vasodilator response since most myocardial blood flow occurs during
diastole (Domenech, 1978; Archie, 1978). Higher end-diastolic pressures would lead
to an early increase in end-diastolic wall tension and a consequent increase in basal
myocardial blood flow due to increased myocardial oxygen demand might be expected
(Braunwald, 1971). A reduction in maximal flow due to an increase in resistance
would reduce the maximal blood flow response to dipyridamole. However, we did
not observe an increase in basal myocardial blood flow and in addition, transmural
coronary flow is not thought to be affected significantly when coronary perfusion
pressures are greater than 70 mmHg (Archie & Brown, 1974).
Conclusions
In patients after a mean of 8 days from a myocardial infarction, the coronary
vasodilator reserve to dipyridamole is markedly impaired in the infarct region.
Although unrelated to the residual severity of the infarct-related stenosis, a relationship
exists between the vasodilator response to dipyridamole and the viability of the
residual myocardium. To a lesser extent, the coronary vasodilator reserve is also
impaired in the remote regions possibly due to acute resistive vessel dysfunction. The
coronary vasodilator reserve in the remote myocardium undergoes an incomplete
recovery after several months but still remains lower than in controls. Although the
mechanism for both this acute and chronic alteration in resistive vessel function is
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unknown, it may be of clinical relevance in the immediate and short-term management
of patients after acute myocardial infarction.
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CHAPTER 9. IMPAIRMENT OF THE
MYOCARDIAL BLOOD FLOW RESPONSE TO
COLD PRESSOR STRESS IN COLLATERAL-
DEPENDENT MYOCARDIUM
9.1 Abstract
Myocardium subtended by an occluded epicardial coronary artery is dependent for
perfusion on collateral vessels. The purpose of this study was to determine the effect
of reflex sympathetic stimulation on coronary collateral and resistive vessel function.
Eight patients, mean age 54±6 years (six male), with chronic stable angina were
studied, in whom one coronary artery was occluded, but supplied by collaterals from
the other angiographically normal arteries. All had normal left ventricular function,
normal ECGs and positive exercise tests. All anti-anginal medication was
discontinued for >48 h. Cold pressor after a mean duration of 5.9 min (range 5-6.5
min) caused chest pain in two, but none developed ECG changes. Regional
myocardial blood flow (MBF) was measured in the collateral-dependent and in a
remote region using positron emission tomography with i) 150-water at basal and at
cold pressor, and ii) 18F-fluoro-deoxyglucose (FDG). The coronary reserve was
defined as cold pressor MBF/basal MBF. Heart rate was 62±7 beats-min-1 at basal
and 67±12 beats-min1 during cold pressor (p=NS). There was an increase in systolic
blood pressure, 118+20 vs. 160±26 mmHg (p<0.01), and rate-pressure product,
7,420±1,820 vs. 10,800±3,080 mmHg-min1 (p<0.01), at basal and during cold
pressor, respectively. In a remote region, basal and cold pressor MBF were
1.03±0.25 ml-min +g1 and 1.55±0.57 ml-mnr+g"1 (p<0.05 vs. basal MBF)
respectively, and the coronary reserve was 1.51±0.45. In the collateral-dependent
region, basal and cold pressor MBF were 0.93±0.21 ml-min1-g1 (p=NS vs. remote
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region) and 0.92±0.34 ml-min+g1 (p<0.05 vs. remote region) respectively, a
coronary reserve of 1.01±0.44 (p<0.05 vs. remote region). In the remote region,
with cold pressor, there was a significant decrease in the mean coronary vascular
resistance from 97.8±32.6 mmHg-min-g-mk1 to 81.5±31.9 mmHg-min-g-mk1
(p<0.05) at basal and at cold pressor respectively, whereas in the collateral-dependent
region, the mean coronary vascular resistance increased from 106.4+32.6
mmHg-min-g-ml"1 to 142.8±64.0 mmHg-min-g-ml"1 (p<0.05 vs. remote region).
No increase in FDG uptake after cold pressor was seen in collateral-dependent regions
compared to remote regions.
These data indicate that resistive vessel dilatation occurs with cold pressor in the
remote region. In the collateral-dependent region, in response to the same stress,
there is either a failure of the collateral or resistive vessels to dilate or an increased
tendency to vasoconstrict, although this occurs in the absence of demonstrable
transmural myocardial ischaemia.
9.2 Introduction
After coronary artery occlusion, there is often no myocardial necrosis in the
jeopardised region because collateral coronary blood flow from other myocardial
regions is sufficient to maintain basal perfusion and thus, myocardial viability (Frye et
al, 1977; Schwartz et al, 1978). Early studies using thallium-201 imaging have also
indicated normal myocardial perfusion in these collateral-dependent areas not only at
rest but also on exertion (Rigo et al, 1979; Eng et al, 1982; Kolibash et al,1982).
However, a more recent study using positron emission tomography has shown a
reduced coronary vasodilator response to dipyridamole in collateral-dependent
myocardium (McFalls et al, 1993). Furthermore, when cardiac work is increased by
atrial pacing, regional wall motion abnormalities develop in the myocardial segments
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perfused by collateral vessels (Schwartz et al, 1978), indicating a limitation of their
^ability to maintain adequate myocardial perfusion in the face of increased myocardial
metabolic requirements. Pupita et al have suggested that in patients with coronary
artery disease, changes in vasomotor tone at the level of the coronary collateral and
resistive vessels may alter the ischaemic threshold (Pupita et al, 1990). Several other
groups (Nabel et al, 1988; Mudge et al, 1976; Yeung et al, 1991) have suggested that
this functional abnormality of the coronary collateral and resistive vessels which
appears to occur occurring as part of the atherosclerotic process may lead to an altered
sensitivity to sympathetic activation. This may be manifest by the collateral and
resistive vessels showing either an inability to vasodilate adequately or an increased
tendency to vasoconstrict inappropriately, and this might then result in the
development ofmyocardial ischaemia. Myocardial blood flow in collateral-dependent
myocardium may thus serve as a model of resistive vessel function (Gregg &
Patterson, 1980).
Investigation of the vasomotor responses of the collateral and resistive vessels in
man is problematic since it is difficult to exclude the effects of concomitant changes in
the vasomotor tone of the epicardial coronary arteries. In order to avoid this problem
as far as possible, we have investigated coronary blood flow in a group of patients
with normal left ventricular function but who have one occluded coronary artery.
Thus in these patients, one myocardial region is entirely dependent on collateral blood
flow. In this study, cold pressor stress was used as a sympathetic nervous system
stimulus. Regional myocardial blood flow and glucose metabolism was measured
using positron emission tomography in order to compare the collateral-dependent




Eight patients (mean age 54±6 years; 6 male) with single vessel coronary artery
occlusion were studied. The occluded artery was the left anterior descending (LAD)
in 2 patients, dominant left circumflex artery (LCX) in 2 patients, and dominant right
coronary artery (RCA) in 4 patients. No patient had ECG evidence of previous
myocardial infarction and all patients had normal left ventricular function (Table 9.1).
All had a positive exercise test (>0.1 mV ST segment depression) at moderate
workload on the modified Bruce protocol (Section 9.4, Table 9.2).
9.3.2. Study Protocol
The protocol was approved by the Research Ethics Committee of Hammersmith
Hospital and all patients gave informed and written consent.
Patients were studied on three separate occasions. Any anti-anginal medications
were discontinued at least 48 hours before any part of the study. On one occasion,
exercise testing was performed under basal conditions and after sublingual nitrates.
On another occasion, the other non-invasive stress tests were performed. The stress
tests were i) mental arithmetic (serial 7 subtraction for up to 5 minutes), ii) handgrip
(to 30% maximum grip for up to 5 minutes), and iii) cold pressor (immersion of right
hand in ice for as long as tolerated, or up to 6 minutes). These stress tests were
performed with continuous ECG monitoring, and a 12 lead ECG together with the
blood pressure were recorded after each minute of the test. On the third occasion,
patients underwent PET scanning at basal and during cold pressor.
9.3.2.1. Coronary Arteriography and Left Ventriculography
(Table 9.1)
All patients enrolled in the study had undergone coronary arteriography within 6
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months of PET scanning. Coronary arteriograms were analysed by an automated
edge contour detection computer analysis system (Chapter 5, Section 5.3.2.2) (Reiber
et al, 1984). Collaterals were graded according to the method of Rentrop et al
(Rentrop et al, 1985) (Chapter 7, Section 7.3).
Global and regional left ventricular function was measured according to the
method described previously (Chapter 7, Section 7.3.2.1). In patients with an
occluded LAD, the postero-basal and inferior regions were considered remote; in
patients with a dominant LCX or RCA occlusion, the antero-basal and antero-lateral
regions were considered remote from the site of coronary occlusion.
9.3.2.2. Measurement of Regional Myocardial Blood Flow and Metabolism
1. PET Scanning
Patients were fasted overnight and all had been off anti-anginal medication (except
for sublingual nitrates) for at least 48 hours. No nitrates were taken for at least two
hours before the study.
All PET scans were performed with an ECAT 931-08/12 camera (CTI Inc.,
Knoxville, Tennessee, USA) (Spinks et al, 1988). Regional myocardial blood flow
(MBF, in ml.min-kg'1) was measured in patients using oxygen-15-labelled water
(H2150) as a flow tracer using the previously validated C15C>2 inhalation technique
(Araujo et al, 1991). Measurements were made at basal and during the cold pressor
stress. The protocol during cold pressor was as follows; after a background scan of
30 seconds, the right hand was immersed in ice simultaneous with the start of C15C>2
inhalation, which was given for 210 seconds. The hand was removed from ice
between the end of C15C>2 inhalation and the end of the scan at 420 seconds.
Systemic blood pressure and heart rate were monitored throughout the study and a 12
lead ECG was recorded every minute during the stress. Immediately following the
cold pressor stress, 185 MBq-mk1 of FDG was given by intravenous infusion over 5
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minutes, and the duration of this dynamic scan was 65 minutes. These studies were
done without glucose loading. Images were analysed over the last of 36 frames which
had a duration of 5 minutes. Under ischaemic conditions, there is an increased
utilization of glucose by the myocardium both from glycogen breakdown and from
exogenous glucose (Chapter 3, Section 3.8). Global and regional changes in glucose
utilisation under controlled conditions may be studied using FDG (MacGregor et al,
1977; Phelps et al, 1978; Bergmann et al, 1985), to demonstrate regions of
myocardial ischaemia. In this study, regional FDG uptake was measured in absolute
counts of activity (Bonow et al, 1991; Vanoverschelde et al, 1992).
The sinograms were corrected for attenuation and reconstructed on a Microvax II
computer (Digital Equipment Corporation, Marlboro, Mass.,USA) (Spinks et al,
1988; Araujo et al, 1991). Images were transferred to a SUN 3/60 work-station for
further analysis using Analyze™ (Mayo Foundation, Rochester, Minn., USA) and
Pro-Matlab™ (The Mathworks Inc., South Natick, Mass., USA) software packages.
Images were created and analysed as previously described (Araujo et al, 1991).
In patients with the LAD as the occluded artery, the anterior region was
designated as the collateral-dependent region and the infero-posterior region as the
remote region of interest. In patients with a dominant RCA or LCX as the occluded
artery, the infero-posterior region was designated as the collateral-dependent region
and the anterior region as the remote region of interest. Basal MBF and MBF during
cold pressor were determined. The coronary reserve was defined as the quotient of
cold pressorMBF to basal MBF.
To exclude the effect of changes in mean arterial pressure, and thus perfusion
pressure, on coronary flow, regional coronary resistance was calculated from the
quotient of mean arterial pressure and regional myocardial blood flow both under
basal conditions and during cold pressor, and expressed as mmHg-min-g-mk1.
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With PET, the extent of myocardial damage may be determined from the
background (transmission) scan generated by external positron irradiation of the
patient, and the dynamic flow scan generated by C15C>2 inhalation under basal
conditions. As described in Chapter 3, the total anatomical tissue fraction (ATF, in
g-ml"1 of region) is the perfused tissue fraction (PTF) and the non-perfused tissue
fraction together. The ratio of PTF/ATF for each region may be determined in
collateral-dependent and remote regions, and expressed as an index of water-
perfusable tissue (PTI) (Iida et al, 1988). Previous work in our institution has shown
a strong positive and negative predictive accuracy with the PTI for the recovery of
myocardial contractility in hypokinetic or akinetic myocardial regions after myocardial
infarction (Yamamoto et al, 1992), or after revascularisation (de Silva et al, 1992)
(Chapter 3, Section 3.9.1).
9.3.2.3. Ambulatory Electrocardiographic Monitoring
Ambulatory ECG monitoring over a 24 period was performed with the patients
off any anti-anginal medication for at least 48 hours in the case of calcium antagonists
and 72 hours with (3-blockers. Two-channel amplitude-modulated recorders
(Marquette 8500) were used with the two chest leads showing the most impressive
ECG changes at exercise testing selected. The effect on the ST segment of changes in
posture was carefully assessed. Patients were provided with diaries to note the time at
which episodes of angina occurred and the circumstances with which they occurred.
Analysis was performed with a laser Holter system (Marquette 8000). An episode of
transient ischaemia was defined as a horizontal or down-sloping depression of the ST
segment of more than 0.1 mV occurring 80 msec after the J point and lasting longer
than one minute. The duration of each ischaemic episode and the heart rate at the
onset of the ST segment shift, in each of the preceding 10 minutes, and at 0.1 mV
depression of the ST segment were measured.
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Variability of the threshold of myocardial ischaemia was determined by two
methods; i) >15% difference in heart rate at the onset of ST segment depression on
exercise testing and ambulatory monitoring, and ii) >15% difference in minimum and
maximum heart rate at the onset of ST segment depression.
9.3.3. Statistical Analysis
Results are expressed as mean±SD. Analysis of data was performed by the





Patients underwent exercise testing at basal and after sublingual nitrates. Rate-
pressure product was 10,940±2,380 and 11,78012,540 mmHg-min-1 at rest, and
25,47016,050 and 26,02015,810 mmHg-min-1 at peak exercise (both p=NS) under
basal conditions and after nitrates, respectively (Table 9.2). All 8 patients had positive
tests (>0.1 mV ST segment depression) under basal conditions; after sublingual
nitrates, one patient had a negative test and the other 7 increased their ischaemic
threshold from a rate-pressure product of 19,650 to 23,095 mmHg-min-1 (Table 9.2),
due to a increase in heart rate at the ischaemic threshold.
9.4.2. Non-Invasive Stress Testing
(Tables 9.3, 9.4 and 95)
Mental stress (Table 9.3), handgrip (Table 9.4) and cold pressor (Table 9.5) had




























































































































































































thus the rate-pressure product. Mental stress caused only a small increase in mean
arterial pressure compared to basal. However, isometric handgrip and cold pressor
had marked effects on increasing both diastolic and mean arterial pressure. There
were no significant ST segment changes (>0.1 mV depression) with any of the non¬
invasive tests in any of the patients. There was no chest pain with mental stress or
handgrip, but two patients reported mild chest pain during cold pressor.
9.4.3. PET Scanning
(Table 9.6; Figures 9.1 and 9.2)
Cold pressor testing was sustained for a mean duration of 5.9 min (range 5-6.5) at
PET scanning. Cold pressor increased systolic blood pressure (118±20 to 160±26
mmHg, p<0.01) and rate-pressure product (7,420±1,820 to 10,800±3,080
mmHg-min1, p<0.01) from basal to cold pressor respectively, but had no major effect
on heart rate (62±7 to 67±12, p=NS). Two patients reported chest pain during cold
pressor, but no significant ST segment changes were seen in any patient.
In the remote region, basal and cold pressor MBF were 1.03±0.25 and
1.55±0.57 ml-min-'-g"1 (p<0.05 vs. basal MBF) respectively, a coronary reserve of
1.51±0.45. In the collateral-dependent region, basal and cold pressor MBF were
0.93±0.21 (p=NS vs. remote region) and 0.92±0.34 ml-min^-g1 (p=NS vs. basal
MBF, p<0.05 vs. remote region) respectively, a coronary reserve of 1.01±0.44
(p<0.05 vs. remote region) (Figure 9.1). In the remote region, coronary vascular
resistance decreased from 97.8±32.6 to 81.5±31.9 mmHg-min-g-ml1 (p<0.05) at
basal and cold pressor, respectively. In the collateral-dependent region, coronary
vascular resistance was 106.4±32.6 mmHg-min-g-ml1 at basal (p=NS vs. remote
region) (Figure 9.2). The coronary vascular resistance increased in 6 of the 8 patients
with cold pressor, giving an overall mean value of 142.8±64.0 mmHg-min-g-ml'1.
Although this was not significantly different from basal, it was higher than in the
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Figure 9.1. Individual values of the myocardial blood flow response from basal to
cold pressor in collateral-dependent (black symbols) and remote regions (open

































Figure 9.2. Individual values of the coronary resistance at basal and cold pressor in
collateral-dependent (black symbols) and remote regions (open symbols). * p<0.05
vs. Basal.
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remote region (p<0.05) (Figure 9.2).
No regional increase in FDG uptake was seen in collateral-dependent regions
compared to remote regions, after cold pressor (Table 9.6). The PTI, although
higher in remote regions, was greater than the threshold of 0.7 in the collateral-
dependent regions (Table 9.6). No correlation was demonstrated between PTI and
basal MBF, cold pressor MBF, or the coronary blood flow response in the collateral-
dependent region.
9.4,4. Ambulatory ECG Monitoring
(Table 9.7; Figure 9.3)
Four patients had transient episodes of >0.1 mV ST segment depression and four
had no episodes within a 24 hour period (Table 9.7). All 4 patients with ST segment
depression had evidence of variable threshold myocardial ischaemia, using the
definition of the difference between heart rate at the onset of ischaemia on exercise and
on Holter, although only two demonstrated variability when comparing episodes of
ischaemia on Holter alone (Section 9.3) (Table 9.7). Comparing these two subgroups
with and without ambulatory myocardial ischaemia, the 4 patients with recurrent
ambulatory ischaemia had a higher basal MBF in the collateral-dependent region
(1.08±0.20 vs. 0.79±0.05 ml-min^-g1, p<0.05), although the MBF response to cold
pressor (0.86+0.29 vs. 0.97±0.42 ml-mim+g1, p=NS) and ultimately coronary
reserve (0.78±0.14 and 1.24+0.54, p=NS) in those with and without ambulatory
ischaemia, was not significantly different (Figure 9.3). It remains likely that the lack
of a difference in coronary reserve reflects the small numbers in the study.
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Table 9.7. 24 Hour Ambulatory Electrocardiographic Monitoring
HR at 0.1 Difference in Difference
HR at 0.1 mV ST HR between Between
mV ST Depression Exercise Min. and
Duration Depression on Test and Max. Holter
Patient No. Pain (minutes) on Holter Exercise Holter HR
2 33 102 110 8 0
- 12 108 2 6
- 15 104 6 2
- 5 109 1 7
- 15 144 -34 42
3 + 10 103 127 24 11
+ 8 100 27 8
+ 6 105 22 13
+ 10 92 35 0
+ 40 94 33 2
+ 35 100 37 8
+ 15 144 -17 52
6 7 137 148 11 11
- 6 126 22 0
- 12 132 16 6
7 + 26 107 144 37 4
+ 15 105 39 2
+ 10 108 36 5
+ 15 103 41 0
+ 10 109 35 6
+ 15 105 39 2
HR = heart rate (beats-min1)- Patients 1, 4, 5 and 8 had no episodes of significant
ST segment depression during daily activity. (+) or (-) denotes painful or painless
episodes of myocardial ischaemia. Duration refers to the time period from the
beginning to the end of an episode resulting in >0.1 mV ST segment depression.
Heart rates at the onset of 0.1 mV ST segment depression either on exercise at Holter
monitoring are given. Differences described are between exercise and Holter heart
rates at the beginning of ischaemia, and between the minimum and maximum heart
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9.5 Discussion
In this study, mental arithmetic, handgrip and cold pressor testing caused no
demonstrable myocardial ischaemia, as measured by significant ST segment change
on continuous ECG, despite an increase in myocardial oxygen demand, measured as
the rate-pressure product. However, the peak rate-pressure product achieved with
these non-invasive stress tests was much lower than the ischaemic threshold
determined at treadmill exercise testing, making significant myocardial ischaemia
unlikely without an additional (primary) reduction in coronary flow (Maseri, 1983).
Four of the patients did demonstrate variable threshold myocardial ischaemia, which
although lower than the heart rate at the ischaemic threshold of myocardial ischaemia
on exercise, was still higher than that during any of the non-invasive stress tests. This
may be an indication of an additional vasoconstrictive component in the genesis of
ischaemia in these patients (Pupita et al, 1990). It is also of interest that patients with
transient ischaemia at ambulatory monitoring had higher basal flow, perhaps
suggesting early impairment in the autoregulation of myocardial perfusion (Chapter 1,
Section 1.4).
Cold pressor, an a-adrenergic stimulus (Mudge et al, 1976), did however
induce chest pain in two patients. There was no difference between the basal
myocardial blood flow in the collateral-dependent myocardium and the remote region
at PET, indicating that the collateral vessels were sufficient to maintain resting
perfusion. Reflex sympathetic stimulation using cold pressor did result in an increase
in myocardial blood flow in remote myocardium, but not in viable, collateral-
dependent myocardium, with a value much lower than that in the remote region.
Indeed, in 6 of the patients, cold pressor resulted in an increase in coronary resistance,
although there was no overall difference in regional FDG uptake in any of the 8
patients, excluding prolonged transmural myocardial ischaemia as a consequence of
this inappropriate resistive vessel vasoconstriction or inability to vasodilate.
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Coronary Collaterals and Myocardial Perfusion
In the dog model, a coronary stenosis does not stimulate collateral development
until the stenosis decreases luminal area by about 80%, but this collateral growth is
much less than that which occurs in response to compete coronary occlusion (Schaper
et al, 1988). The vasomotor function of collaterals remains poorly understood.
Although, in animal models, the functional capacity of collateral vessels is unrelated to
visual assessment, in clinical studies, patients with larger collaterals generally have a
higher peripheral coronary perfusion pressure and retrograde flow into diseased
vessels (Goldstein et al, 1974; 1975). Under normal conditions, in a dog model, the
resistance through native collateral vessels is much higher, up to 60-80 times greater
than the minimal resistance through the coronary resistive vessels (Schaper et al,
1987). However, using microspheres, maximal flow to an ischaemic zone via native
collaterals may approach 30-50% of normal flow implying resistance only 2-3 times
normal in the beating dog heart (Becker & Pitt, 1971; Marcus et al, 1975). Much of
this variability occurs because of the problem of heterogeneous tissue sampling from
both normal and collateral dependent areas (Schaper et al, 1976). Positron emission
tomography may be used to measure regional blood flow without such limitations,
and has shown that there is a functional impairment of collateral vessels when
supplying a myocardial territory, without support from other epicardial vessels
(McFalls et al, 1993).
Collateral Vasomotion and Resistive Vessel Function
There is some evidence which tends to suggest that ai-adrenergic mechanisms are
unlikely to modulate collateral vasomotion (Harrison et al, 1986). In one study,
noradrenaline (combined ai- and (X2-adrenergic stimulation) did not alter trans-
collateral resistance in an open-chest dog model, although of interest selective 0t2-
adrenergic stimulation alone with the agonist BHT 920 did increase trans-collateral
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resistance (Maruoka et al, 1987), perhaps implying an 0C2-adrenergic component to the
modulation of collateral vasomotion. In contrast, mature collaterals have functional (3-
adrenergic receptors to a similar extent to other coronary vessels; increased |3-
adrenergic stimulation leads to vasodilatation thus improving collateral perfusion at
times of stress (Harrison et al, 1991).
Only coronary collaterals greater than 100-200 (im are apparent angiographically,
and are responsible for at least 50% of the coronary resistance (Marcus et al, 1990).
As smaller resistive vessels, the arterioles, have no neural efferents, it is possible that
the impaired response to the predominately a-adrenergic stimulation of the cold
pressor test reflects an increased tendency to vasoconstriction in the resistive vessels
greater than 100 |a.m, the so-called "pre-arterioles" (Maseri et al, 1991) (Chapter 1,
Section 1.4.1.4). Unlike the arterioles which are directly influenced by cellular
metabolism and tissue pH, these pre-arterioles respond to changes in coronary blood
flow and thus perfusion pressure, to ensure the match of flow to metabolic
requirements. It is possible that in coronary artery disease, abnormal resistive vessel
function in the pre-arterioles may cause or contribute to myocardial ischaemia, if there
is sufficient impairment of vasomotor function in these vessels with an increase in
myocardial demand. Previous work has shown that infusion of noradrenaline
(Chilian et al, 1989b), and serotonin (Lamping & Eastham, 1989), constrict resistive
vessels greater than 100 p.m, but dilate smaller vessels. It is possible therefore that the
local vasoconstrictor response in the collateral-dependent region, is an inappropriate
response to a-adrenergic stimulation by the resistive vessels perfused by the
collaterals (Heusch, 1990), occurring with the reflex a-adrenergic stimulation of the
cold pressor test. However, whether this inappropriate vasoconstriction is ever
sufficient to cause myocardial ischaemia in its own right, is not known.
An additional mechanism for impaired resistive vessel dilatation or inappropriate
vasoconstriction is endothelial dysfunction in chronically perfused mature collaterals.
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This has been suggested by the vasoconstrictor response of collateral-dependent
myocardium in open chest dogs to physiological doses of vasopressin (Peters et al,
1989). This has been confirmed using in vitro microvessel imaging; relaxation to the
endothelium-dependent vasodilators acetylcholine and ADP are markedly impaired in
resistive vessels from collateral-dependent myocardium compared to controls (Sellke
et al, 1990). Two possibilities for this impairment are chronic hypoperfusion down-
regulating nitric oxide synthetase from membrane receptors or growth factors from
collateral vessels causing proliferation of functionally less active resistive vessel
endothelium (Harrison et al, 1991) (Chapter 1, Section 1.4.3).
The decrease in myocardial blood flow in the collateral-dependent myocardium
with cold pressor could also occur due to a collateral steal effect ie. a relative reduction
in collateral flow due to an increase in flow to normal myocardium. This has been
demonstrated in intact animals (Cohen et al, 1976), although often confounded by the
effect of pharmacological vasodilatation on systemic haemodynamics. In a study
using an isolated heart, during adenosine vasodilatation, collateral perfusion appeared
to be inversely related to perfusion in normal myocardium, a five-fold increase in flow
to normal myocardium associated with a 50% reduction in collateral flow (Simonetti et
al, 1987). This reverse steal may of course still occur because of an inability of
resistive vessels to vasodilate adequately in the collateral-dependent myocardium.
Conclusions
There is impaired resistive vessel function in myocardial regions entirely perfused
by collateral vessels, with normal basal myocardial blood flow and contractile function
at rest. Overall, there is an inability of the collateral or resistive vessels to vasodilate
adequately or an inappropriate vasoconstrictor response to cold pressor compared to
remote myocardium. This abnormality occurred at a cardiac workload lower than that
associated with exercise-induced myocardial ischaemia, and this model of resistive
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vessel dysfunction was unassociated with objective evidence of transmural myocardial
ischaemia. Nonetheless, this phenomenon may still contribute to causing ischaemia
perhaps in the presence of an increased sympathetic drive or a reduction in coronary
perfusion pressure.
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CHAPTER 10. SUMMARY AND PERSPECTIVE
10.1 The Evidence for Resistive Vessel
Dysfunction in Clinical Models of Coronary
Artery Disease
The objective of this thesis has been to describe coronary resistive vessel function
which has been suggested as a cause of an impaired coronary vasodilator reserve by
several independent groups in the past (Wilson et al, 1988; Pupita et al, 1990; Marcus
et al, 1990). Although a resistive vessel abnormality has been suggested as a cause of
reduced vasodilator responsiveness in other conditions such as hypertension, after
cardiac transplantation and in syndrome X (Chapter 1), the prevalence in coronary
artery disease is poorly described and understood. However, in several models
described in this thesis, coronary resistive vessel dysfunction has been defined and the
time course of the abnormality carefully described. Although the mechanism(s) for
these abnormalities remain poorly understood, several lines of research have been
suggested on the basis of the findings reported here. A hypothesis for the
development of coronary resistive vessel dysfunction at the level of the pre-arteriolar
vessels has been suggested based on existing experimental studies. It is now
imperative that the clinical relevance of coronary resistive vessel dysfunction and the
mechanism of dysfunction at the level of the pre-arteriolar vessels is defined.
Following the removal of a significant epicardial coronary artery stenosis by
successful coronary angioplasty, the coronary vasodilator reserve is unchanged from
pre-angioplasty values. For the first time, the components of this reduction have been
defined and described in Chapter 5. The vasodilator response to dipyridamole is
impaired acutely and persists for at least 24 hours. It is likely that this is due to the
angioplasty procedure itself perhaps due to platelet activation, endothelial disruption
and vasoconstrictor release, and/or embolisation of debris, as the recovery is relatively
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quick. Basal myocardial blood flow takes over a week to recover which suggests that
there has been a chronic adaptation to the reduction in coronary perfusion pressure.
There is evidence suggesting a process of vascular remodelling in the coronary
microcirculation distal to a severe epicardial stenosis, and this could account for the
longer time period for the recovery of basal flow to lower normal values. In the
absence of restenosis, the recovery of resistive vessel function is sustained at three
months follow-up and the coronary vasodilator reserve is the same as described in
remote regions of patients with stable single vessel disease.
The mechanism for this acute abnormality in coronary resistive vessel function
after coronary angioplasty was investigated in Chapter 6. Several groups have
proposed that coronary vasodilatation at a microvascular level is impaired as part of the
atherosclerotic process and due to impaired production or release of EDRF (nitric
oxide) (Drexler et al, 1991: Kuo et al, 1992). As previous experimental work has
suggested that the vascular smooth muscle response to exogenous nitric oxide donors
is enhanced by impaired endothelial function, this hypothesis was tested with regard to
the impaired coronary vasodilator reserve after angioplasty. However, intracoronary
sodium nitroprusside at a dose sufficient to cause systemic effects did not augment the
impaired coronary vasodilator response to dipyridamole. Thus, the acute impairment
of the coronary vasodilator reserve is probably not due to reduced production or
release of nitric oxide at the level of the resistive vessels, but does not exclude an
impairment of release or production of other endothelium-derived vasodilator
products. Alternatively, this finding may be further evidence for injury at the level of
the epicardial vessel wall during angioplasty balloon inflation as a factor in the
impaired vasodilator response.
It has been assumed that when studying the coronary vasodilator reserve in one
region of myocardium in patients with coronary artery disease that remote myocardium
subtended by an angiographically normal artery is functionally normal. However,
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given evidence for both impaired epicardial artery dilatation and an impaired coronary
vasodilator response in hypercholesterolaemia (Drexler et al, 1991; Zeiher et al, 1991)
and early atherosclerosis (Cox et al, 1989; Sellke et al, 1990; McLenachan et al,
1991), it is likely that resistive vessel dysfunction is present before the angiographic
development of disease. This was demonstrated by comparing myocardial blood flow
the remote regions of patients with single vessel coronary artery disease with a group
of normal controls (Chapter 7). The coronary vasodilator reserve, although higher
than that in the stenosis-related region, was lower than that in the controls. This was
due to both a reduction in the vasodilator response to dipyridamole as well as a higher
basal flow. The mechanisms of abnormality in basal and vasodilator flow are unclear.
There is no previous evidence to suggest that the atherosclerotic process leads to an
alteration in basal flow itself. A possible mechanism for this could therefore be an
increase in sympathetic nervous activity resetting the autoregulation of basal flow at the
level of pre-arteriolar vessels. Additionally, although atherosclerosis may diminish
maximal resistive vessel dilatation, increased a-adrenergic stimulation in the coronary
microcirculation may also cause this reduction. Measurement of metabolic substrate
handling showed no difference between remote myocardium and normal controls in
the basal state however. During pacing, increased glucose and alanine uptake in the
absence of net lactate production did occur in remote regions compared to controls,
which may be evidence of increased regional sympathetic activity. This functional
difference independent of systemic haemodynamics but in the presence of regional
ischaemia and wall motion abnormality elsewhere may be an early marker of the
functional consequences of resistive vessel dysfunction.
Further evidence for the interaction of the sympathetic nervous system and the
atherosclerotic process was demonstrated in patients after myocardial infarction
(Chapter 8). In the infarct region, there was a marked reduction in the coronary
vasodilator reserve consistent with acute myocardial injury, with a small degree of
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recovery at follow-up several months after the event. Basal flow in the infarct region
and the remote region were inversely related to each other perhaps indicating an inter¬
relationship between different myocardial regions such as "reverse steal" ofmyocardial
blood flow away from areas of ischaemia. In the remote region in the acute phase of
recovery, there was a marked impairment of the vasodilator response to dipyridamole
which made only a partial recovery at subsequent follow-up compared to remote
regions in stable patients with uncomplicated myocardial infarction. This may be
evidence for an acute resistive vessel dysfunction remote from and independent of both
coronary occlusion and reperfusion injury pertaining to the infarct region. Although
the neurohumoral response to myocardial infarction involves an increase in oc-
adrenergic sympathetic activity which could impair vasodilator responsiveness acutely,
it is equally possible that vasoconstrictor agents such as endothelin released in
increasing concentrations after myocardial endothelial injury could impede the
vasodilator reserve.
The relationship between resistive vessel function and myocardial viability was
also examined in Chapter 8. Residual basal flow and the ability of coronary resistive
vessels to vasodilate following direct injury appears to be closely related to the fraction
of perfused tissue in the same myocardial region of interest. This measure of
myocardial viability also correlates with the time to thrombolysis, consistent with other
clinical studies. This is the first evidence to suggest that there may be a relationship
between "microvascular stunning" and myocardial stunning (Bolli, 1992). Whether the
integrity of a proportion of resistive vessels ie. a threshold of vasodilatation, is a
determinant of recovery ofmyocardial contraction or simply a reflection of the amount
of viable muscle and thus viable microvascular bed is not known.
Visible coronary collateral vessels derived from an angiographically normal
epicardial artery sufficient to maintain normal contraction and basal myocardial blood
flow were used as final model of resistive vessel function (Chapter 9). Using cold
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pressor, a means of eliciting reflex a-adrenergic sympathetic stimulation, it was
shown that collateral vessels are unable to permit any significant increase in
myocardial blood flow to the collateral-dependent myocardium. In the majority, it
was possible to demonstrate an inappropriate vasoconstrictor response to cold pressor
compared to remote myocardium. Although again this could be interpreted as
increased sensitivity to a-adrenergic sympathetic stimulation in the pre-arteriolar
vessels, it was unassociated with objective macroscopic evidence of myocardial
ischaemia.
These models are to a large part observational and it has proven difficult to
demonstrate a cause and effect relationship between resistive vessel dysfunction and
objective evidence of myocardial ischaemia. The next stage of investigation should be
to determine the mechanism of resistive vessel dysfunction using other methodologies
and to determine therapeutic strategies to counter or reverse this early but potentially
devastating abnormality of coronary blood flow.
10.2 Future Studies
The work reported in this thesis has shown that coronary resistive vessel
dysfunction occurs in several different coronary artery disease syndromes; both
chronic and acute. Many questions regarding the mechanism, site and clinical
significance of this abnormality still need to be addressed; a combination of clinical
investigation together with experimental models will be necessary to define further the
mechanisms controlling the behaviour of the coronary microvascular bed and the
control of myocardial perfusion. I think that several areas of research could be
usefully pursued and these are described below:
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1. The mechanism of resistive vessel dysfunction after angioplasty will become more
apparent with detailed study of platelet activation during angioplasty and the
development of techniques to image or quantify endothelial and vascular smooth
muscle function in vivo. Further studies are required to determine the correlates of an
impaired coronary vasodilator reserve with respect to disease history, total ischaemic
burden before angioplasty, and microvascular remodelling. Larger studies should be
performed to examine whether there is any relationship between resistive vessel
dysfunction and the process of coronary restenosis.
2. The influence of endothelial cell integrity on resistive vessel function is
controversial. Most experimental work on the role of endothelium has been confined
to the study of epicardial vessels which have little influence on coronary blood flow in
unobstructed vessels. There is evidence to suggest that nitric oxide is not the only
endothelium-dependent vasoactive influence on the control of microvascular flow, as
inhibition of nitric oxide production has no effect on the vasodilator action of
acetylcholine at a microvascular level (Lefroy et al, 1993). Furthermore, it is unclear
at which level EDRF operates in the microvascular bed, although the hypothesis
suggested at the beginning of the thesis would favour a role at the level of the pre-
arteriolar resistive vessels. Studies of nitrovasodilators in experimental models of the
human microvasculature would confirm this hypothesis. Studies using the precursor
of nitric oxide, such as L-arginine, given at the time of coronary angioplasty may help
to define the role of the endothelium in determining resistive vessel function after the
procedure. The role of the various plasma lipid components and microvascular
dysfunction requires further study.
3. The role of the sympathetic nervous system in the development and modulation of
resistive vessel dysfunction should be elucidated. Many methods now exist to
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quantify the effect of the autonomic nervous system on the cardiovascular system such
as spectral analysis of heart rate variability (Malliani et al, 1991), and QT interval
dispersion (Day et al, 1991), as well as more traditional methods of autonomic
function testing and cathecholamine measurement. PET may now be used to measure
the end-effects of sympathetic nervous system activity with the in vivo quantitation of
p-receptor density in myocardium (Merlet et al, 1993) and pre-junctional reuptake-1
receptor density (Schwaiger et al, 1991). Techniques should be developed to study
the direct effect of adrenergic afferent activity on resistive vessel function and its
modulation by specific therapy, with particular reference to the a-adrenergic
component of the sympathetic system. Since acute resistive vessel dysfunction occurs
in remote myocardium after myocardial infarction, a particular line of investigation
may include the mechanism whereby P-blockade reduces mortality after infarction, and
whether its effect is predominately on remote myocardium.
4. The relationship between resistive vessel dysfunction and myocardial viability
should be investigated further. Since hibernating myocardium is defined by a
reduction in contractility and myocardial oxygen demand together with basal
myocardial blood flow (Braunwald & Rutherford, 1986), it would be of interest to
determine the magnitude of the reduction in the coronary vasodilator reserve that
occurs in association, as an understanding of changes at the level of the resistive
vessels may help to elucidate the mechanism of hibernation. Whether or not the
resistive vessel function is further affected by myocardial stunning and determines
recovery of contractility independent of or dependent on the amount of viable tissue
should also be established.
5. The clinical significance of resistive vessel dysfunction requires further validation.
This requires correlative study of PET scanning with other techniques used to
249
document myocardial ischaemia. Ischaemia caused by altered resistive vessel function
may be predominately subendocardial and not accurately quantified by techniques
dependent on ST segment depression such as exercise treadmill testing or Holter
monitoring. Even using a well-validated non-invasive technique such as FDG
scanning may not be adequately sensitive to detect transient non-transmural ischaemia.
With the development of other tracers such as 1 ^-acetate and 15C>2 to measure
oxidative metabolism and an improvement in the resolution of PET cameras, this may
become possible. Other techniques such as echocardiography and magnetic resonance
spectroscopy may complement developments in the measurement of ischaemia with
PET. Nonetheless, in order to extend the observation of resistive vessel dysfunction
to a wider arena, it is imperative that other methods of demonstrating this important
abnormality are developed in addition to invasive Doppler catheterisation and non¬
invasive positron emission tomography.
10.3 Conclusions
Coronary artery disease is the major epidemic afflicting the developed world in
this latter half of the twentieth century, accounting for two-thirds of all premature
deaths. Much clinical and experimental research has focussed on the effect of
atherosclerosis on epicardial coronary arteries and the territory subtended by the
diseased vessel. In this thesis, I have tried to show that the coronary resistive vessels
which are to a large part invisible may cause or contribute to causing some of the
pathophysiological manifestations of the coronary artery disease process.
Furthermore, as a consequence, I have shown that coronary resistive vessel
dysfunction occurs not only in the territory subtended by a diseased epicardial vessel
but also in myocardium remote from the visible atherosclerotic process, in both the
acute and chronic state. It is only with wider acceptance of coronary resistive vessel
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dysfunction into modern clinical practice that its true relevance will be determined.
Then, with wider confirmation of these findings, it will cease to be simply an
interesting laboratory phenomenon or clinical anomaly and may be seen as one of the
major influences on the outcome of acute and chronic coronary artery disease states.
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APPENDIX 1.
The Application of lsO-Water Delivery to the
Measurement of Myocardial Blood Flow
The behaviour of 150-water in tissue can be described by the following equation
for a single tissue compartment model:
dCt(t)/dt = F.Ca(t)-(F/Vd+l).Ct(t) (1)
where Q(t) is the regional tissue concentration of H2150, Ca(t) the arterial whole
blood concentration of H2150, F the regional flow in ml-min'-ml1, Vd the volume of
distribution of water, and 1 the decay constant of 150.
The solution to this differential equation is as follows:
Q(t) = F.Ca(t) * exp(-[F/Vd + l].t) (2)
where * denotes the operation of convolution. Q(t) represents the tissue response to
arterial input function Ca(t).
In Equation 1, two assumptions are made: i) both F and Vd are constant during the
measurement period, ii) water is freely diffusible (ie. the extraction fraction of water is
unity and no binding of water in tissue occurs). In practice, it is the actual
concentration in within a region of interest (which includes blood) which is measured
rather than the actual tissue concentration. However, it is assumed that the venous and
tissue concentrations may be treated as a single compartment for freely diffusible
tracers such as H2150. Furthermore, the arterial activity is negligible because of its
small volume. Thus Equations (1) and (2) hold with these assumptions.
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Compared to the brain, there are no diffusion limitations in the heart because of the
much larger permeability surface area. Thus one may calculate from the estimated
value for permeability and surface area (c. COOOcm^ml"1) that even for flows as high
as 8 ml-min^g1 there will be an extraction fraction for water of at least 98%. For a
freely diffusible tracer, venous and tissue concentrations may be considered similar if
the volume of distribution of the tracer in tissue is unity, which is virtually so.
The main problem for the application of Equations (1) and (2) to myocardium is
the invalidity of the assumption that the arterial fraction of blood vessels is low. More
important than this consideration is the contamination of signal by spillover from the
cardiac chambers, which may be higher than that from arterial blood. Thus, Equation
(2) may be expanded to allow for spillover:
Ctot(t) = Ct(t) + V,Ca(t) = F.Ca(t)* exp(-[F/Vd + l].t + Va.Ca(t) (3)
where Ctot(t) is the measured tissue concentration in a region of interest and Va the
arterial spillover fraction. Due to the finite resolution of PET cameras, there are the
problems of spillover and of underestimation of Ct(t) (the partial volume effect), which
is identical for F and Vd. This can be corrected for by introducing a tissue fraction
component (Iida et al, 1988):
F = a.MBF (4)
Vd=a.p (5)
where a is the fraction of exchangeable tissue (ml of tissue per ml of region of
interest), p the partition coefficient of water (ml of blood per ml of tissue), and MBF
the flow for the exchangeable tissue (ml of blood per ml of tissue per minute, or
ml-min^-ml4).
253
In Equation 5, it was assumed that the volume of distribution of water for
exchangeable tissue is the same as the partition coefficient of water for normal
myocardial tissue. Substituting Equations 4 and 5 into Equation 3:
Clot(t) = a.MBF.Ca(t) * exp(-[MBF/p + l]t) + Va.Ca(t) (6)
Using dynamic PET scanning, Ca (left atrium) and Clot (myocardium) can be measured
non-invasively as a function of time. Equation 6 can be fitted for an MBF, with Va
assuming a value for p. In the reported studies, a value of 0.96 ml-mT1 was used
based on previous data (Araujo et al, 1991). Of course, Equation 6 assumes that the
partition coefficient (the amount of water in myocardial tissue) remains constant.
Subsequent validation work has shown that as Equation 6 is less sensitive to
resolution effects as the MBF obtained is independent of the limitations of spatial
resolution, and thus less sensitive to the drawing of myocardial regions of interest.





At a cellular level in the normoxic state, oxidative phosphorylation of metabolic
substrates occurs in the mitochondria to generate high-energy phosphates, namely
adenosine triphosphate (ATP), to fuel cellular function and myocardial contractility.
Under fasting conditions, the heart preferentially uses free fatty acids as its source of
energy, using up to 10% of the whole body turnover despite receiving only 5% of
cardiac output (Camici et al, 1989b). Oxidation of lipid-derived substrates accounts
for up to 80% of myocardial oxygen consumption, with the majority of the remaining
energy requirement provided by carbohydrates (glucose, pyruvate and lactate).
However, with the increase in glucose loading in the fed state, glucose and insulin
levels increase with subsequent reduction in fatty acid uptake through insulin inhibition
of adipose tissue lipolysis. With greater production of energy from glucose for each
f-
unit of oxygen consumed, there is improved efficiency of oxygen (O2) usage after
feeding (5.01 kcalT1 of O2 vs. 4.66 kcalT1 of O2 from fatty acids) (Camici et al,
1989b).
Normal Cardiac Metabolism of Carbohydrate
At rest, normal subjects and patients with coronary artery disease have similar
metabolism with all major substrates (free fatty acids, glucose, ketone bodies,
pyruvate, lactate and glutamate) extracted to generate acetyl Coenzyme A (acetyl CoA)
to fuel the tricarboxylic acid cycle (Appendix Figure A).
Glucose is transported into the cell by a specific carrier system which is not energy-
dependent. Myocardial glucose uptake is determined by cardiac workload, insulin
concentration, glucose concentration, the degree of adrenergic activation, and tissue
oxygen tension (Camici et al, 1989b). After trans-sarcolemmal transport, glucose is
rapidly phosphorylated into glucose-6-phosphate by the enzyme
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VASCULAR SPACE CYTOPLASM MITOCHONDRION
BASAL (FASTING) STATE
INCREASED CARDIAC WORKLOAD
Figure A. Upper panel) The major metabolic pathways in resting human myocardium
under fasting conditions. Most of the energy produced (>80%) derives from oxidation of
free fatty acids. Most of the pyruvate formed from lactate and glucose through glycolysis is
used aerobically and enters the tricarboxylic cycle after conversion to acetyl coenzyme A.
A small amount of pyruvate is transaminated to alanine, which is then released, at the
expense of glutamate which is converted to a-ketoglutarate. The inhibition of glycolysis at
the level of the enzyme phosphofructokinase (PFK) is the result of accumulation of excess
citrate during oxidation of free fatty acids. Pyruvate dehydrogenase (PDH) is inhibited by
accumulated reduced coenzyme nicotinamide adenine dinucleotide (NADH). NADH,
which is formed during glycolysis in the cytosol, is normally reoxidised (NAD) in the
mitochondrion by way of the malate-aspartate cycle. Lower panel) Metabolic changes
during increased cardiac workload in normal myocardium. There is rapid activation of
glycogen breakdown and increased utilisation of exogenous glucose and lactate.
Carbohydrate (glucose, lactate, pyruvate, and alanine) oxidation is significantly increased
and accounts for more than 60% of energy production, acting as a booster and contributing
to the extra energy required during maximum stress. (Modified from Camici et al, 1989b).
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hexokinase, even in conditions of high glucose transport such as tissue hypoxia.
Normally, the rate of trans-sarcolemmal transport and hexokinase activity are the
limiting steps for myocardial glucose utilization. Glucose-6-phosphate may then be
converted to glycogen by glycogen synthetase or to pyruvate through the glycolysis
(the Embden-Meyerhof pathway). Glucose-6-phosphate may also be metabolised via
the pentose-phosphate pathway but this pathway, although very important for cellular
survival, is of lesser quantitative importance.
Glycolysis is controlled by feedback from the distal products of aerobic and
anaerobic glucose metabolism and by fatty acid metabolism at discrete sites
(Newsholme & Crabtree, 1979), which depends on whether the subject is in the fed
state (because of the increased levels of circulating glucose and insulin, with increased
glucose oxidation) or fasting state (where oxidation of lipid-derived substrates
provides most of the energy for ATP production) (Randle et al, 1963). Hexokinase
activation shifts control of glucose metabolism to the enzyme phosphofructokinase,
which is a major rate-limiting step.
Phosphofructokinase activity is amplified by reduced concentrations of ATP and
creatine phopshate and increased concentrations of ADP, adenosine monophosphate
(AMP) and inorganic phosphate (Pi). Citrate is also a powerful inhibitor of this
enzyme (Figure A). In the fasting state, fatty acid and ketone body oxidation lead to
acetyl CoA production with the excess accumulation of citrate through the tricarboxylic
acid cycle countering the usual positive feedback of high levels of fructose-6-
phosphate (a subsequent product of glucose-6-phosphate) on phosphofructokinase,
thus inhibiting glycolysis.
Pyruvate occupies a central role in the ultimate disposal of glucose: it may be
reduced to lactate (completing anaerobic glycolysis); transaminated to alanine at the
expense of glutamate which serves as amine group donor, or oxidised to acetyl CoA
inside the mitochondrion by pyruvate dehydrogenase, which is the predominant route
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under aerobic conditions. A decreased ratio of [ATP]/[ADP], the fasting state,
adrenaline, and increased cardiac workload all facilitate conversion of the enzyme from
the inactive to the active form. Under aerobic conditions, there is also a net balance in
favour of lactate extraction from the circulation into myocardium with conversion to
pyruvate, underlining the versatility of the heart to use a variety of different substrates
for energy production depending on their plasma concentration. In general, in both
normal subjects and patients with coronary artery disease at rest under fasting
conditions, carbohydrate (mainly glucose) uptake exceeds oxidation, indicating non-
oxidative disposal of these substrates.
The tricarboxylic (citric) acid cycle is tightly controlled in the mitochondria by
extramitochondrial [ATP]/[ADP], intramitochondrial [NAD]/[NADH], and oxygen
tension. This prevents unnecessary utilisation of substrate when ATP levels are
adequate for cellular respiration. However, under conditions of stress such as exercise
or atrial pacing, the heart needs to increase oxygen consumption and generate an
increased amount of high energy phosphates. This is achieved by increasing
utilisation of exogenous substrates such as glucose and free fatty acids whose delivery
is facilitated by the increase in coronary blood flow. At moderate workload, free fatty
acids remain the preferential substrate providing acetyl CoA for oxidative
phosphorylation. With increasing cardiac workload, glucose uptake and utilisation
increases with no further change in free fatty acid uptake (Appendix Figure A), with
additional substrate for glycolysis derived from glycogen breakdown (Camici et al,
1989b). This may be because of the greater energy yield (amount of ADP
phosphorylated per oxygen consumed) with glucose compared to free fatty acids.
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